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 Fatty acid β-oxidation disorders (FAODs), the most frequent group of inborn 
errors of metabolism, are clinically heterogeneous and clear genotype-phenotype 
correlations have not been described. Very long chain acyl-CoA dehydrogenase 
(VLCAD) deficiency and short chain acyl-CoA dehydrogenase (SCAD) deficiency result 
from mutations on the ACADVL and ACADS genes, respectively. Multiple mutations 
have been described in both disorders. Acute symptoms are often induced by 
physiological stress such as fasting, but the pathophysiologic mechanism underlying 
disease symptoms and phenotypic heterogeneity remains unknown. The aim of this 
dissertation was to explore the biological changes induced by genetic mutations and the 
gene-gene interactions and environmental effects on these defects. 
Proteomic changes in SCAD and VLCAD deficient mice, as well as the changes 
induced by fasting in VLCAD deficiency, were measured quantitatively using a 
combination of proteomics techniques. Broad mitochondrial dysfunction and 
derangements in multiple energy metabolism related proteins were altered in SCAD 
deficiency, indicating a complex mechanism for development of symptoms. Overall, a 
pattern associated with hepatotoxicity implicated in mitochondrial dysfunction and 
alteration of fatty acid metabolism was identified. Affected pathways converge on 
disorders with neurologic symptoms, suggesting that even asymptomatic individuals with  
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SCAD deficiency may be at risk to develop more severe symptoms. Several candidate 
biomarkers were suggested through Ingenuity Pathway Analysis. Numerous proteomic 
changes were characterized in VLCAD deficient mice in both fed and fasting states, and 
relevant biological pathway were identified. Fasting in both deficient and wild type 
animals induced alterations in several proteins. The pattern of alterations induced by 
fasting was different in VLCAD deficient mice from that in wild type animals. 
Mitochondrial chaperonins HSP60 and HSP10 altered differently in VLCAD deficient 
mice depending on the feeding state. Fasting altered an apparent compensatory increase 
in oxidative phosphorylation seen in the fed state. Thus, environmental factors and gene-
environment interaction play important roles in the pathogenesis of VLCAD deficiency. 
The diversity of protein changes in variable pathways due to deficiencies in SCAD and 
VLCAD may help explain the phenotypic heterogeneity in patients. 
These proteomic studies present new paradigm for exploring the mechanisms of 
disease, gene-environment interactions, and their contribution to gene-gene interactions 
in FAODs, one group of the mandatory target diseases in newborn screening program. 
The results advanced the knowledge about FAODs and had the public health significance 
by offering the benefits for the improvement in the diagnosis and treatment of theses 
disorders of great public health interest. Future characterization of functionally 
interactive genes and association studies in humans will provide further insight into 
disease mechanism. Further studies on candidate biomarkers are necessary to identify 
novel markers for prognosis prediction, adjunct diagnosis and therapy guidance in 
patients. 
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1.0  INTRODUCTION 
1.1 INBORN ERRORS OF METABOLISM  
Inborn Errors of Metabolism (IEM) are a group of genetic disorders caused by 
impairment of a specific biochemical reaction in a metabolic pathway. They have traditionally 
been viewed as Mendelian traits resulting from mutations in single gene and have served as 
important models for understanding the mechanism of pathogenesis of monogenic disorders 
(Lanpher et al, 2006). But while most IEMs are inherited as monogenic traits, they are typically 
caused by heterogeneous mutations and exhibit extremely variable clinical spectra with poor 
correlation of genotype with phenotype. The diagnosis of IEM often relies on the detection of 
abnormal metabolites that accumulate as a result of the deficient enzyme. While a diagnostic 
evaluation for IEMs is traditionally triggered by clinical symptoms in an individual, newborn 
screening that aims to detect disease before the development of symptoms has become 
increasingly important in recent years, and has expanded to include nearly 50 disorders. Pre-
symptomatic identification of disease adds a further need to understand the etiology, 
pathogenesis and natural history of these disorders. Environmental factors such as diet, stress, 
and intercurrent illnesses also often impose important effects on clinical symptoms and 
outcomes. However, the exact mechanism and role that such environmental effectors play in 
most disorders are unknown. Discerning the relative impact of genes and environment on 
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Mendelian disorders presents many of the same challenges faced in the study of complex genetic 
diseases, and serve as good models to examine the relative role of genetic factors, environmental 
factors, and their interactions in determining phenotypes. Thus, exploration of gene interactions 
and environmental effectors would not only help in understanding the pathogeneses of these 
disorders and the diversities of phenotypes in this group of clinically recognizable deficiencies, 
but also would help in elucidating the pathogenesis and genotype-phenotype correlations in other 
more complex genetic diseases. 
1.2 FATTY ACID Β-OXIDATION AND ITS DISORDERS 
FAO is a complex process involving transport of activated acyl-CoA moieties into 
mitochondria, followed by sequential removal of 2 carbon units in the form of acetyl-CoA 
(Figure 1)(Courtesy J.Vockley). These products, in turn, are used as fuel by the tricarboxylic acid 
(TCA) cycle or for the production of ketone bodies. Energy derived from various steps of the 
cycle is efficiently utilized to generate ATP through oxidative phosphorylation. β-oxidation 
represents an important source of energy for the body during times of fasting and metabolic 
stress. At least 25 enzymes and specific transport proteins are involved in mitochondrial fatty 
acid metabolism(Eaton et al, 1996; Saudubray et al, 1999). Of these, defects in at least 22 
proteins have been shown to cause disease in humans(Andersen et al, 2002). The most common 
of these are deficiencies of acyl-CoA dehydrogenases (ACADs). The ACADs are a group of 
evolutionarily related enzymes that consists of at least 9 family members, each with 
characteristic substrate specificity. The ACADs involved in energy metabolism are very long 
chain acyl-CoA dehydrogenase (VLCAD), long chain acyl-CoA dehydrogenase (LCAD), acyl-
  3 
CoA dehydrogenase 9 (ACAD9), medium-chain acyl- CoA dehydrogenase (MCAD), and short 
chain acyl-CoA dehydrogenase (SACD). All of them catalyze the α−β-dehydrogenation of acyl-
CoA esters with a conserved enzyme mechanism(Aoyama et al, 1995; Binzak et al, 1998), 
transferring electrons to electron transferring flavoprotein (ETF). They have been purified to 
homogeneity and share 30-35% identical amino acid residues (Tanaka & Indo, 1992). VLCAD 
catalyzes the initial reaction in the fatty acid oxidation cycle in the mitochondrial matrix, and is 
the rate-limiting step in that compartment. It is most active against activated fatty acids with a 
chain length of 14 to 20 carbons. SCAD catalyzes short chain acyl-CoAs with a length of 4-6 
carbons. 
 
 
Figure 1. Mitochondrial ß-oxidation spiral 
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Disorders of mitochondrial fatty acid β-oxidation (FAOD), one of the most frequent 
groups of IEMs in humans, offer an excellent example of the multifactorial nature of clinical 
disease in IEMs. IEMs affecting this pathway are typically inherited in a recessive fashion.  
Affected individuals with FAODs may present at any age with recurrent rhabdomyolysis, 
hypoglycemia, hypotonia, and peripheral neuropathy, but they may also remain asymptomatic 
for a lifetime (Bennett et al, 2000; Vockley & Whiteman, 2002). Symptoms are most often 
induced by fasting or physiologic stress. As an additional complexity, patients with multiple 
partial defects in FAO have been described (Vockley et al, 2000) and multiple genetic variations 
have been identified in asymptomatic individuals (Pedersen et al, 2008; Tein et al, 2008; van 
Maldegem et al, 2006). The identification of FAO disorders has been tremendously improved 
through the introduction of acylcarnitine analysis by tandem mass spectrometry. Mutation 
analysis of specific genes may confirm the diagnosis, but explanation of differences in the 
phenotype of patients with the same enzyme deficiency remains a challenge. Importantly, 
different mutations have variable effects on protein function. Missense mutations that result in 
misfolded but stable proteins may have different effects on the integrity and function of the 
putative FAO metabolome than null mutations with absence of protein (Gregersen & Olsen, 
2010). Systematic clinical and laboratory studies are needed to elucidate the pathophysiology of 
the different FAO disorders. 
VLCAD and SCAD deficiencies are caused by mutations in the ACADVL and ACADS 
genes, respectively, that impair gene expression or enzyme stability or function. Some genotype-
phenotype correlations have been described in VLCAD deficiency (Andresen et al, 1999). 
Mutations causing severe disease including hypoglycemia and cardiomyopathy with a high 
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mortality rate have been reported, however, genotype alone remains limited in its ability to 
predict phenotype (Coughlin & Ficicioglu, 2010; Wilcken, 2010). SCAD deficiency provides an 
even greater example of complexities in FAODs with extreme heterogeneous clinical 
presentations and a large number of genetic variations in ACADS. Whereas this condition was 
regarded a potentially life-threatening disorder prior to expanded newborn screening (NBS), 
patients identified by NBS for the most part remain asymptomatic despite confirmation of severe 
enzyme deficiency (Lindner et al, 2010). No clear genotype-phenotype relationships have ever 
been seen in either group of patients (Waisbren et al, 2008; Wilcken et al, 2003). Affected 
individuals with VLCAD deficiency may also present with acute symptoms in the newborn 
period, with milder symptoms in early childhood and rhabdomyolysis in adults. The observed 
acute symptoms are often induced by physiological stress or by conditions such as fasting or 
endurance exercise. However, the pathophysiologic and molecular mechanism underlying stress-
induced illness in patients with VLCAD deficiency is not yet well understood. 
As a group, FAO disorders are among the most prevalent autosomal recessive conditions 
in humans (Spiekerkoetter et al, 2009a). However, the individual gene defects only offer a partial 
view of the spectrum of disease related to this family of genes. Patients with some of these 
disorders can remain asymptomatic for life, and many require exposure to environmental 
stressors to express disease. Thus, a more complicated mechanism may exist in the pathogenesis 
of this group of diseases. Gene expression and functional cellular studies detailing secondary 
dysfunction at multiple levels would offer such a potential in help understand the complexities in 
the disease mechanism. In addition, multiple partial defects in energy pathways have been 
described in patients presenting with symptoms of energy dysfunction (Vockley et al, 2000). The 
presence of concurrent partial defects in more than one gene in individual or related metabolic 
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pathways has been termed “synergistic heterogeneity”, a genetic phenomenon that shares much 
in common with multifactorial and polygenic disease. A systemic examination of the interaction 
of genes and environment would be of great value in understanding the pathogenesis of FAODs 
and explaining the variations in phenotype. However, such studies are difficult or impossible in 
humans. 
1.3 MOUSE MODELS 
Mouse models for many of the fatty acid oxidation disorders have been described and 
have been helpful in studying the pathophysiology of these diseases (Schuler & Wood, 2002; 
Spiekerkoetter & Wood, 2010). The VLCAD gene for mouse was mapped to mouse 
chromosome 11 and has been found to be similar to that of the human VLCAD locus (ACADVL) 
(Cox et al, 1998b). Two mouse models of VLCAD deficiency have been produced independently 
using different strategies and presented with biochemical and pathological features resembling 
those of human VLCAD deficiency (Cox et al. 2001; Exil et al. 1998, 2003). The Cox model of 
VLCAD deficiency was generated by targeting the ACADVL gene using a replacement approach 
that resulted in a null allele with deletion of exons 7 to 19 (Cox et al. 2001). Clinical findings in 
these animals included mild hepatic steatosis, mild fatty change in the heart in response to 
fasting, and cold intolerance (Cox et al. 2001; Exil et al. 1998, 2003). The gene for mouse SCAD 
(Acads) originally known as butyryl-CoA dehydrogenase (Bcd-1) was mapped to chromosome 5 
and later renamed as ACADS. A mouse with SCAD deficiency was serendipitously discovered in 
a mutant strain of BALB/cByJ mice (Armstrong et al. 1993; Wood et al. 1989). The complete 
enzyme deficiency in these mice resulted from a 278-base pair deletion involving exons 9 and 10 
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of Acads gene(Hinsdale et al, 1993). Mice with SCAD deficiency manifested the biochemical 
and pathological features of human SCAD deficiency after fasting but remained asymptomatic. 
Mouse studies with animal heterozygous for mutations at multiple loci of fatty acid oxidation 
related genes have confirmed the physiologic relevance of the accumulation of mutations at 
multiple loci in related pathways(Schuler et al, 2005).  
Stress-induced changes have been investigated in several FAO deficient mouse models. 
Fasting and cold exposure resulted in severe hypoglycemia and hypothermia with lethality in one 
third of VLCAD deficient mice (Spiekerkoetter et al, 2004). Long chain acylcarnitines in the 
blood of these animals were elevated and free carnitine was decreased as compared to unstressed 
wild type animals after fasting. However, a lesser increase in C14-C18 acylcarnitines and a 
decrease of free carnitine were also observed in fasted heterozygous compared to wild-type mice. 
Fatal cold intolerance and fasting induced microvesicular fatty changes in hepatocytes have been 
described in SCAD deficient mice (Armstrong et al, 1993). Differential induction of several 
genes regulated by peroxisome proliferator-activated receptor-α (PPARα) in liver and brown 
adipose tissue during fasting and cold exposure in LCAD and VLCAD null mice has also been 
reported (Goetzman et al, 2005). The similarities between these mouse models and human 
disease make them an ideal platform to rigorously study the effects of the primary gene 
mutations, and the interaction of environmental stressors with these mutations, on cellular 
functions. 
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1.4 PROTEOMICS TECHNOLOGY 
The global survey of functionally related genes offers the potential to gain insight into the 
complex molecular events related to the introduction of a mutant gene into a cell. Gene 
expression profiling using cDNA and oligonucleotide arrays to examine mRNA, as well as other 
genotyping approaches, have proven to be powerful tools to address gene interactions in complex 
diseases. However, they suffer from several inherent limitations. mRNA abundance does not 
typically correlate well with protein abundance. Moreover, protein structure, function, and 
interactions can be altered and regulated by subcellular localization or post-translational 
modifications such as phosphorylation, glycosylation, ubiqination, or acylation that are not 
predicted by mRNA abundance. In contrast, a screening approach with mass spectrometry based 
on differential detection of proteins in isolated organelles from samples of interest offers the 
potential to measure all such changes directly.  
Proteomics takes a broad, comprehensive and systematic approach to understand biology, 
which is generally unbiased and not dependent upon existing knowledge. For the last three 
decades, proteomics techniques have emerged to deal with complicated issues that cannot be 
approached by genomic analysis. Global analysis of protein abundance based on differential 
detection of proteins in isolated organellar compartments using high-throughput mass 
spectrometry offers great potential to study the complex disease. Integrated analyses of gene 
expression and proteomic profiling of mouse mitochondria have identified a network of at least 
90 co-regulated genes involved in oxidative phosphorylation, β-oxidation, and the TCA cycle 
and highly expressed in brown fat, skeletal muscle and heart. It has been estimated that there are 
approximately 1500 mitochondrial proteins or so different polypeptides in the mitochondria 
(Kislinger et al, 2006; Mootha et al, 2003). One combined proteomic and transcriptomic 
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profiling study using tandem mass spectrometry (MS/MS) created an inventory of 667 
mitochondrial proteins in heart and 776 proteins in liver (Kislinger et al, 2006). 
Comparative proteomics aims to quantitatively compare proteins levels from two or more 
samples. The most commonly used method for comparative proteomic studies is two-
dimensional gel electrophoresis (2DGE). This technology has been used to investigate 
differential protein abundance in large-scale proteomic experiments prior to mass spectrometric 
identification(Gygi et al, 2000; Tanaka & Indo, 1992). Difference gel electrophoresis (DIGE) 
allows comparison of multiple two-dimensional (2D)-gels and allows different samples to be 
analyzed concurrently on the same gel (Unlu et al, 1997). Compared with conventional 2DGE, in 
which protein samples are separated on individual gels, stained and quantified, followed by 
image comparison with computer aided image analysis programs, DIGE shortens the procedure, 
eliminates to a great extent gel-gel variations, and has a large dynamic range allowing both the 
differential analysis of abundant proteins, as well as proteins present at low concentration (Ong 
et al, 2003). Development in quantitative proteomics has led to the application of fluorescent 
cyanine dyes (Cy2, Cy3 and Cy5) to label proteins before they are separated on a single 2D gel. 
In DIGE, the proteins in each sample are covalently tagged with different color fluorescent 
cyanine dyes that are designed to have no effect on the relative migration of proteins during 
electrophoresis(Tonge et al, 2001; Viswanathan et al, 2006) 
With the rapid expansion of protein sequence databases, mass spectrometry based 
identification of proteins is becoming more realistic and more reliable. The development of 
liquid chromatography-mass spectrometry (LC-MS) based profiling techniques has emerged as a 
robust tool in this area. Isobaric tags for relative and absolute quantification (iTRAQ) have been 
recently applied in proteomic studies (Ross et al, 2004; Wiese et al, 2007). It employs 
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incorporation of 4 to 8 different mass labels into peptides in different samples that can then be 
compared in one experiment. During peptide sequencing by tandem mass spectrometry, 
differentially labeled peptides are selected in the mass spectrometer as a single mass precursor 
ion since a balance group equalizes the size difference of the tags. The quantification values are 
determined by the mass labels, which give rise to distinct low mass peptide fragment ions. 
Labeling multiple peptides per protein increases confidence in identification and quantitation. 
This technique also offers a greater tolerance to any steric hindrance effect associated with 
labeling and provides access to peptides whose labeling sites may otherwise not be accessible to 
CyDyes used in DIGE analysis (Wiese et al, 2007; Wu et al, 2006). 
No global analysis of proteomic changes has been performed on either animals or 
humans with VLCAD deficiency or SCAD deficiency. The objective of my projects employing 
multiple proteomic approaches was to examine global changes in mouse models of these 
disorders in order to identify secondary changes related to the primary gene defects and to 
characterize the effects of those changes on the physiologic response to environmental stress.  
1.5 HYPOTHESES AND SPECIFIC AIMS 
The hypotheses addressed in this dissertation were as follows. 1) The qualitative pattern 
and/or relative abundance of mitochondrial proteins changes in mice deficient in ACADVL and 
ACADS will help explain the heterogeneous symptoms in these two deficiencies. 2) Specific 
cellular functions and pathways as determined by the pattern of proteins altered in the mouse 
models will provide insight into the pathogenesis of these disorders. 3) Measuring proteomic 
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changes from the deficient mouse models would identify novel markers for diagnosis and to 
follow treatment in humans with these diseases. My project had three specific aims. 
Specific Aim 1 was to examine changes in mitochondrial protein expression in SCAD 
deficient mice, characterize the cellular functions and canonical pathways associated with altered 
proteins, and explore candidate biomarkers for diagnosis and treatment. 
Specific aim 2 was to examine changes in mitochondrial protein expression in VLCAD 
deficient mice under fed and fasting conditions, analyze the cellular functions and canonical 
pathways associated with altered proteins under each condition, and explore candidate 
biomarkers and related pathological damage.  
Specific aim 3 was to identify mitochondrial proteins overlapping and differentiating 
VLCAD and SCAD deficiency in mice, and elucidate the roles of annotated cellular functions 
and associated pathways in the pathogenesis of two FAO disorders.   
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2.0  PROTEOMIC STUDY ON SHORT CHAIN ACYLCOA DEHYDROGENASE 
DEFICIENT MOUSE 
2.1 ABSTRACT 
Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is an autosomal recessive 
inborn error of metabolism that leads to the impaired mitochondrial fatty acid ß-oxidation of 
short chain fatty acids. It is clinically heterogeneous and multiple mutations have been identified 
in patients .No clear genotype-phenotype relationships have been seen. Nor is there a good 
correlation between the genotypes and the current biochemical marker for the diagnosis. The 
mechanism and definition of this deficiency remain unclear. The aim of this study was to better 
understand the mechanism of molecular changes at a global level, gain insight into the 
pathophysiology of this deficiency and to identify biomarkers that predict the development of 
symptoms. The quantitative changes of mitochondrial proteome in SCAD deficient mice 
compared to wild type mice were examined using two-dimensional gel difference electrophoresis 
(2DIGE) followed by protein identification with MALDI-TOF/TOF and iTRAQ labeling 
followed by nano-LC/MALDI-TOF/TOF. A broad spectrum of mitochondrial dysfunction and 
multiple energy metabolism related proteins were identified indicating that a more complex 
mechanism for development of symptoms may exist. Affected pathways converge on disorders 
with neurologic symptoms, suggesting that even asymptomatic individuals with SCAD 
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deficiency may be at risk to develop more severe disease. The results from this study largely 
identified a pattern associated with hepatotoxicity implicated in mitochondrial dysfunction, fatty 
acid metabolism, decrease of depolarization of mitochondria and mitochondrial membrane and 
swelling of mitochondria demonstrating that SCAD deficiency relates more directly to 
mitochondrial dysfunction and alteration of fatty acid metabolism. I proposed several candidate 
biomarkers that can serve as potential markers for adjunct diagnosis and monitoring of therapy. 
2.2 INTRODUCTION 
 
Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is an autosomal recessive 
inborn error of metabolism that leads to the impaired mitochondrial fatty acid ß-oxidation of 
fatty acids with a chain length of 4 to 6 carbon units. Short chain acyl-CoA dehydrogenase 
(SCAD) is a member of the acyl-CoA dehydrogenase (ACAD) family that catalyzes the initial 
reaction of the fatty acid oxidation spiral with sequential cleavage of two carbon units, and 
serves as an important energy source for the body during times of fasting and metabolic stress. 
Electrons from reduced SCAD are passed to electron transfer flavoprotein and then directed into 
the electron transport chain via electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-
QO), an inner mitochondrial membrane protein (Ghisla et al, 1984); (Thorpe & Kim, 1995).  
SCAD is a homotetrameric enzyme that is encoded in the nuclear genome and functions 
in mitochondria. It shares structural and functional similarity with other ACADs (Ikeda et al, 
1987; Matsubara et al, 1989a) but differs from them in substrate specificity. The human ACADS 
gene is located at chromosomal position 12q22-qter and spans approximately 13 kb, consisting 
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of 10 exons (Corydon et al, 1997). The mouse ACADS gene maps to chromosome 5 at the Bed-1 
locus (Prochazka and Leiter 1986), and is a compact, single-copy gene approximately 5kb in size 
containing 10 exons (Kelly & Wood, 1996). An SCAD deficient Balb/cByJ mouse has been 
described and is due to a 278-bp deletion in the 3' end of the ACADS gene leading to reduced 
steady-state levels of SCAD mRNA (Hinsdale et al. 1993).  
Deficiency of SCAD results in the accumulation of butyryl-CoA, which in turn leads to 
accumulation of butyrylcarnitine, butyrylglycine, ethylmalonic acid (EMA), and methylsuccinic 
acid in blood, urine, and cells (Amendt et al, 1987; Coates et al, 1988; Corydon et al, 1996). It 
was originally identified in symptomatic children and adults with heterogeneous symptoms 
including metabolic acidosis, ketotic hypoglycemia, epilepsy, myopathy, hypotonia, 
developmental delay and behavioral changes (Amendt et al, 1987; Corydon et al, 2001; Kurian et 
al, 2004; van Maldegem et al, 2006). However, other patients were reported have minimal or no 
symptoms (Ribes et al, 1998). With the widespread implementation of expanded newborn 
screening programs through tandem mass spectrometry measurement of acylcarntines in blood 
spots, many SCAD deficient infants have been identified. However, most or all of these infants 
have remained asymptomatic (van Maldegem et al, 2010). This has led to the recognition of 
many individuals carrying ACADS mutations but lack of related symptoms. 
Approximate 70 genetic variations have been identified in the ACADS gene in 
symptomatic and asymptomatic individuals (Pedersen et al, 2008; Tein et al, 2008; van 
Maldegem et al, 2006). No clear genotype-phenotype relationships have been seen in either 
clinical patients or those identified through newborn screening (Waisbren et al, 2008; Wilcken et 
al, 2003). Nor is there a good correlation between the genotypes and the biochemical 
characteristics of EMA and butyrylglycine excretion (Bhala et al, 1995; van Maldegem et al, 
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2006). In addition, two common coding polymorphisms in the ACADS gene have been identified 
that lead to variant proteins and increased EMA excretion in some individuals, but seem not to 
be disease causing. Finally, decreased SCAD activity in skin fibroblasts or muscle is not a good 
predictor of clinical symptom (Ribes et al, 1998). Thus the clinical relevance of the biochemical 
defect and the need to treat affected individuals remain unclear. In the SCAD deficient mouse, 
most of the biochemical findings parallel those seen in the human disease, including organic 
aciduria with excretion of ethylmalonic, methylsuccinic acids and N-butyrylglycine, and 
development of a fatty liver upon fasting or dietary fat challenge (Wood et al. 1989; Schiffer et 
al. 1989). In contrast to the complicated genetic situation in humans with heterogeneous 
SCADD, the mouse provides an excellent model to study pathogenesis of this disease in vivo. 
The clinical heterogeneity seen in SCADD raises fundamental questions about the 
pathophysiologic changes induced by deficiency of this enzyme, as they appear to differ from the 
other fatty acid oxidation disorders. However, the reason for these differences, and the 
heterogeneity seen within the disorder, remain unknown. It is clear that the biomarkers currently 
characterized in SCADD patients, including increased urinary EMA and butyrylglycine, 
increased plasma butyrylcarnitine, and decreased SCAD activity, are not sufficient to predict 
clinical symptoms and disease severity. Thus, additional biomarkers to categorize the effects of 
SCADD would be of great value. Recent experiments have called attention to the possible role of 
abnormal protein folding and interactions in cell lines from patients with SCADD and proposed 
the hypothesis that misfolded SCAD protein may play a role in the mitochondrial toxicity 
(Schmidt et al, 2010).  
In the last three decades, proteomics has found broad application in many areas of 
biology, biochemistry and biomedicine. Several proteomic approaches have been developed for 
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quantitatively assessing proteomes to study the systemic differences between the healthy and 
diseased state. Two quantitative proteomic approaches, two-dimensional gel difference 
electrophoresis (2DIGE) and isobaric tags for relative and absolute quantification (iTRAQ) are 
available to measure the molecular changes induced by mutations in disease models. DIGE 
allows comparison of multiple 2D-gels and different samples to be analyzed concurrently on the 
same gel eliminating a great extent gel-gel variations (Unlu et al, 1997), and has advantages in 
allowing both the differential analysis of abundant proteins and proteins at relative low 
concentration as compared to 2DGE. iTRAQ analysis has recently come into more general use in 
quantitative proteomics (Ross et al, 2004; Wiese et al, 2007). It utilizes the incorporation of 4 to 
8 different mass labels into peptides in different samples of interest for comparison in one 
experiment. The quantification values are determined by the distinct mass labels with low mass 
peptide fragment ions. This technique offers an increased confidence in identification and 
quantitation by labeling multiple peptides per protein and provides access to peptides whose 
labeling sites may otherwise not be accessible to CyDyes used in DIGE analysis (Wiese et al, 
2007; Wu et al, 2006). In this study, quantitative changes in the mitochondrial proteome of 
SCAD deficient mice compared to wild type were examined to better understand the biological 
changes induced by SCAD deficiency and identify the potential biomarkers predictive of clinical 
outcome. The use of two quantitative proteomic approaches has allowed us to generate 
complementary information on the quantification and identification of changes in the 
mitochondrial proteome and explore the novel potential protein markers of disease pathogenesis 
and severity. Characterization of such changes will offer new insight into the mechanisms of 
disease and provide novel markers for diagnosis. 
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2.3 MATERIALS AND METHODS 
2.3.1 Mice  
SCAD deficient mutant mouse (BALB/cByJ) and wild type mice (BALB/cBy) were 
originally purchased from the Jackson Laboratory (Bar Harbor, Maine) at age of 4-5 weeks, and 
further propagated in the animal facilities at the Children’s Hospital of Pittsburgh of UPMC. All 
mice were maintained pathogen-free, complying with standard housing procedures. 3 or 5 male 
offspring mice for each genotype were obtained before tissue harvest. All animals were 
sacrificed at age 6-8 weeks following standard protocols approved by the Animal Care and Use 
Committee of the University of Pittsburgh. Tissues were removed immediately after rapid 
euthanasia with CO2. 
 
2.3.2 Isolation of mitochondria 
Freshly removed liver was finely minced in ice cold isolation buffer A containing 225 
mM mannitol, 75 mM sucrose, 10 mM HEPES free acid, 10 mM EDTA, pH7.4, then gently 
homogenized with a glass Dounce homogenizer in isolation buffer B containing 225 mM 
mannitol, 75 mM sucrose, 10 mM HEPES free acid, 0.1% BSA fatty acid free, 10 mM EDTA, 
pH 7.4, with the addition of 10 µl/ml HaltTM protease inhibitor cocktail (Pierce, Rockfold, IL). 
The homogenate was centrifuged at 1,300 x g for 10 minutes at 4 °C, and the supernatant was 
recovered and centrifuged at 10,000 x g for 10 minutes. The pellet was carefully preserved and 
resuspended in 12% Percoll solution, then layered on top of a 30-70% Percoll gradient and 
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centrifuged at 62,000 x g for 35 minutes at 4 °C. The mitochondrial band located between the 
30% and 70% layers was removed and washed with cold isolation buffer A, then collected by 
centrifugation at 10,000 x g for 10 minutes 4 °C. A small aliquot of the sample was taken for 
organelle marker analysis and purity testing by western blotting. Twenty micrograms of the 
remaining sample were run on a 10% SDS acrylamide gel and transferred to PVDF membrane 
for western blotting. The membrane was probed with anti-cytochrome C (a mitochondrial 
marker) and anti-calreticulin (an ER marker) antibodies (Santa Cruz Biologicals). Two 
approaches to examine the mitochondrial proteome in the final samples were employed. The 
overall workflow is shown in Figure 2. 
 
                                    Figure 2. Overall workflow of experiment 
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2.3.3 Difference gel electrophoresis  
Mitochondrial protein was extracted using M-PER Mammalian Protein Extraction 
Reagent (Pierce, Rockfold, IL). Ten microliters per milliliter of sample of HaltTM protease 
inhibitor cocktail (Pierce, Rockfold, IL) and 1µl/ml phosphatase inhibitor cocktail 2 (Sigma, 
Saint Louis, MO) were added to the extraction buffer. The mixture was shaken gently for 10 
minutes at 4 °C, and cellular debris was removed by centrifugation at 14,000 x g for 15-30 
minutes at 4 °C. Protein samples were then treated with the 2D Clean-up Kit (GE Healthcare, 
Piscataway, NJ) according the manufacturer’s instructions. Briefly, approximately 100 μg of 
protein were precipitated, and resuspended in 7 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) and 2% Amidosulfobetaine-
14 (ASB-14). Protein concentration was measured with the 2-D Quant Kit (GE Healthcare, 
Piscataway, NJ) according the manufacturer’s instructions.  
Cy-dye labeling.    A stock solution of PrCy3-N-hydroxysuccinimide ester and MeCy5-
N-hydroxysuccinimide ester (Cy3 and Cy5, respectively), were prepared as described (Unlu et 
al, 1997) and stored in anhydrous N,N-dimethylformamide (DMF) at -80 °C. Cyanine dye 2 
(Cy2) was purchased from GE Healthcare. Equal amounts of protein samples from SCAD 
deficient and wild type mice were individually labeled in a reciprocal manner with equal 
volumes of Cy3 or Cy5 to produce balanced covalent labeling of 1–5% of the available lysine 
side chains without significantly altering the protein isoelectric points. An equal amount of 
pooled samples from both genotypic mice was labeled with Cy2 as an internal standard for the 
normalization of each gel. The labeling reaction was incubated on ice in the dark for 30 min and 
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then terminated by addition of 1 µl of quench (40% aqueous methylamine, pH 8.0) (Beckner et 
al, 2005) and further incubation on ice in the dark for 10 minutes.  
Difference gel electrophoresis (DIGE).     Equal volumes of samples In buffer containing 
7 M urea, 2 M thiourea, 2% amidosulfobetaine-14, 10 mg/ml DTT and 1% Pharmalytes 3–11 
(GE Healthcare, Piscataway, NJ) were added to each of the labeled protein samples and paired 
protein samples from deficient and wild type mice were mixed together for subsequent 
isoelectric focusing on long wide pH range Immobiline DryStrips, 24 cm, pH 3-11 nonlinear (3-
11 NL). After active rehydration for 10 hours at 30 v, IEF was performed with an Ettan IPGphor 
Π system (GE Healthcare, Piscataway, NJ) at 300 v for 30 minutes, 500 v for 30 minutes, 1000v 
for 1 hour and up to 80000 vh, and then maintained at 30 v as needed. After equilibration with 50 
mM Tris-HCl pH 8.8, 6M urea, 30% glycerol, 2% SDS plus 100 mg DTT added per gel for 10-
15 minutes, and additional alkylation by 250 mg iodoacetamide per gel, the strips were placed on 
freshly made 12.5% SDS-polyacrylamide gels. The resolved proteins were separated with a 
vertical Ettan DALTsix electrophoresis system (Amersham Bioscicences) in a running buffer of 
1X TGS (Tris-Glycine-SDS, Bio-Rad, Hercules, CA).  
Gels were visualized and evaluated with the Typhoon 9400 Variable Imager (GE 
Healthcare, Piscataway, NJ). Appropriate emission filters and lasers were selected to give 
optimum results with minimal cross talk. The Cy3 images were scanned using a 532 nm laser 
and a 580 nm band pass BP30 emission filter; Cy5 images were scanned using a 633 nm laser 
and a 670 nm-BP30 emission filter; and Cy2 images were scanned using a 488 nm laser and an 
emission filter of 520 nm BP40. All gels were scanned at 100 microns pixel size for the best 
resolution. The photomultiplier tube voltage was chosen to achieve the best image quality. The  
photomultiplier tube was set to ensure a maximum pixel intensity between 40–60 000 pixels. A 
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focal plane of +3mm b/c of glass plates was chosen. ImageQuant v5.2 (GE Healthcare, 
Piscataway, NJ) was used to crop the images to exclude the nonessential information prior to 
image analysis. 
Gel analysis was performed using DeCyder DIA v5.2 (GE Healthcare, Piscataway, NJ). 
Quantitative comparison of proteins between samples was performed using the differential in-gel 
analysis module for each gel, comparing the normalized volume ratio of each spot from a Cy3- 
or Cy5-labeled sample to the corresponding Cy2 signal from the pooled sample internal standard. 
The estimated number of spots for each co-detection procedure was set to 2000. Dust or other 
artifacts were detected and removed by applying an exclusion filter with peak slope values of 
greater than one or as clusters of sharp spikes. Visual inspection confirmed the differences 
indicated by the DeCyder software prior to removal. The biological variation analysis module, 
which allows integral matching and calculation of average abundance for each protein spot, was 
used to match the multiple images from three different gels and provide statistical data on 
differential protein expression levels between deficient and wild type groups collectively. 
Student’s t-test was selected to compare differences in protein levels. Though a threshold of 1.25 
was set to call differences, only proteins with ≥1.3 fold changes and visible spots were picked 
and subjected to mass spectrometric analysis. Coomassie blue stain was used to detect abundant 
proteins.  
Identification of differentially expressed proteins from DIGE analysis.    Protein spots 
that differed on DIGE between deficient and wild type animals were manually retrieved, digested 
with trypsin, and submitted for mass spectrometry analysis. The peptides derived from each 
protein spot were analyzed with matrix assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF-MS) in a 4700 Proteomics Analyzer with TOF/TOF (Applied 
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Biosystems, Foster City, CA). Each peptide sample was spotted four times onto a MALDI plate. 
The reflector positive ion mode acquisition and processing methods were chosen to collect 
peptide spectra in the mass range of 800-4000 Da with minimum s/n filter set to 10 and mass 
exclusion tolerance set to 50 ppm. The highest ten intensity peptides were selected for analysis 
using MS/MS acquisition mode of the 1kV positive ion, and the processing method with a mass 
exclusion tolerance of 100 ppm and minimum s/n filter of 10 in the mass range 60 Da to 20 Da. 
Data were processed with a GPS Explorer Workstation (Applied Biosystems, Foster City, 
CA,). The MASCOT algorithm (Matrix Science, Boston, MA) was used to search the Mass 
Spectrometry Protein Sequence DataBase (MSDB). MASCOT parameters were set to include 
only Mus species with the following parameters: tolerance of one missed trypsin cleavage per 
protein, allowance of cysteine modification by acrylamide, oxidation of methionine, 
carbamidomethyl oxidation peptide charge of +1, and peptide tolerance of 100 ppm with MS/MS 
fragment tolerance of 0.2Da. Protein identifications were accepted when scores over 65 indicated 
nonrandom identification at a significance level of P=0.05 and the protein IDs were consistent in 
at least 3 of 4 quadruplicates spots on MALDI plates from two individual gels.  
 
2.3.4 iTRAQ experiments 
 
Mitochondrial pellets isolated as above were suspended in sample buffer containing 0.5 
M triethylammonium bicarbonate buffer (TEAB, pH 8.5), 0.1% SDS at 4°C. The samples were 
sonicated 3 times for 10 seconds at 4°C, and debris was removed by centrifugation at 14,000 x g 
for 15 minutes at 4°C. The protein concentration was measured using the BCA protein assay 
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reagent according to the manufacturer’s protocol (Pierce, Rockford, IL). Absorbance was 
measured at 590 nm on a microplate reader (Bio-Rad, Hercules, CA)  
iTRAQ labeling.    Equal amounts of 100 µg of protein from both genotypes were 
precipitated with acetone and resuspended in 0.5 M TEAB and 0.5% Rapigest (Waters, Milford, 
MA). Protein samples were denaturated, reduced, alkylated, and digested with trypsin according 
to the manufacturer’s protocol (Applied Biosystems, Foster City, CA). Four iTRAQ reagents 
(Applied Biosystems, Foster City, CA) with mass labels of 114, 115, 116 and 117 Da were used 
to separately label samples from deficient or wild type mice. Each sample was labeled twice for 
each experiment, and a total of 3 experiments were performed with the tagged samples in a 
reciprocal manner (Table 1). Equal amounts of pooled samples from 2 of the same genotype 
samples were used as an individual sample in the second and third experiments in order to reduce 
the sample variations. Three hundred microliters of 0.5% formic acid in H2O were added to the 
tubes, and the samples were stored at 4 °C overnight to quench the unreacted iTRAQ reagent and 
hydrolyze the Rapigest. The samples were dried by vacuum and reconstituted in 20 µl of 10 mM 
potassium phosphate pH 3.0, 25% acetonitrile (ACN). The reporter ions were checked in a 4700 
MALDI-MS/MS (Applied Biosystems, Foster City, CA) to ensure sample labeling. All of the 
iTRAQ labeled peptide samples were then pooled for fractionation.  
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Table 1. Experimental design for iTRAQ proteome profiling  
Experiment 
No. 
Labeled Samples Labeled Samples Labeled Samples Labeled Samples 
1 114-SCAD+/+ 1 115-SCAD-/- 1 116- SCAD +/+ 1 117- SCAD-/- 1 
2 114 -SCAD -/- 2&3* 115-SCAD+/+ 2&3 116- SCAD -/- 
2&3 
117- SCAD+/+ 
2&3 
3 114-SCAD+/+4&5** 115-SCAD-/- 
4&5** 
116- SCAD +/+ 
4&5** 
117- SCAD-/- 
4&5** 
*2&3: pooled sample from animals 2 and 3 **4&5: pooled sample from animals 4 and 5 
 
 
Strong cation exchange fractionation.    PolySULFOETHYL A macro-Spin columns (12 
µm, 300 Å, 50-450 µL (The Nest Group, Inc, Southborough, MA) were employed to fractionate 
peptide samples. The columns were pretreated with methanol and with water, and then 
equilibrated with 10 mM potassium phosphate, pH 3.0, 25% ACN. The samples were then 
diluted in 10 mM potassium phosphate, pH 3.0, 25% ACN, and loaded onto the column. Six 
fractions were collected by stepwise elution with 20 mM potassium chloride (KCL), 40 mM 
KCL, 80 mM KCL, 100 mM KCL, 200 mM KCL and 400 mM KCL in 10 mM potassium 
phosphate, pH 3.0, 25% ACN. The eluted fractions were lyopylized, resuspended in 0.5% 
trifluoroacetic acid, 5%ACN, and desalted using a PepClean C-18 column (Pierce, Rockford, IL) 
according to the manufacturer’s instructions. 
Nano-LC separation.    Peptide samples were further separated using an RP LC-Packing 
Ultimate system (Dionex, Sunnyvale, CA) with a trap column (300 μm i.d. x 5 mm, PepMap 100 
C18 material 5 μm, 100 Å) (Dionex). The system was washed with a 5-85% ACN gradient 
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containing 1% trifluoroacetic acid (TFA) for 9 minutes then 85% ACN, 0.1% TFA for 30 
minutes at a flow of 300 nl/min before loading onto an analytical column (75 μm i.d. x 100 mm, 
ProtePep II C18 material 3 μm, 100 Å; New Objective, Woburn, MA).  The peptide samples 
were fractionated using a multi step protocol as follows: Buffer A was 5% ACN, 0.1% TFA, and 
buffer B was 85% ACN, 5% isopropyl alcohol and 0.1% TFA. A gradient of 0-56% B in 115 
minutes, 56%-100% B in 5 minutes, 100% B for 5 minutes was run all at a flow rate of 300 
nl/min. Before and after the runs, BSA peptides were loaded as control. The BSA peptide 
samples were fractionated using a multiple gradient of 0-56% B in 30 minutes, 56%-100% B in 5 
minutes, 100% B for 5 minutes all at a flow rate of 300 nl/min. The fractionated peptides were 
collected using the Probot™Micro Fraction Collector system. 30 second flow spots were spotted 
on an ABI 4800 LC-MALDI metal target plate (ABI, Foster City, CA) in a 16 x 48 array. A total 
of 576 spots were collected for each strong cation exchange (SCX) fraction of samples and 192 
spots were collected for each fraction of control BSA peptides. BSA fractions were spotted on 
the plate before and after the sample fractions. During the LC run, 10 mg/ml α-cyano-4-hydroxy 
cynnamic acid (CHCA) with 10 mM ammonium citrate dibasic and 10 fM angiotensin II in 85% 
ACN, 0.1% TFA were mixed with the flow and co-spotted on the plate using a μTee mixer at a 
flow rate of 1.5 µl/min.  
Mass Spectrometry of iTRAQ labeled peptides.    A 4800 Analyzer equipped with 
TOF/TOF ion optics (Applied Biosystems) was used to analyze the MALDI target plates and 
MS-MS/MS data were acquired using the 4000 Series Explorer software, version 3.5.1. The 
instrument was calibrated before each run. The operating mode of MS was set to MS reflector 
positive. MS spectra were acquired from 900 to 4000 Da with a focus mass of 2000 Da to 
determine the mass of the precursor peaks of interest. MS was performed using angiotensin II 
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spiked into the matrix as an internal standard with a 5-ppm maximum outlier error. The top 10 
peptide peaks with a S/N filter of 20 were selected for MS/MS analysis. Peptide CID (air) was 
performed at 2 kV in positive mode with an accumulation of 2000 shots for each spectrum. The 
MS/MS default calibration was updated before each target was run by using a peptide in the 
calibration mix spots. 
Protein quantification and identification of iTRAQ labeled samples.     MS/MS data were 
collected and processed using ProteinPilotTM Software 2.0 (Applied Biosystems). All 6 
fractions of each experiment were combined into one dataset for the analysis. The LC-based 
Paragon algorithm was used to search against the mouse International Protein Index (IPI) 
database v 3.68. The species Mus musculus was specified. The ID search was focused on 
biological modifications. Search parameters also included iTRAQ labeling of the N-terminus and 
lysine residues, cysteine modification by methylmethanethiosulfonate (MMTS), and digestion by 
trypsin. Isoform specific identification and quantification was done by excluding all shared 
peptides and including only unique peptides. The bias and background correction was processed 
to optimize quantification data. Proteins with ProtScore ≥ 1.3 (unused) at a significance level of 
0.05 (95% confidence) were selected for further analysis.  
Proteins were identified on the basis of having at least 2 peptides with an ion score above 
99% confidence. Only peptides identified with ≥95% confidence were confirmed and included in 
the quantitative analysis. Only peptides for which peaks corresponding to the iTRAQ labels were 
detected were included. The protein sequence coverage (95%) for a specific protein was 
estimated as the percentage of matching amino acids from the identified peptides having 
confidence greater than or equal to 95% divided by the total number of amino acids in the 
sequence. Estimates of fold change ratios of differential expression between labeled protein 
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samples and the error factors provided by ProteinPilot were utilized. Proteins with at least 2 
peptides (sequence coverage 95%) and error factor lower than 1 were then exported into Excel 
for further data analysis.  
Data analysis.    All quantification values in one experiment used for the calculation of 
proteins ratios were summed and averaged to obtain the averaged reference baseline value in one 
data set. The quantification value of each protein was then normalized to this reference value by 
setting it to 1. Student’s t-test was used to test the difference at p≤0.05 between the quantification 
values of mutant and wild type for each protein. The averaged fold change of a protein 
expression in mutant compared to that in wild type was recalculated. The cut-off fold change of 
significant proteins was set to 1.3 or 0.7. Proteins with significant changes (p≤0.05) and over 1.3 
fold change or less than 0.7 fold change in at least 2 experiments were classified as significantly 
changed proteins. 
 
2.3.5 Pathway and network analysis 
The complete set of differentially expressed proteins from two proteomic analysis 
approaches with their gene symbol names as identifiers and corresponding expression values 
were examined with Ingenuity Pathways Analysis software (Ingenuity Systems, Redwood City, 
CA; www.ingenuity.com). Each identifier was mapped to its corresponding object (gene/protein) 
in the Ingenuity Knowledge database. These focus genes were overlaid onto a global molecular 
network developed from knowledge-based information previously reported in the literature. The 
canonical pathway analysis utilizes well characterized metabolic and cell signaling pathways that 
were available prior to data input. The filters and general settings for the core analysis were set to 
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consider all molecules including endogenous chemicals, as well as both direct and indirect 
relationships. The taxae of human and mouse were selected. All data sources, including cell lines 
and liver tissue, were considered, and a stringent filter for molecules and relationships was 
chosen. Networks of the focus genes were then algorithmically generated based on their 
connectivity and ordered by score. The software computes a score for each possible network 
according to the fit of that network to the input proteins/genes. This score is calculated as the 
negative base-10 logarithm of the p-value that indicates the probability that the network-eligible 
molecules are found together as a result of random chance. Scores 2 or higher have at least a 
99% confidence of not being generated randomly. Networks were also associated to the 
biological functions (and/or diseases) that were most related to the genes in the network. Genes 
or gene products are represented as nodes, and the biological relationship between two nodes is 
represented as an edge. All edges are supported by at least one reference from the literature or 
from canonical information in the software. The intensity of the node color indicates increased 
(red) or decreased (green) abundance. Nodes are displayed using various shapes that represent 
the functional class of the gene product. I utilized the toxicity analysis function incorporated in 
IPA software to assess the secondary physiologic impact of the primary ACADS gene deficiency.  
2.3.6 Western blotting 
To validate significant findings, western blot analysis was performed on several selected 
proteins that were likely to be of biological interest. Equal amounts of 50 µg or 100 µg of 
mitochondrial protein from wild type mice and mutant mice were separated on 10% Bis-Tris 
SDS polyacrylamide gels (Bio-Rad, Hercules, CA) in MOPS buffer (Bio-Rad, Hercules, CA). 
The separated proteins were transferred to 0.2 um nitrocellulose membrane (Bio-Rad, Hercules, 
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CA) using a TE Series Transphore Electrophoresis Unit (Hoefer Scientific Instruments, San 
Francisco, CA). The membrane was immunoblotted with the desired antibodies. Primary 
antibodies used were SCAD and LCAD (Vockley Lab), Complex III subunit core 2 
(Mitoscience, Eugene, OR), SCP2 and HSP60 (Santa Cruz Biotech, Santac Cruz, CA). SDH 
(Complex II) antibody (Santa Cruz Biotech, Santa Cruz, CA) was used as loading control. The 
secondary antibodies conjugated to horseradish peroxidase included rabbit anti-goat IgG and 
anti-mouse IgG (Santa Cruz Biotech), selected based on the primary antibody. Bound secondary 
antibody was detected with Western Blotting Luminol Reagent (Santa Cruz Biotech) and 
scanned using Fujifilm LAS-3000 (Fujifilm Medical Systems, Stanford, CT).  
2.4 RESULTS  
To characterize mitochondrial proteome changes related to SCAD deficiency, DIGE 
analysis of purified mitochondria followed by protein identification with MALDI-TOF/TOF was 
first utilized. iTRAQ labeling followed by peptide separation and identification with LC-
MALDI-TOF/TOF was then performed. An overview of the experimental approach is shown in 
Figure 2. A total of 49 proteins with differential expression in SCAD deficient mice were 
identified. A variety of energy metabolism related proteins were identified to be altered. 
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2.4.1 Differentially expressed proteins in SCAD deficient mice identified through DIGE 
analysis 
An identical internal standard comprised of pooled aliquots from all samples from each 
experiment was incorporated to enable the comparison of protein abundance between samples on 
different 2D gels. This standard allowed accurate comparison of protein spots across all gels. 
Protein samples were also labeled in a reciprocal manner to eliminate the variation in labeling 
with the cyanine dyes. Three individual images corresponding to Cy2-, Cy3-, and Cy5-labeled 
samples from each gel were analyzed using DeCyder software. Biological Variation Analysis 
was used for integral matching and calculation of the average abundance of each protein spot 
across all gels. After applying an exclusion filter and manually excluding the control spots by 
inspection, a total of 161 spots were matched among all gels through biological variation 
analysis of the 1354 detected spots. A standardized average spot volume ratio exceeding 1.25 in 
three analyzed gels (Student’s t-test, p≤0.05) was considered to be a significant change. Analysis 
identified a significant increase in 12 (7.5%) spots and a decrease in 16 spots (9.9%) in 
mitochondria from SCAD deficient mice. These spots are depicted on a DIGE gel image shown 
in Figure 3. Proteins spots with at least 1.3 fold change were excised manually and subjected to 
in-gel digestion, and their mass spectra were analyzed by MALDI-TOF-TOF.  
A Mascot database search of the MS spectra resulted in the identification of 10 proteins 
obtained from quadruplicate MALDI spots in 2 individual gels (Table 2). A consistent 
identification from at least 3 MALDI spots with a score ≥100 was considered reliable ID for the 
specified protein. Protein spots with the same protein IDs were reported with an averaged ratio. 
Proteins identified and their average ratios are listed in Table 2 with information on experimental 
or theoretical molecular weight and PI values, accession number, Mascot scores, and involved 
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pathway or functions. A representative 2D DIGE image showing the significantly changed 
proteins in SCAD deficient mice was shown in Figure 3. Sterol carrier protein 2 and sterol 
carrier protein X were identified in 2 different positions. They represent the same protein with 
synonymous names in the UniPro database (non-specific lipid-transfer protein). Catalase/mutant 
catalase was assigned to 3 spots (5, 6, and 14). Beta-alanine oxoglutarate amino-transferase and 
its synonymous 4-aminobutyrate aminotransferase were identified as spot 9. The database search 
revealed that all of the identified proteins were predicted to be located in mitochondria. Catalase, 
typically viewed as a peroxisomal protein, has been shown to be more abundant in rat liver 
mitochondria than in peroxisomes (Jiang et al, 2005);(Murayama et al, 2001).  
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Figure 3. Representative 2D DIGE image showing the significantly changed proteins in SCAD deficient mice. 
Mitochondrial proteins were separated in the first dimension by IEF with pH range from 3-11 then 12.5% SDS-
polyacrylamide in the second dimension. Proteins from deficient and wild type mice were labeled with Cy3 or Cy5 
in a reciprocal manner. In each gel, an internal standard from pooled samples was labeled with Cy2 to allow 
matching of spots in different gels and to normalize the amount of loaded protein. Protein spots that were 
differentially expressed (over 1.3 fold change, p≤0.05) and successfully identified with MALDI-TOF/TOF are 
marked with numbers. 
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Table 2. Differentially expressed mitochondrial proteins identified by DIGE in SCAD deficient mice 
 
 
Protein name 
 
Accession No. 
 
Protein MW 
 
Protein 
PI 
 
Spot  
Mascot score SCAD-/- : SCAD+/+ Function 
Average ratio  p-value Sterol carrier protein2/ Sterol carrier protein X AAH18384 JU0157 59087.8 7.16 2 217 +1.92 0.018 Lipid transport H+-transporting two-sector ATPase, alpha-chain JC1473 59715.6 9.22 13 427 +1.72 0.031 OXPHOS Aldehyde dehydrogenase 4 family, member A1 Q8BXM3 61713.6 8.7 3 260 +1.62 0.012 Amino acid metabolism Catalase A36695 59727.6 7.72 5,6,7 277 +1.59 0.038 Fatty acid oxidation Epoxide hydrolase A47504 62489.6 5.85 4 248 +1.50 0.017 Amino acid metabolism Sterol carrier Protein X/ Sterol carrier protein 2 JU0157 59119.7 7.15 1 112  +1.46  0.008 Lipid transport Aldehyde dehdrogenase2 precursor, mitochondrial I48966 56501.8 7.53 8 443 +1.32 0.026 Amino acid metabolism Ornithine carbamoyltransferase precursor OWMS 39739.6 8.81 12 435 -1.30 0.0005 Urea cycle 4-aminobutyrate aminotransferase AAH58079 56415.6 8.35 9 191 -1.47 0.041 GABA shunt Beta-alanine oxoglutarate aminotransferase Q8BZA3 50204.8 8.79 9 265 -1.47 0.041 GABA shunt Acetyl-Coenzyme A dehydrogenase, short chain Q91w85 44861.1 8.68 11 188 -3.53 0.0005 Fatty acid beta-oxidation 
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Table 3. Differentially expressed mitochondrial proteins identified by iTRAQ experiment. 
Unused 
score 
%Cov 
(95) 
Accession Gene 
symbol 
Protein Name Peptide 
(95%) 
Averaged 
Ratio 
SCAD-/-: 
SCAD+/+ 
No. 
Exp. 
Function 
15.86 15.61 IPI00111218.1 Aldh2   Aldehyde dehydrogenase, mitochondrial 8 3.11 3 Amino acid metabolism 10.61 12.33 IPI00134809.2 Dlst   Isoform 1 of Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex 6 2.42 2 Amino acid metabolism 4.02 6.38 IPI00129178.1 Oat  Ornithine aminotransferase, mitochondrial 2 2.1 3 Amino acid metabolism 2 2.12 IPI00124372.3 Aldh9a1  Aldehyde dehydrogenase 9A1 1 1.88 2 Amino acid metabolism 7.4 7.30 IPI00890092.1 Aldh7a1  Alpha-aminoadipic semialdehyde dehydrogenase 4 1.67 2 Amino acid metabolism 4.01 5.32 IPI00759940.2 Fh1  Fumarate hydratase 1 precursor 2 1.49 3 Amino acid metabolism 3.75 5.85 IPI00379694.4 Hmgcl 3-hydroxy-3-methylglutaryl CoA lyase precursor 2 2.22 2 Ketogenesis& AA  32.72 52.64 IPI00653158.1 Acaa2  Acetyl-Coenzyme A acyltransferase 2, isoform CRA K 23 2.6 3 Fatty acid oxidation 8.52 9.49 IPI00894588.1 Acadl  Long-chain acyl-CoA dehydrogenase precursor 5 2 2 Fatty acid oxidation 6.28 14.11 IPI00116753.4 Etfa  Electron transfer flavoprotein subunit alpha 5 1.98 2 OXPHOS 12.97 6.11 IPI00943457.1 Pcx  Pyruvate carboxylase isoform 1 6 1.56 3 TCA cycle 18.71 29.59 IPI00323592.2 Mdh2  Malate dehydrogenase, mitochondrial 9 1.36 3 TCA cycle 3.16 14.99 IPI00331692.1 Dci  Dodecenoyl-Coenzyme A delta isomerase precursor 4 1.5 2 Lipid /fatty acid metabolism 14.63 14.83 IPI00308885.6 Hspd1   Isoform 1 of 60 kDa heat shock protein 7 1.65 3 Mito protein folding/import 4.05 1.50 IPI00755120.2 Rrbp1  Ribosome binding protein 1 isoform a 2 1.74 2 Gene translation 4.3 4.20 IPI00454008.1 Shmt2 Serine hydroxymethyltransferase 2 1.71 2 One-carbon unit metabolism 2 8.50 IPI00885646.1 Coq9 Coq9 Protein 2 2.29 2 biosythesis of CoQ 2 11.76 IPI00556699.1 Gcsh   Isoform CRA_b 1 2.54 2 Unknown 6 24.54 IPI00133034.3 Hint2  Histidine triad nucleotide-binding protein 2, mitochondrial 3 2.27 2 Undefined 3 14.00 IPI00133215.3 Ndufb7  NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 2 0.47 3 OXPHOS/ETC-Complex I 6.15 8.83 IPI00119138.1 Uqcrc2   Cytochrome b-c1 complex subunit 2, mitochondrial 3 0.47 2 OXPHOS/ETC-Complex III 3.92 7.66 IPI00133240.1 Uqcrfs1   Cytochrome b-c1 complex subunit Rieske, 2 0.61 2 OXPHOS/ETC 
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mitochondrial Complex III 2.39 4.46 IPI00120232.1 Ndufs7   NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial 1 0.59 2 OXPHO/ETC-Complex I 12.74 52.00 IPI00130322.5 Ndufa7 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 6 0.57 2 OXPHOS/ETC-Complex I 3.52 15.32 IPI00555000.2 Uqcrb Cytochrome b-c1 complex subunit 7 2 0.3 2 OXPHOS/ETC-Complex III 3.48 17.44 IPI00225390.5 Cox6b1   Cytochrome c oxidase subunit 6B1 3 0.45 2 OXPHOS/ETC-Complex IV 2 7.00 IPI00881401.1 Cpt2  Carnitine O-palmitoyltransferase precursor 2 0.37 2 Lipid metabolism, FAO 9.33 10.22 IPI00114209.1 Glud1 Glutamate dehydrogenase 1, mitochondrial 6 0.49 2 Ubiquitous--Carbon and Nitrogen metabolism 5.6 3.62 IPI00776047.1 Aifm1  Apoptosis-inducing factor, mitochondrion associated 1 3 0.65 3 apoptosis 3.53 7.60 IPI00322760.7 Prodh Proline dehydrogenase 2 0.56 2 Amino Acid metabolism 2.52 4.10 IPI00319973.3 Pgrmc1 Membrane-associated progesterone receptor component 1 2 0.56 2 Receptor for Progeserone 92.81 29.20 IPI00111908.8 Cps1  Carbamoyl-phosphate synthase [ammonia], mitochondrial 59 0.49 3 Urea cycle 10.48 18.38 IPI00133440.1 Phb   Prohibitin 6 0.56 2 Transcription activator 8.67 4.88 IPI00330747.2 Nphp3; Acad11  Acyl-CoA dehydrogenase family member 11 4 0.55 3 Unknown 3.52 9.59 IPI00125325.1 Decr2   Peroxisomal 2,4-dienoyl-CoA reductase 2 0.63 2  6.55 3.16 IPI00554845.2 Immt  Isoform 5 of Mitochondrial inner membrane protein 3 0.67 2 Undefined 8.27 25.62 IPI00623553.1   Hypothetical protein 4 0.66 3 Undefined 2.01 2.66 IPI00625588.1   Hypothetical protein 2 0.6 2 Undefined 
 
Differentially expressed mitochondrial proteins identified by iTRAQ analysis. 38 unique proteins showed significant increase in SCAD deficient mice in at least 
two replicate experiments with ≥95% confidence, corresponding to a protein score cutoff 1.3. The table details the altered proteins with unused scores 
(uniqueness of peptides used, protein confidence), gene names; accession numbers; average ratios and p-values of expression between knock-out and wild type 
mice, percent coverage of matching amino acids from identified peptides (95%) (%Cov95), number of experiments that showed significant changes, and 
biological functions described for these proteins. Averaged ratio values were calculated from 2 or 3 experiments if significant alterations (p≤0.05) were seen in 
the same direction.  Additionally, proteins in a single experiment were considered to show a significant up-regulation or down-regulation if their expression 
ratios were 1.3 or 0.7, respectively. 
Table 3   Continued  
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2.4.2 Differentially expressed proteins in SCAD deficient mice identified by iTRAQ 
experiments 
Mitochondrial membrane proteins are typically amphipathic with large hydrophobic 
domains, often leading to inconsistent iTRAQ labeling. To counter this problem, we added SDS 
to 0.1% before labeling followed by use of Rapigest after labeling to increase the solubility of 
mitochondrial membrane proteins. Two different reagents were also used to label the same 
peptide sample to better control for variation in labeling efficiency. Moreover, to minimize the 
effect of biological variance among individual mice, mitochondria from two individual mice 
were pooled together to give one mixed protein sample. Peptide samples were first fractionated 
via strong cation exchange chromatography and then separated by nano-LC. BSA was spiked 
into each step of the procedure to control for experimental processing.  
A total of 741 proteins with unused score ≥1.3 (95% CI) were identified by iTRAQ in 
three different experiments, giving an average of 247 proteins with high confidence of 
unambiguity. Only peptides with over 95% confidence were included in the quantification 
calculation for that protein using the algorithm in the ProteinPilot software. Proteins identified by 
at least 2 peptides were used for further analysis. Among the proteins that were differentially 
expressed in SCAD deficient mice, 38 proteins were classified as being increased by 1.3-fold or 
decreased by 0.7-fold in at least 2 experiments. Key identifiers are provided in Table 2. Some 
proteins identified are not recognized as being mitochondrial in location, whereas others are 
reported to localize to multiple organelles (Table 2).  
Examination of the biological functions associated with up-regulated proteins revealed 
that 5/19 (26%) of them are involved in amino acid metabolism, 2/19 (10%) are related to fatty 
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acid oxidation, and 2/19 (10%) proteins are in the TCA cycle. The down-regulated proteins 
included 7 proteins belonging to complexes of I, III and IV of the mitochondrial electron 
transport chain. Only 1 down-regulated protein was associated with fatty acid oxidation. About 
18% (7/38) were not associated with clear or defined functions.  
2.4.3 Overview of differentially expressed proteins in SCAD deficient mice  
All Differentially expressed proteins identified by combined DIGE analysis and iTRAQ 
experiments were further grouped and characterized according to their basic biological function 
annotation in UniPro/Swiss-Prot. (Figure 4A, 4B). A 1.3-fold-change cutoff was applied to 
classify proteins as up- or down-regulated. 48 proteins displayed in Table 2 and Table 3 were 
grouped into different clusters based on their functional relations. Expression of 25 proteins was 
significantly increased and 21 proteins (not counting SCAD) showed a significantly decreased 
level. Among the up-regulated proteins, 4/25 (16%) were associated with fatty acid metabolism 
and 9/25 (36%) were associated with amino acid metabolism, whereas, among down-regulated 
proteins, only 1/21 (5%) proteins was associated with fatty acid metabolism and 1/21 (5%) 
proteins was associated with amino acid metabolism. Therefore, both fatty acid metabolism and 
amino acid metabolism were generally up-regulated in response to defect in fatty acid beta-
oxidation. Several different aldehyde dehydrogenases had increased expression in both DIGE 
analysis and iTRAQ experiments (Table 2 and 3). 
Most of identified down-regulated proteins (29%) were involved in oxidative 
phosphorylation including components of complexes I, III, and IV in the electron transport chain. 
While, complex V was observed to be up-regulated by DIGE analysis, this complex was 
identified as being down-regulated in iTRAQ experiments. However, it did not meet the 
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minimum cutoff of 0.7x. Two enzymes/proteins in the TCA cycle were up-regulated but none of 
enzymes in TCA cycle were down-regulated. 
Several proteins were identified as being altered similarly in DIGE and one, but not all of 
the iTRAQ experiments. For example, ornithine transcarbamylase (OTC) was found to be 
reduced by DIGE analysis and one of the iTRAQ experiments but it didn’t meet the defined 
criterion in the second study. Thus, the two approaches appear to be complementary rather than 
providing identical information. Data derived from iTRAQ labeling was more consistent 
following strong cation exchange fractionation and LC separation. 
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Figure 4. Functional distributions of differentially expressed proteins  
(A) Proteins increased in level; (B) Proteins decreased in level. The numbers of proteins that are grouped related 
biological functions were marked.  Biological functions are as follows: fatty acid oxidation metabolism (FAO), 
amino acid metabolism (AA), lipid trasferation or lipid metabolism (LM), protein folding or import (PFI), oxidative 
phosphorylation (OXPHOS), gene translation (GT), not any of the above (others) and undefined. 
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2.4.4 Western blot analysis  
It is important to validate DIGE and mass spectrometry data by independent techniques 
when possible. To provide further support of the previous findings, three proteins of high 
biological interest were selected to validate by western blotting. Not surprisingly, SCAD was 
almost absent in western blot analysis and was 3-4 fold reduced on DIGE gels  and one of 
iTRAQ experiments (Figure 5C). As was seen in the proteomic experiments, expression of 
complex III, cyctochrome b-c1 subunit 2 (uqcrc2) differed between deficient mice and wild type 
mice (Figure 5A), though the difference was less dramatic than was seen with iTRAQ (Table 3). 
Similarly, the expression of sterol carrier protein 2 was increased in SCAD deficient mice, 
though the change was less than appeared by DIGE analysis (Figure 5B). HSP60 (heat shock 
protein 60) appeared unchanged by western blot analysis (Figure 5E) but at least one isoform 
was identified as being significantly altered in the proteomic experiments. The level of the 
housekeeping protein succinate dehydrogenase (complex II) was constant in both western blot 
and proteomic analysis (Figure 5C). 
 
 
 
Figure 5. Western blot analysis  
A, cytochrome b-c1 complex subunit 2 using anti-UQCR2 antibody; B, sterol carrier protein 2 using anti-SCP2 
antibody; C, succinate dehydrogenase (complex II) using anti-SDH antibody; D, SCAD using anti-SCAD antibody, 
and E, heat shock protein 60 using anti-HSP60 antibody. Mitochondria proteins were isolated from SCAD deficient 
(-/-) and wild type (+/+) mouse livers. Samples were run on 10% polyacrylaminde, tris-bis gels. 
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2.4.5 Ingenuity pathway and Gene Ontology Analysis 
IPA was next used to classify changed proteins into different functional groups 
(Appendix A for definitions in IPA) and identify cellular activities and related pathways that 
were altered due to SCAD deficiency. Of the identified 48 proteins with differential changes, 20 
could be inputted for network analysis and 37 could be used for canonical pathway analysis. The 
remainder of the differentially expressed proteins could not be included in the analysis due to the 
lack of the information in current literature, or inadequate identification. The proteins that were 
classified into the top 5 molecular and cellular functional groups are shown in (Table 4). 
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Table 4. Top 5 significant molecular and cellular functions associated with altered proteins 
in SCAD deficient mice 
Name p-value # Molecules 
Molecular and Cellular Functions 
Free radical scavenging 2.2 E-5 —2.2E-5 4 
Cell death 7.22 E-5 —3.27 E-2 8 
Amino acid metabolism 3.22 E-4—2.73 E-3 2 
Small molecule biochemistry 3.22 E-4—4.84 E-2 1 
Carbohydrate metabolism 2.73 E-3—2.16 E-2 4 
 
Physiological System Development and Function 
Cardiovascular system development and function 2.81 E-3 —2.43E-2 2 
Organismal development 2.81 E-3 —2.43 E-2 2 
Tissue morphology 2.81 E-3—2.40 E-2 2 
Reproductive system development and function 5.46 E-3—8.17 E-3 2 
Embryonic development 8.17 E-3—8.17 E-3 1 
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Figure 6. Top-rated network of lipid metabolism, molecular transport in SCADD mice 
The network of “lipid metabolism, molecular transport” associated with altered proteins in SCAD deficient mice 
was generated and scored as the top-rated network by IPA. Red nodes indicate that the protein is up regulated in 
SCAD deficient mice. Proteins colored green indicate that the protein is down-regulated. The color intensity 
corresponds to the degree of abundance. Proteins in white are those identified through the Ingenuity Pathways 
Knowledge Base. The shapes denote the molecular class of the protein. A solid line indicates a direct molecular 
interaction, and a dashed line indicates an indirect molecular interaction. A full explanation of lines and 
relationships is provided in Appendix B. 
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Five protein networks (score >2) containing a total of 20 proteins were generated. Figure 
6 shows the most significant network with a score of 32. This network, named “lipid metabolism, 
molecular transport and small molecules biochemistry”, was composed of 16 proteins identified 
experimentally and 19 proteins known from the Ingenuity Pathways Analysis database to interact 
with them. 5 down-regulated and 8 down-regulated proteins in this group with the greatest 
changes were enzymes. Two transporters were shown to be up-regulated. This network is linked 
by several transcription regulators described in the literature including HNF1A, STAT3 and HTT, 
as well as the transporters SLCO1A1, SCARB1 and LDLR. The transmembrane transporter H+ 
transporting ATPase (Complex V) in the oxidative phosphorylation pathway, which also has the 
functions of “protein, nucleotide and ATP binding“, also function in this group, suggesting an 
up-regulation of ATPase activity in mitochondrial function. SCP2, a non-specific lipid transfer 
protein with multiple functions of protein and lipid binding, and as a sterol carrier, was up 
regulated in SCAD deficient mice in the DIGE analysis. Similarly, HPSD1 with the activity in 
the ubiquitination pathway and functions in unfolded protein and chaperone binding was also 
implicated as being up regulated. 
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Table 5. Top 5 Significant diseases and disorders associated with changed proteins 
 
Diseases and Disorders p-value # Molecules 
Neurologic Disease 3.05 E-6—4.28 E-2 6 
Metabolic Disease 1.87 E-4 — 2.43 E-2 18 
Endocrine System Disorders 2.73 E-3 — 2.43 E-2 2 
Genetic Disorders 2.73 E-3 — 4.02 E-3 26 
Hematologic Disease 2.73 E-3 — 2.73 E-3 1 
 
 
A number of proteins could be further grouped according to the diseases with which they 
have been associated (Table 5). The largest number of altered proteins (18/37) have previously 
been associated with metabolic diseases, including 8 down-regulated proteins (encoded by 
ABAT, AIFM1, CPS1, CPT2, GLUD1, IMMT, OTC and PRODH) and 9 up-regulated proteins. 
Six proteins encoded by NDUFS7, GLUD1, MDH2, OTC, ABAT and HSPD1 have previously 
been associated with neurologic disease. Specifically, abnormalities in NDUFS7 are seen Leigh 
syndrome in human, and GlUD1, MDH2 and OTC are reported altered in Reye syndrome 
(Deshmukh et al, 1985; Holt et al, 1983; Mitchell et al, 1985) Reye syndrome is a fatal disease of 
unknown cause with symptoms that overlap many disorders of energy metabolism. It is 
characterized by acute encephalopathy and hepatic failure presenting with confusion, behavioral 
changes, seizures and loss of consciousness. Patients show multi-organs involvement, especially 
the brain and liver. Glutamate dehydrogenase, malate dehydrogenase, medium chain acyl-CoA 
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dehydrogenase, and ornithine carbamoyltransferase deficiencies (among many others) have been 
documented in patients with Reye-like symptoms (Deshmukh & Remington, 1984; Deshmukh et 
al, 1985; Holt et al, 1983; Lai et al, 1994; Mitchell et al, 1980). 
Two enzymes known to be altered in other metabolic disorders were decreased in SCAD 
deficient mice: carbamylphosphate synthetase 1, an enzyme in the urea cycle that catalyzes the 
reaction of ATP and bicarbonate to produce carbonylphosphate and ADP, and 4-aminobutyrate 
transaminase, an enzyme that catalyzes the conversion of 4-aminobutanoic acid (GABA) and 2-
oxoglutarate into succinic semialldehyde and glutarate in mitochondria. Additionally, 4-
aminobutyrate aminotransferase (ABAT) abnormalities are reported in spinal muscular atrophy 
and other neurological diseases. This enzyme metabolizes gamma-aminobutyric acid (GABA), 
an important, mostly inhibitory neurotransmitter in the central nervous system) into succinic 
semialdehyde. Patients with ABAT deficiency show psychomotor retardation, hypotonia, 
hyperreflexia, lethargy, refractory seizures, and electroencephalogram (EEG) 
abnormalities(Gibson et al, 1985; Medina-Kauwe et al, 1999). 
 
Table 6. Top-rated canonical pathways and functions associated with changed proteins 
 
Pathway p-value Ratio 
Valine, leucine, and isoleucine degradation 6.23 E-12 8/65 (0.123) 
Mitochondrial dysfunction 1.7 E-11 9/117 (0.077) 
Arginine and proline metabolism 2.04 E-11 8/75 (0.107) 
Fatty Acid Metabolism 1.29 E-9 8/125 (0.063) 
ß-alanine metabolism 3.49 E-9 6/49 (0.122) 
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Figure 7. The most significantly affected pathways in SCAD deficient mice 
The Canonical Pathways that are associated with changed proteins are displayed along the x-axis. The y-axis displays the percentage which is calculated as 
follows:   number of genes in a given pathway that meet cutoff criteria, divided by total number of genes that make up that pathway. The orange dotted line 
displays the Significance of –log (p-value) (P≤0.05, Fisher’s exact test). Red denotes the gene/protein that is up-regulated, green denotes the gene/protein that is 
down-regulated. 
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Ingenuity Pathways Analysis highlighted several canonical pathways as being affected in 
SCAD deficient mice. The most affected canonical pathway was that of “branched chain amino 
acid metabolism and mitochondrial dysfunction (Figure 7, Table 6). A total of 8 changed 
proteins were mapped to branched chain amino acid metabolism“ with coverage of 12.3% 
molecules (8 of possible 65 molecules, p≤0.05) in this pathway. Besides SCAD, only one protein 
encoded by ABAT was reduced, while the other 6 proteins were increased (1.62-2.60 fold). Nine 
proteins were involved in “mitochondrial dysfunction“, comprising 7.7% of all molecules in this 
pathway (p≤0.05; Table 6). The other two top-related canonical pathways were involved in 
amino acid metabolism and fatty acid metabolism, the latter of which included all altered 
proteins in the OXPHOS pathway.  
To further explore the connections of significant networks, the network was reconstructed 
by merging the three top-rated networks overlaid with the canonical pathways involved (Figure 
8). This analysis suggests that reduced proteins were mostly involved in the urea cycle and 
oxidative phosphorylation. Three of the up-regulated proteins were involved in pyruvate 
metabolism. The highest proportion of changed proteins was in the mitochondrial dysfunction 
and branched chain amino acid metabolism pathways.  
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Figure 8. Merged networks overlay with pathways identified from SCADD mice 
Proteins colored in green indicate decreased expression in SCAD deficient mice. Proteins colored in red indicate 
increased expression. The color intensity corresponds to the degree of abundance. Proteins in white are those 
identified through the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. A 
solid line indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction. The 
CP (canonical pathway) in ovals denotes the significant pathways identified. A full explanation of lines and 
relationships is provided in Appendix B (Software legend). 
 
 
Among the 9 proteins involved in mitochondrial dysfunction, 7 proteins were down-
regulated in SCAD deficient mice (Table 3, Figure 4, Figure 7), 6 of which were involved in 
OXPHOS. Most of the proteins associated with the fatty acid oxidation pathway were increased 
in SCAD deficient mice except for carnitine palmitoyltransferase II (CPT2), which was less 
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abundant. Transcription regulators such as HNF1A, STAT3, SREBF2 and HTT, and transporters 
such as ATP5A, FABP1 and SCARB1 link these pathways as illustrated in Figure 8. The nuclear 
receptor PPARA also participates in the regulation of both networks. Although these regulators 
were not identified as significantly altered in all experiments, smaller changes in their levels may 
play important roles in determining the pattern of protein abnormalities seen in SCAD 
deficiency. For example, ACADS is connected to CPS1 through PPARA and LEP. Such 
unidentified changes may also be important in the development of pathophysiologic changes and 
symptoms. 
 
 
 
 
Figure 9. Hepatotoxicity of changed proteins 
The prediction of clinically relevant pathologies associated with altered proteins in SCAD deficiency. Y-axis 
displays the significance of association (p≤0.05). 
 
 
 
  51 
 
 
Figure 10. The “toxicity” of altered proteins in SCAD deficient mice  
This bar chart shows the significance of altered proteins associated with the Ingenuity Tox Lists of molecules that 
are known to be involved in a particular type of toxicity. The left Y-axis displays the significance and corresponds to 
the height of the bars; the right Y-axis displays the ratio and corresponds to the dotted line. 
 
To help characterize the clinically relevant secondary changes associated with SCAD 
gene deficiency and provide additional insight into the pathologic alterations induced by SCAD 
gene deficiency, the toxicity analysis function in the IPA software was utilized. In this analysis, 
SCAD deficiency was essentially defined as a “toxin”, secondary changes identified in the 
proteome was assessed and assigned to functional pathways as with more traditional small 
molecule studies. The results largely identified a pattern associated with hepatotoxicity and 
significant toxicity on implicated in mitochondrial dysfunction, fatty acid metabolism, decrease 
of depolarization of mitochondria and mitochondrial membrane and swelling of mitochondria 
involving 5 down-regulated proteins (Figure 9, 10). The analytical tool does not provide 
parameters to assess specific impacts on skeletal muscle, thus, the toxicity changes on skeletal 
muscles were not identifiable.  
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Table 7. Candidate biomarkers identified in differentially expressed proteins  
Gene 
Symbol Entrez Gene Name Family 
GenPept/IPI/Un
iProt/Swiss-
Prot Accession 
Fold 
Change 
ACAA2 acetyl-CoA acyltransferase 2 enzyme IPI00653158.1 2.600 
ACADL 
acyl-CoA dehydrogenase, long 
chain enzyme IPI00894588.1 2.000 
ACADS 
acyl-CoA dehydrogenase, C-2 to 
C-3 short chain enzyme Q91W85 -3.580 
ALDH2 
aldehyde dehydrogenase 2 family 
(mitochondrial) enzyme IPI00111218.1 3.110 
CPT2 carnitine palmitoyltransferase 2 enzyme IPI00881401.1 -2.703 
EPHX1 
epoxide hydrolase 1, microsomal 
(xenobiotic) peptidase Q9D379 1.500 
GLUD1 glutamate dehydrogenase 1 enzyme IPI00114209.1 -2.041 
PC pyruvate carboxylase enzyme IPI00943457.1 1.560 
 
One goal of proteomic analysis is to identify biomarkers that identify disease or predict 
the development of symptoms. Biomarker analysis by IPA identifies and prioritizes the most 
relevant and promising molecular biomarker candidates from the differentially expressed 
proteins. The Biomarker filter to explore molecular biomarker candidates was selected to focus 
on contextual information related to human and mouse genes associated with diseases shown to 
be significantly altered in SCAD deficient mice. 7 candidate markers that have been associated 
with related diseases (Table 7) were identified. Five of them were up regulated. ACAA2 encoding 
protein is involved in fatty acid elongation and valine, leucine and isoleucine degradation. It is 
associated with non-insulin dependent diabetes mellitus and microvesicular hepatic steatosis. 
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Proteins encoded by ACADL and CPT2 were identified as potential biomarkers but with changes 
in opposite directions. GLUD1 is associated with Reye’s syndrome and hyperinsulinism-
hyperammonemia disorders. To magnify the filter findings, the analysis was filtered for all body 
fluids where a biomarker has been used in the diagnosis, efficacy, prognosis, progression, 
response or safety as well as identification of a specific disease. However, when applying more 
restricted filter parameters on human or mouse and including only tissue specificity of liver did, 
the analysis did not identify any additional biomarker candidates.  
2.5 DISCUSSION  
 
A wide array of symptoms has been in reported in patients affected with SCAD 
deficiency, but the vast majority of infants identified through newborn screening remain well. 
The clinical and physiologic ramifications of SCAD deficiency are unknown. The purpose of this 
study was to gain insight into the pathophysiology of this condition and to identify biomarkers 
that predict the development of symptoms by surveying changes in the mitochondrial proteome 
of SCAD deficient mice. Proteomic changes in liver mitochondria from SCAD deficient mice 
were first profiled. These experiments revealed a broad mitochondrial dysfunction beyond fatty 
acid oxidation induced by SCAD deficiency. Multiple energy related metabolism pathways were 
altered, indicating that a more complex mechanism for development of symptoms may exist. 
This finding differentiates SCAD from other fatty acid beta-oxidation disorders such as very 
long chain and medium chain acyl-CoA dehydrogenase deficiency in spite of the fact that they 
are caused by the genes within the same ACAD family.  
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While only limited data are available on the secondary effects of fatty acid oxidation 
defects on the proteome, the primary symptoms in most of these disorders can be viewed as a 
direct manifestation of the energy deficit caused by interruption of fatty acid oxidation. 
Specifically, patients experience stress or fasting induced hypoglycemia with or without 
rhabdomyolysis and may have long term skeletal or cardiomyopathy. The severity of SCADD 
varies from asymptomatic in most individuals, to rare life threatening metabolic crises in some of 
them, but rarely includes the more common symptoms seen in the longer chain defects. The 
diverse changes in energy metabolism in SCAD deficiency may, in part, explain these 
heterogeneous symptoms. The diversity of other pathways altered in SCAD deficient mice 
suggests that differential compensatory or secondary deleterious effects may play the dominant 
role in determining the pathophysiology of this deficiency. Up regulated amino acid catabolism 
and TCA cycle enzymes imply that short chain fatty acids are less available to produce energy, 
and that the mice compensate by generating energy from other sources. While these 
compensatory changes may overcome the primary deleterious effects of impaired energy 
production in SCAD deficiency, it provides opportunities for variable expression of other genes 
to impact phenotypes leading to the less severe symptoms in most patients with this deficiency. 
A decrease of almost all complexes in electron transport chain implies that less efficient 
fatty acid oxidation is magnified by a secondary defect in oxidative phosphorylation, thus further 
impairing ATP production. Deficiency of the respiratory chain complexes is a common cause of 
Leigh syndrome, a rare neurometabolic condition presenting with seizures, hypotonia, fatigue, 
nystagmus, poor motor function and ataxia (DiMauro and Schon 2003;(de Lonlay et al, 2001; 
Lebon et al, 2007; Tiranti et al, 1999; Triepels et al, 1999). In addition to one subunit of NADH 
dehydrogenase (iron-sulfur protein 7) previously implicated in the pathogenesis of Leigh 
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syndrome, reduction of 5 subunits of other respiratory chain complexes and UGRCB encoding 
complex III binding protein (cytochrome b-c1 complex subunit 7), which is also part of the 
ubiquinol-cytochrome c oxidoreductase complex, was also demonstrated. Mutations in this gene 
are associated with mitochondrial complex III deficiency. This correlation between fatty acid 
oxidation and oxidative phosphorylation is consistent with the recognition that many patients 
with respiratory chain complex deficiencies accumulate metabolites suggestive of fatty acid beta-
oxidation dysfunction, and the recent description of a multi-functional enzyme complex 
encompassing all the activities of fatty acid oxidation and the respiratory chain (Schuck et al, 
2009);(Wang et al, 2010) In addition, mutations in ACAD9, another member of the ACAD gene 
family can lead to either a fatty acid oxidation defect of deficiency of respiratory chain complex I 
deficiency (He et al, 2007) Sauer et al, 2008; (Bortolami et al, 2008; Gianazza et al, 2006; Haack 
et al, 2010; Sauer et al, 2008; Wang et al, 2010). Thus, to understand SCAD deficiency, it 
becomes necessary to consider other energy pathways as well. 
Various proteins related to other metabolic pathways were also altered in SCADD mice. 
These include carbamylphosphate synthase I (CPS1), carnitine palmitoyltransferase II (CPT2), 
pyroline-5-carboxylate reductase (ALDH4A1), fumarase (FH), ornithine carbamoyltransferase 
(OTC), and pyruvate carboxylase (PC), as well as the enzymes implicated in glutaric aciduria 
(ETFA), hyperinsulinism-hyperammonemia syndrome (GLUD1), hyperprolinemia 1(PRODH), 
and hypolipidemia of mice (SCP2). While the physiologic cause of these changes and their effect 
on cellular metabolism are unknown, they underscore the complexity of secondary alterations 
that must be taken into account to fully understand the physiologic effects of a single gene defect 
such as SCADD. 
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It has also been noted that most symptomatic patients have presented with predominantly 
neurologic manifestations, which are rarely seen in the other ACAD defects. Disease association 
analysis identified additional genes involved in neurological disease as being altered in SCAD 
deficient mice. For example, 4-aminobutyrate aminotransferase encoded by ABAT, also named 
GABA transferase, is an enzyme that catalyzes the conversion of 4-aminobutanoic acid (GABA), 
an inhibitory neurotransmitter, and 2-oxoglutarate into succinic semialdehyde and glutamate. 
The phenotype of GABA-transferase deficiency includes psychomotor retardation, hypotonia, 
hyperreflexia, lethargy and refractory seizures (Medina-Kauwe et al, 1999). It is also interesting 
to note that SCADD deficient mice have very abnormal EEGs, though overt seizures are not 
seen. Further assessment of GABA metabolism in SCAD deficient patients may provide further 
insight into the role of this pathway in the development of clinical symptoms. The most frequent 
clinical findings reported in SCAD deficiency in humans are hypotonia and developmental 
delay. Many disorders with prominent neurologic symptoms, including Parkinson disease, cystic 
fibrosis, alpha 1-antitrypsinogin deficiency, and spinal cerebellar atrophies, share a common 
cellular pathology related to abnormal protein folding, aggregation, and eventual cellular 
damage. Point mutations in the ACADS gene are predominate in SCADD in humans. Many of 
these point mutations have been demonstrated to lead to abnormal protein folding and 
degradation but the physiologic relevance of these findings remains unclear. Alteration of 
proteins in the neurologic disease category in SCADD mice and the heat shock protein HSP60 
(HSPD1) provide further impetus to better characterize these changes and their role in the 
development of symptoms in humans.  
Network analysis revealed that components of the most highly altered network in 
SCADD mice are linked by several transcription regulators and transporters. In addition, several 
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transporters, including transmembrane transporter ATP5A1 and heat shock protein HSP60 
(HSPD1), functioning in protein and ATP binding and protein folding in mitochondria were 
identified as altered. These findings highlight yet an additional level of secondary cellular 
response resulting from SCAD deficiency. While alterations in other transporters or transcription 
regulators were not seen, it is important to realize that most are of very low abundance in the cell 
and present in other cellular locations than mitochondria. They therefore are not likely to be 
identified in the current experiments. However, their potential importance is highlighted by 
identification of factors such as PPARA, HNF1A, STAT3 and HTT and transporters SLCO1A1, 
SCARB1 and LDLR that serve as hubs in networks encompassing many of the proteins/enzymes 
altered in SCAD deficiency. Further studies will be necessary to elucidate their role in 
mitochondrial dysfunctions. 
One goal of the current study was to identify biomarkers to distinguish asymptomatic 
SCAD deficiency from individuals at risk to develop symptoms that thus can serve as potential 
markers for adjunct diagnosis and monitoring of therapy. To examine this question, biomarker 
analysis was performed with filtering for all body fluids and all tissues but excluding cell lines, 
and including known diseases in humans and mice. These analyses identify ACADL and CPT2 as 
candidate biomarkers. Both are of interest due to their role in fatty acid oxidation and that they 
are significantly changed in SCAD deficiency mice, though in opposite directions. In addition, 
GLUD1, linked with Reye’s syndrome and hyperinsulinism-hyperammonemia is also of interest. 
Future studies are necessary to determine if these markers are better than the current biochemical 
markers (urinary EMA and butyrylglycine and plasma butyrylcarnitine) that provide a sensitive 
means of diagnosing SCAD deficiency, but not determining its severity.  
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Animal models of inborn errors of metabolism provide an ideal system to explore the 
potential biological relevance of specific markers, eliminating the diverse effects introduced by a 
heterogeneous genetic background. This study is the first large scale quantitative proteomics 
profiling of SCAD deficient animals. Historically, a combination of histopathology and clinical 
chemistry has been used to estimate the toxicity of a specific treatment, and differentiating toxic 
effects of treatment from disease-associated changes was problematic. Nucleotide array profiling 
is helpful to identify global expression changes that correlate with clinical pathology and to 
generate a hypothesis as to the causes of cellular toxicity. I have applied the traditional 
pharmacologic approach of molecular toxicity analysis to evaluate the clinically relevant toxic 
effects as defined by changes in the proteome in SCAD deficient mice that reflect pathologic 
processes in the animals. In these analyses, I treated the presence of SCAD deficiency essentially 
as a pharmacologic agent, and queried the analytical software for evidence of “treatment” 
toxicity. The result revealed that these changes were majorly correlated with hepatotoxicity 
which involved changed gene/proteins resulting in abnormalities in mitochondrial dysfunction, 
fatty acid metabolism, decrease of depolarization of mitochondria and mitochondrial membrane 
and swelling of mitochondria. The toxicity analysis revealed a change in one protein linked to 
oxidative stress (but without a known role) making this an unlikely mechanism of cellular 
toxicity. A previous report of proteomic screening of SCAD deficient human fibroblasts found 
that the level of superoxide dismutase 2 was reduced, a finding of unknown significance 
(Pedersen et al, 2010; Zolkipli et al, 2011). In contrast, eight proteins with altered levels were 
involved in toxicity related to mitochondrial dysfunction and eight were linked to the toxicity of 
fatty acid metabolism. Thus, it appears that the major toxicity arising from SCAD deficiency 
relates more directly to mitochondrial dysfunction and alteration of fatty acid metabolism. Such a 
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toxicity analysis approach should be of general use in studying the pathophysiologic effects of 
single gene mutations in genetic models of disease.  
The novelty of this study lies in the application of proteomic approaches to identify 
alterations in molecular pathways induced by SCAD deficiency, and provides additional insight 
into the fundamental pathophysiology of this condition. Variability of symptoms in humans with 
SCAD deficiency suggests that this autosomal recessive genetic disorder behaves more as a 
polygenic disorder than as a traditional monogenetic trait. Additional study of the primary 
deficiency on other genetic backgrounds will help provide insight into the other critical genes 
that affect the biochemical and clinical phenotype in this disorder. Multiple experimental details 
provide robustness to the final conclusions. Replicate experiments and complementary proteomic 
approaches serve to provide confidence in the changes seen, as does verification by western 
blotting. Use of multiple separation and sample preparation techniques also increases the ability 
to identify disease specific markers within a complex proteome containing thousands of proteins. 
Of the two methods used, iTRAQ labeling proved to be more sensitive and more robust at 
generating data for statistical comparisons. However, protein changes could be independently 
confirmed by western blotting and DIGE. Liver is a mitotic tissue with a high rate of cell 
division and thus, typically, rapid protein turnover and a high level of innate variation in protein 
abundance. The range of biological variation that can be tolerated by the cell depends on the 
individual protein. Such inherent biological variations cannot be eliminated completely, 
however, their effects on experimental outcome can be minimized by analyzing multiple samples 
in each genotypic group and pooling of samples. The proteomic analysis in this study evaluated 
both proteins encoded in the nuclear genome and imported into mitochondria as well as those 
encoded on the mitochondrial chromosome. Thus, the changes identified in mutant mice reflect a 
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compilation of all dynamic changes including gene expression as well as protein modification 
and the processes of mitochondrial targeting, import, and protein folding. It is important to note 
that a protein must be relatively abundant to be detected by the techniques used in this study, 
although additional changes can be underrated by network analysis. 
In conclusion, changes in the mitochondrial proteome in animals with SCAD deficiency 
were first identified and quantitated. The secondarily changed proteins implicate a complicated 
process of cellular toxicity with multiply altered metabolic pathways and disease associated 
networks. Additionally, these pathways converge on disorders with neurologic symptoms, 
suggesting that even asymptomatic individuals with SCAD deficiency may be at risk to develop 
more severe disease. Several candidate biomarkers that can serve as potential markers for adjunct 
diagnosis and monitoring of therapy were then proposed. Further studies will allow delineation 
of changes in the proteome that can serve as biomarker(s) for the development of symptoms, and 
provide opportunities to develop therapies based on the recognition of new cellular protein 
interactions. 
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3.0  PROTEOMIC STUDY ON VERY LONG CHAIN ACYLCOA 
DEHYDROGENASE DEFICIENT MOUSE 
3.1 ABSTRACT 
Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency identified through 
newborn screening is a clinically heterogeneous fatty acid ß-oxidation disorder without clear 
genotype-phenotype correlations. Acute symptoms are often induced by physiological stress 
such as illness and fasting. The pathophysiologic mechanisms underlying disease symptoms and 
phenotypic heterogeneity remain unclear. The interaction between the genetic and environment 
factors is typically measured in epidemiologic studies on individuals with a specific genetic 
susceptible to the exposure. However, ascertaining reproducible cellular changes in an individual 
at risk due to environmental effects remains a challenge. The objective of this study was to better 
understand the mechanism of molecular changes at a global level and to explore the 
environmental effects on the gene products and the relevant biological pathways that interact. 
The mitochondrial proteome of VLCAD deficient mice was quantitatively compared to wild type 
mice in fed and fasted states. Isobaric tags for relative and absolute quantification (iTRAQ) 
labeling followed by nano-LC/LTQ-Orbitrap mass spectrometry were employed to identify the 
changes in both deficient and wild type groups and the differences in response to fasting. The 
affected pathways and clinical relevance associated with altered proteins were evaluated using 
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Ingenuity Pathway Analysis. Numerous proteomic changes associated with gene deficiency and 
fasting as well as gene-gene interactions within relevant pathways were identified. Most of 
changes induced by fasting were different in deficient mice as compared to wild type mice and 
few changes induced by fasting were shared in the mutant and wild type mice. The pattern of 
changes in chaperone proteins including HSP60 and HSP10 upon fasting was different in them. 
Fasting altered the compensatory increase in oxidative phosphorylation in fed deficient mice. 
Secondary changes in fasted deficient mice were involved in cardiac dysfunction. Fasting 
induced different proteomic changes in deficient mice indicating differences in the interactions 
of genes and gene-environment, and important roles of these interactions in the pathogenesis of 
VLCAD deficiency. Particularly, fasting in mutants reversed the protective response in oxidative 
phosphorylation pathway induced by genetic deficiency alone. Global survey of fasting effects 
on a genetic mouse model presents an approach to explore gene-environment interaction and 
their contribution to gene-gene interactions. Future characterization of functional interactive 
genes and association studies in humans will provide further insight into disease mechanism and 
guidance in therapy.  
3.2 INTRODUCTION 
Mitochondrial fatty acid ß-oxidation plays a major role in energy production in the body, 
especially during fasting conditions. At least 25 enzymes and transport proteins are involved in 
mitochondrial FAO, which is predominantly responsible for the oxidation of fatty acids of 
carbon chain length 20 or less. Fatty acids are transferred across the mitochondrial membrane as 
carnitine esters by carnitinepalmitoyl transferase 1 and 2 in conjunction with the carnitine-
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acylcarnitine translocase. The four reactions of the ß-oxidation cycle, catalyzed by four 
enzymatic activities [acyl-CoA dehydrogenase (ACAD), enoyl-CoA hydratase, L-3-
hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase], sequentially remove two 
carbons until the acyl-CoA is converted to acetyl-CoA molecules. Electrons are transferred to 
respiratory chain through complex I of the electron transfer chain or directly to coenzyme Q 
(ubiquinone) by electron transfer flavoprotein (ETF). Very long-chain acyl-CoA dehydrogenase 
(VLCAD) is the initial enzyme involved in mitochondrial fatty acid -oxidation, fueling hepatic 
ketogenesis during periods of high energy demand after hepatic glycogen stores have been 
depleted. VLCAD is a member of the ACAD enzyme family, which currently has eleven known 
members. The ACADs catalyze the rate-limiting step in the mitochondrial β-oxidation of 
activated fatty acids and branched-chain amino acids. Each possesses a characteristic pattern of 
substrate utilization but these partially overlap for some enzymes. VLCAD appears to be the 
major ACD responsible for the catalysis of acyl-CoAs 16 to 20 carbons in length in human liver, 
heart, and muscle. 
VLCAD deficiency (VLCADD) is an autosomal inborn error resulting from mutations in 
the ACADVL gene that impair enzyme expression or function. Patients with VLCAD deficiency 
present with a broad spectrum of clinical symptoms ranging from lethal hypoketotic 
hypoglycemia, hepatomegaly, and cardiomyopathy in infancy to episodic rhabdomyolysis in 
adolescents and adults. The underlying mechanisms leading to heterogeneous manifestations in 
these patients at different periods of ages still remain unknown. Acylcarnitine analysis of dried 
blood spots by electrospray ionization tandem mass spectrometry (MS/MS) allows pre-
symptomatic identification of VLCAD deficiency in newborns. However, some children may 
escape detection and present with later onset symptoms (Boneh et al, 2006; Ficicioglu et al, 
  64 
2010). In addition, as some asymptomatic newborns may develop rhabdomyolysis after 
excessive physical exercise at an older age, it is still unknown whether those individuals may 
remain asymptomatic throughout their life-time (Spiekerkoetter et al, 2009a). The observed acute 
symptoms are often induced by physiological stress or by conditions such as fasting or endurance 
exercise that fatty acid oxidation, through mechanisms that are not well understood. The 
pathophysiologic and molecular mechanism underlying stress-induced symptoms and the clinical 
heterogeneity in this disease is unknown.  
Numerous mutations have been reported in VLCADD patients. They include null, 
missense, frameshift, and splice consensus sequence mutations as well as in-frame deletions 
(Andresen et al, 1996a; Andresen et al, 1996b; Mathur et al, 1999). A genotype-phenotype 
correlation was described on the basis of clinical phenotype in 55 unrelated VLCAD deficient 
patients with known mutations. Children with the severe phenotype tended to have null 
mutations while patients with the two milder forms of the disease were more likely to have 
missense mutations(Andresen et al, 1999). Nevertheless, a few missense mutations were clearly 
associated with the severe phenotype(Coughlin & Ficicioglu, 2010).Genotype alone remains 
limited in its predictive ability to determine the phenotype. The clear correlations between 
genotype and phenotypes have not been well established.  
Clinical diagnosis of VLCAD deficiency relies on tandem mass spectrometry to identify 
elevations of the hallmark metabolites in blood (C14: 1, C12: 1, 14:2, 16:2, and C18:1 carnitines) 
followed by molecular analysis of the ACADVL gene. Urine dicarboxylic aciduria may be 
present during acute illness but is typically normal otherwise. Additional diagnostic tools include 
assay of enzyme activity and functional measurements of whole cell fatty acid ß-oxidation in 
fibroblasts or lymphocytes. As with most enzyme disorders, the level of residual enzyme activity 
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correlates with the severity of the clinical phenotype, but the relationship is inexact (Andresen et 
al, 1999; Gregersen et al, 2001). The genetic and pathophysiological basis for this variation is not 
known. 
The severe episodes of metabolic crisis or sudden death in patients with fatty acid ß-
oxidation disorders were usually induced by the physiologic stressor, fasting, in adolescence or 
early childhood. The fasting was the most important inducer in the episodes of metabolic crisis 
and sudden death in VLCAD deficient individuals. During fasting, glucose supplies become 
limited. Under this condition, the liver converts fatty acids into ketone bodies, which serve as an 
additional energy source for all tissues but are of particular importance in brain, heart, and 
skeletal muscle. Therapy of VLCAD deficiency focuses on avoiding the stressors that induce 
catabolism and provide alternative fuel sources that can bypass the metabolic block. These 
efforts include avoidance of fasting, and addition of medium chain fats as a dietary supplement 
(Brown-Harrison et al, 1996; Cox et al, 1998a). It is noteworthy, however, that there are no 
formal studies evaluating the effectiveness of any of these therapies (Spiekerkoetter et al, 2009a; 
Spiekerkoetter et al, 2009b), and in spite of them, 10–20% or more of treated patients still have 
episodic rhabdomyolysis (Wilcken, 2010). The heterogeneous biochemical abnormalities and the 
variable outcomes in treated patients suggest that secondary abnormalities in pathways other than 
fatty acid oxidation, as well as other genetic and environmental factors, play roles in the 
pathophysiology of this disorder. However, the full scope of biological changes induced by 
VLCAD deficiency with or without fasting has been impossible to characterize directly in 
patients. 
Mouse models of human inborn errors of metabolism offer an excellent opportunity to 
explore more complicated questions than is often possible in patients with these disorders. Two 
  66 
independently VLCAD-deficient mouse models have been developed and characterized (Cox et 
al, 2001b; Exil et al, 2003). Both animals exhibit metabolic and biochemical abnormalities 
resembling the human deficiency and have been used to study the stress-induced metabolic 
changes that occur in VLCAD deficiency (Spiekerkoetter and Wood). The ACADVL gene maps 
to mouse chromosome 11 and has a similar gene structure to that of the human locus (Cox et al, 
1998b). However, some key differences are seen in biochemical abnormalities in mouse models. 
In human VLCADD, C14:0 and C14:1 acylcarnitines accumulate predominantly, whereas in 
VLCAD-deficient mice, the C16 and C18:1 species are the “signature” acylcarnitines 
(Spiekerkoetter et al, 2004). VLCAD deficient mice with the genetic background of 
C57BL/6+129svJ have lower concentrations of free carnitine and elevated C14-C18 
acylcarnitines in blood, similar to the metabolite patterns seen in humans with VLCADD (Exil et 
al, 2003). Fasting and cold exposure result in severe hypoglycemia, hypothermia, skeletal 
myopathy and death in one third of VLCAD-deficient mice resembling human VLCADD 
(Spiekerkoetter et al, 2004). Additional studies have documented the development of 
hepatosteatosis in response to fasting with death after prolonged fasting (Cox et al, 2001b). 
Long-term supplementation of VLCAD deficient mice medium chain triglyceride (MCT) oil also 
induces severe hepatosteatosis (Tucci et al, 2010). However, the broader impact of fasting on the 
mouse transcriptome and proteome has not been examined.  
To help understand the underlying mechanism leading to heterogeneous phenotypes and 
response to environmental factors that may involve in the disease manifestation, systematic study 
of the accumulated biological effects of the primary metabolic deficiency is needed. Currently 
available proteomics approaches allow measuring biological changes at a global scale induced by 
mutations and fasting in disease models. A discovery approach with mass spectrometry based on 
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differential detection of proteins by labeling amino acid residue in tryptic peptides offers the 
potential to measure all protein changes directly in subcellular compartments. Isobaric tags for 
relative and absolute quantification (iTRAQ) analysis have recently come into general use in 
quantitative proteomics (Ross et al, 2004; Wiese et al, 2007). iTRAQ reagents are a set of 
multiplexed, amine-specific, stable isotope reagents that can label N-terminus residue of lysine 
of all peptides in up to eight different biological samples enabling simultaneous identification 
and quantitation of different samples that can be compared in one experiment. The labeled 
peptides are identical in mass and hence identical in single MS mode, but each produces strong, 
diagnostic, low mass MS/MS signature ions allowing for quantitation of different samples 
simultaneously. In addition, information such as post-translational modifications is not lost using 
this chemistry. The proteome coverage is expanded and the confidence in identification and 
quantitation is improved by labeling multiple peptides per protein. Utilization of 8-plex reagents 
allows quantitative measurement of the proteomic changes induced by VLCAD deficiency or 
fasting in a simplified experiment by mixing multiple proteome samples from animals with and 
with deficiency or with or without fasting. While, the complexity of the MS and MS/MS data is 
not increased.  
Ingenuity Pathway Analysis is a software that helps understand biology at multiple levels 
by integrating data from various experimental platforms and provide insight into the molecular 
interactions, cellular phenotypes, and disease processes of the biological system under 
investigation (Ingenuity Systems, www.ingenuity.com). It leverages the Ingenuity Knowledge 
Base, a repository of biological interactions and functional annotations created from individually 
modeled relationships between proteins, RNAs, genes, metabolites, complexes, cells, tissues, 
drugs, and diseases. It has been adopted by the research community to understand the complex 
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biological and chemical systems. The pathways and functions associated with the secondarily 
changed proteins resulted from VLCAD defects or fasting could be analyzed using this tool to 
help extend the current understanding and gain further insight into the biological mechanism.  
It is widely accepted that the full clinical spectrum of most diseases is determined by the 
interplay of genetic and environmental factors. In patients with inborn errors of metabolism, the 
primary mutation dictates a specific and severe susceptibility to an otherwise normal 
biomolecular or physiologic state, but a wide range of clinical phenotypes can still be seen. The 
effect of environmental factors is usually measured in epidemiological studies of individuals 
with some genetically susceptibility to an exposure, but such studies are usually not tenable in 
patients with metabolic disorders. In this study, a mouse model of a fatty acid oxidation defect 
(VLCAD deficiency) was used to characterize changes in the mitochondrial proteome in mice 
that are genetically identical except for one mutation and exposure to a specific stressor (fasting) 
to identify the interaction of genes and environment in determining clinical symptoms.  No such 
a systemic study has been done in human beings or animals at a global scale. 
3.3 MATERIALS AND METHODS 
3.3.1 Mice  
VLCAD knock out (C57BL/6+129svJ) and corresponding wild type mice with the same 
genetic background were purchased from Jackson Laboratory (Bar Harbor, Maine) at age 4-5 
weeks. The animals were housed in the animal facilities in Children’s Hospital of Pittsburgh of 
UPMC and bred for all experiments and tissue harvest. At least 6 male mice of each genotype 
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were used for each tissue harvest experiment. For fasting studies, 6 pairs of male mice were 
fasted 16 hours before sacrifice. All animals were sacrificed at 6-8 weeks of age by CO2 
asphyxiation followed by standard protocols as approved by the University of Pittsburgh 
IACUC. Liver was removed immediately after death. 
3.3.2 Isolation of mitochondria from mice liver 
Freshly removed liver was finely minced in ice cold isolation buffer A containing 225 
mM mannitol, 75 mM sucrose, 10 mM HEPES free acid, 10 mM EDTA, pH7.4, then gently 
homogenized with a glass Dounce homogenizer in isolation buffer B containing 225 mM 
mannitol, 75 mM sucrose, 10 mM HEPES free acid, 0.1% BSA fatty acid free, 10 mM EDTA, 
pH 7.4, with the addition of 10 µl/ml HaltTM protease inhibitor cocktail (Pierce, Rockfold, IL). 
The homogenate was centrifuged at 1,300 x g for 10 minutes at 4 °C, and the supernatant was 
recovered and centrifuged at 10,000 x g for 10 minutes. The pellet was carefully preserved and 
resuspended in 12% Percoll solution, then layered on top of a 30-70% Percoll gradient and 
centrifuged at 62,000 x g for 35 minutes at 4 °C. The mitochondrial band located between the 
30% and 70% layers was removed and washed with cold isolation buffer A. The purified 
mitochondria were then collected by centrifugation at 10,000 x g for 10 minutes 4 °C. A small 
aliquot of the sample was taken for organelle marker analysis and purity testing by western 
blotting. 20 μg of the remaining sample were run on a 10% SDS acrylamide gel and transferred 
to PVDF membrane for western blotting. The membrane was probed with anti-cytochrome C (a 
mitochondrial marker) and anti-calreticulin (an ER marker) antibodies (Santa Cruz Biologicals). 
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3.3.3 iTRAQ experiments 
Preparation of mitochondrial protein.     Mitochondrial pellets isolated from wild type 
and deficient mice were suspended in sample buffer containing 0.5 M triethylammonium 
bicarbonate buffer (TEAB, pH 8.5), 0.1% SDS. The samples were sonicated 3 times for 10 
seconds at 4°C, and debris from each sample was removed by centrifugation at 14,000 x g for 15 
minutes at 4°C. The protein concentration was measured using the BCA protein assay reagent 
according to the manufacturer’s protocol (Pierce, Rockford, IL). Absorbance was measured at 
590 nm on a microplate reader (Bio-Rad, Hercules, CA). One hundred micrograms of protein 
from each sample were placed in an eppendorf tube, mixed with pre-chilled acetone, and the 
tubes were incubated at -20°C until precipitate formed (30 minutes -4 hours). The acetone was 
then decanted and the samples dried in air at room temperature. 
iTRAQ  labeling.    An 8-plex isobaric reagent kit (Applied Biosystems, Foster City, CA) 
was used to label samples for each set of experiment. Each sample was labeled twice to represent 
biological replicates for each sample from deficient or wild type mice in the fasted or fed status. 
The labeling procedure for each biological replicates was performed based on the manufacturer’s 
protocol (Applied Biosystems, Foster City, CA). The labeling strategy was designed as shown in 
Table 8. A total of 6 experiments were performed with the tagged samples in a reciprocal manner 
to conduct 3 pairs of comparisons between deficient mice and wild type mice under both normal 
feeding and fasting conditions. Briefly, 100 μg of precipitated mitochondrial proteins from each 
of 8 different samples (Table 8) were resuspended in 20 μL of 0.5 M triethylammonium 
bicarbonate (TEAB), and 1 μl of 2% SDS was added with mixing to allow denaturation. 2 μL of 
the reducing reagent 50 mM tris- (2-carboxyethyl) phosphine (TCEP) were then added to each 
sample and incubated at 60°C for 1 hour. After cooling, the samples were alkylated with 1 μL of 
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the cysteine blocking reagent 200 mM methyl methanethiosulfonate (MMTS) at room 
temperature in the dark for 20 min. Four micrograms of N-tosyl-L-phenylalanine chloromethyl 
ketone (TPCK) treated trypsin were then added to each sample, and the samples were incubated 
at 37° C overnight.  Prior to labeling, the 8 iTRAQ reagents (Applied Biosystems, Foster City, 
CA) 113,114, 115, 116,117,118,117, 119 and 121 were brought to 37° C. 50 μL of isopropanol 
were added to each iTRAQ vial. The iTRAQ reagents were then added to the appropriate 
digested sample as shown in table 1. The pH of each sample was then adjusted to pH 8-8.5 by 
adding an appropriate volume of the TEAB buffer. Tubes were incubated at room temperature 
for 2 hours, and all 8 samples were combined into one tube for peptide purification. 
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Table 8. Experimental design for proteome profiling using iTRAQ labeling 
Experiment 
No. 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
Labeled 
Samples 
1 113- VLCAD-/- 1 (fed) 114- VLCAD+/+1 (fed) 115- VLCAD-/2 (fed) 116- VLCAD+/+2 (fed) 117- VLCAD-/-1 (fed) 118- VLCAD+/+1 (fed) 119- VLCAD-/2 (fed) 121- VLCAD+/+2 (fed) 
2 113- VLCAD+/+ 3&4* (fed) 114- VLCAD-/-3&4*(fed) 115- VLCAD+/+ 5&6**(fed) 116- VLCAD-/- 5&6**(fed) 117- VLCAD+/+ 3&4*(fed) 118- VLCAD-/-3&4*(fed) 119- VLCAD+/+ 5&6**(fed) 121- VLCAD+/+ 5&6**(fed) 
3 113- VLCAD-/- 1 (fasting) 114- VLCAD+/+1 (fasting) 115- VLCAD-/2 (fasting) 116- VLCAD+/+2 (fasting) 117- VLCAD-/-1 (fasting) 118- VLCAD+/+1 (fasting) 119- VLCAD-/2 (fasting) 121- VLCAD+/+2 (fasting) 
4 113- VLCAD-/- 1&2 (fed) 
114- VLCAD-/-1&2 (fasting) 115- VLCAD-/- 3&4 (fed) 
116- VLCAD-/- 3&4 (fasting) 
117- VLCAD-/- 1&2&3*** (fed) 
118- VLCAD-/- 3&4&5&6 (fasting) 
119- VLCAD-/ 3&4&5 (fed) 
121- VLCAD-/- 3&4&5&6 (fasting) 
5 113- VLCAD+/+ 3&4* (fed) 114- VLCAD+/+ 3&4*(fasting) 115- VLCAD+/+ 5&6**(fed) 116- VLCAD+/+ 5&6**(fasting) 117- VLCAD+/+ 3&4*(fed) 118- VLCAD+/+ 3&4*(fasting) 119- VLCAD+/+ 5&6**(fed) 121- VLCAD+/+ 5&6**(fasting) 
 
*3&4 : pooled samples from  mice 3 and mice 4; **5&6: pooled samples from mice 5 and mice 6; ***1&2&3: pooled samples from  mice 1,2  
and mice 3;  3&4&5&6: pooled samples from mice 3,4,5 and mice 6.
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SCX purification.     Peptide samples were purified using strong cation exchange (SCX) 
cartridges, Strata 55 µum,70 Å (Phenomenex, Torrance, CA). Samples were diluted in Buffer A 
(10 mM phosphoric, pH 3.0, 25% acetonitrile) to ensure that the pH was below 3.0. The Strata 
cartridges were conditioned using ACN and Buffer A at a flow rate of 2-4 ml / minutes. Each 
mixed sample for one experiment was then loaded onto the solid phase extraction (SPE) column 
at a rate of 2-4 ml/minute. The column was rinsed with 1-2 ml of Buffer A and dried by 
aspirating air through the syringe. The peptides were eluted from the column using Buffer B (5% 
ammonium hydroxide, 30% methanol). The purified peptides were vacuum dried. 
Peptide fractionation.    Peptides were fractionated using isoelectric focusing (IEF) with 
18 cm pH 3.5-4.5 Immobiline DryStrip (IPG) strips (GE Healthcare, Uppsala, Sweden). The 
dried peptides were resuspended in 340 µl of 8M urea, 2mg/ml DTT, 0.1% Triton X-100, and 
1% ampholytes. The IPG strip was rehydrated in the sample solution for 10-20 hours. The IEF 
for experiment 1 and 2 was performed on a Multiphor II Electrophoresis Unit (Pharmacia 
Biotech AB, Uppsala, Sweden) at 20 °C with a current of 2 mA in gradient mode. The IEF for 
peptide samples for experiment 3, 4, and 5 was run with an Ettan IPGphor Π system (former 
Amersham Biosciences, Piscataway, NJ) following the program with 300v for 10 minutes, 3500v 
for 17.5 hours, 800v for 3 hours and then maintained at 30v as needed (Table 2). After the 
completion, the IPG strip was cut into 10 fragments and placed into tubes containing 100 µl 5% 
acetonitrile (ACN), 0.5% trifluoroacetic acid (TFA). Peptides were extracted 2 or 3 times by 
incubation in 5% ACN, 0.5% TFA at room temperature for 60 minutes. The supernatant 
solutions were then pooled together for the clean-up step. 
Peptide clean-up.    Eluted fractions were desalted using PepClean C-18 spin columns 
(Pierce, Rockford, IL) according to the manufacturer’s protocol. Briefly, 200 µl of activation 
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solution (50% methanol) was loaded onto the column to wet the resin. The column was 
equilibrated with 0.5% TFA in 5% ACN. The fractionated peptides were loaded onto the column 
and washed with 0.5% TFA in 5% ACN. Peptides were then eluted from the column using 70% 
ACN and dried by speed vacuum. Cleaned peptides were resuspended in 0.1% TFA, 2% ACN 
for nano-LC separation. 
Nano-LC Mass spectrometry.    The purified peptide mixtures were separated by reverse 
phase nano-Liquid chromatography on an Easy nLC system (Proxeon, Odense, Denmark). The 
peptides were loaded onto a trap column (0.3 mm id x 5mm Kromasil C18, 5 µm particles) 
followed by the separation with an analytical column (75 µm id x 100 mm, packed with 
Kromasil C18, 3.5 µm)(Eka Chemicals, Bohus, Sweden) at a flow rate of 300 nl/minute using a 
gradient of 5%-35% ACN in 0.4% acetic acid for 100 minutes. Between each analytical run, 100 
fmol bovine serum albumin was run for 31 min to serve as a quality control and equilibration of 
the system. The effluent was directly applied by electrospray with a stainless steel emitter 
(Proxeon, Odense, Denmark) into a LTQ-Orbitrap mass spectrometry (Thermo Fisher Scientific, 
Waltham, USA) system. The electrospray voltage applied was 2 kV. 
The mass spectrometry was operated with Xcalibur v 2.0.7 (Thermo Fisher Scientific, 
Waltham, USA) in a data-dependent mode to alternate between one MS full scan and 6 MS/MS 
scans with linear ion trap (LTQ) detection of the most intense ions. The MS detection parameter 
was set to constitute a full scan of m/z 400–2000 with Orbitrap resolution R = 60,000 at m/z 400. 
The top four MS spectra data were acquired for the most intensive precursor ions in the MS 
survey scans. The m/z values selected for MS/MS were dynamically excluded for 25 s. Rejection 
of charge state +1 was selected. The internal calibration was performed using a lock mass ion (Si 
(CH3)2O)6H, m/z 445.120025) from ambient air (Olsen et al, 2005). Pulsed Q dissociation (PQD) 
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fragmentation was performed with the following settings: activation time of 0.1 s, activation Q of 
0.7, and normalized collision energy of 33.  
Bioinformatics and Database Searching.    The MS/MS spectra (RAW files) were 
processed using extract_msn.exe from February 15, 2010 (Thermo Fischer Scientific). The 
MS/MS data from 10 different fractions of peptides from each experimental study were 
combined to search against the IPI-mouse database (version 3.65 with 56775 sequences, released 
10/16/2009) using Mascot version 2.2.04 (Matrix Science, London, UK, 
www.matrixscience.com) with the multidimensional protein (MudPIT) scoring algorithm(Kersey 
et al, 2004). Up to two missed cleavages, with trypsin as the digestion enzyme, were allowed. 
The full scan tolerance of 5 ppm and MS/MS tolerance of 0.75 Da were accepted. Searches were 
performed allowing variable oxidation of methionine residues (16 Da) and iTRAQ labels on 
tyrosine, and fixed modification of iTRAQ labels on lysine and N terminus, and methylthio 
modification of cysteines. The threshold of protein identification was set to have significance at 
p≤0.001 corresponding to a false discovery frequency of 0.002 for searching against a decoy 
database. iTRAQ values were reported for proteins with four or more measured iTRAQ values 
when each peptide had an expectation value of 0.02 or below. When the identification of a 
protein in an analysis resulted in several possible protein isoforms, all of them were considered 
for quantification. In the quantitative calculations, only protein isoforms with iTRAQ values in 
all analyses were included. The mass spectrometry for the analysis of purified peptides from 
fasted animals and fasted wild type animals and database search was performed by Dr. Johan 
Palmfeldt, PhD, and Research Unit for Molecular Medicine, Aarhus University Hospital, 
Denmark. 
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For each protein, the relative ratio was calculated as the ratio of peptide signals belonging 
to that protein compared to the corresponding peptides signals with label 113 according to the 
Mascot algorithm. The data set was exported for further biostatistics analysis. Proteins with a 
minimum of at least 2 labeled peptides and a mascot score of over 65 were selected for further 
data analysis. In experiments of normal fed mice (experiment 1 and 2), values of all of proteins 
corresponding to wild type in each independent experiment were summed up and averaged to 
obtain a reference value to take into account the lower variation in wild type samples. 
Correspondingly, due to the low coverage of captured proteins in experiments on fasted mice, all 
of proteins with 8 labeled values were summed and averaged to obtain a reference value for each 
data set. Each iTRAQ value was recalculated in its own data set by setting the reference label 
value to be 1 and then log2 transformed to have a normalized value (Appendix C). The equal 
variance was tested for each protein. Student’s t-test was used to test the difference at p≤0.10 
between the log transformed values of mutant and wild type for each protein. The mean of the 
biological and technical replicates were calculated to obtain the averaged fold change of a 
protein expression in mutant compared to that in wild type or fasted compared to that in normal 
fed. Proteins that were significant (p≤0.10) and over 1.25 folds change or less than 0.75 folds 
change in 2 experiments (experiment 1 and 2) were classified as significant changed proteins. 
However, in order to maximize the detection of significant changed proteins in the rest of 
experiments, the p-value for the significance was set to be at p≤0.10 (Student’s t-test) and the 
cut-off of protein changes was also set to have 1.25 or 0.75 but in only one experiment.  
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3.3.4 Pathway and network analysis 
All proteins altered in deficient mice in either the fed or fasting state compared to wild 
type under the same conditions were separately analyzed for independent biological network 
building and pathway analysis by the Ingenuity Pathways Analysis (IPA; Ingenuity Systems, 
Redwood City, CA; www.ingenuity.com). The differentially expressed proteins from direct 
comparison of fasted mice and normal fed mice were analyzed independently. Each identifier of 
changed protein was mapped to its corresponding object (gene/protein) in the Ingenuity 
Knowledge database. The filters and general settings for the core analysis were set to consider all 
molecules including endogenous chemicals, as well as both direct and indirect relationships. The 
taxonomy of mouse was selected. All data sources except cell lines were considered and a 
stringent filter for molecules and relationships was applied. Networks of the focus genes were 
algorithmically generated based on their connectivity and ordered by an IPA score according to a 
global molecular network developed from Ingenuity Knowledge-Base. IPA computes a score for 
each possible network according to the fit of that network to the input proteins/genes. This score 
is calculated as the negative base-10 logarithm of the p-value that indicates the probability of the 
network-eligible molecules that are part of a network being found together as a result of random 
chance (Fisher’s exact test). Scores 2 or higher have at least a 99% confidence of not being 
generated by random chance alone. The association to biological functions (and/or diseases) that 
were most significant to the genes in the network was also grouped. Genes or gene products are 
represented as nodes, and the biological relationship between two nodes is represented as an 
edge. All edges are supported by at least one reference from the literature or from canonical 
information in the software. The intensity of the node color indicates the increased (red) or de- 
creased (green) abundance. Nodes are displayed using various shapes that represent the 
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functional class of the gene product. In this analysis, we selected the top 2 networks with the 
highest as the most significant networks. 
The Global Functional Analysis (GFA) and Global Canonical Pathways (GCP) analysis 
utilizes well characterized metabolic and cell signaling pathways incorporated in IPA that are 
available prior to data input. The canonical pathways and associated diseases related to the 
differentially expressed proteins were generated according to the algorithms in the software and 
listed in order of the significance of relation to the database. In this study, we compared the top-
rated canonical pathways changed in the fed state and fasting state. The p-value associated with a 
function or a pathway is calculated by considering the number of focus genes that participate in 
that process and the total number of genes known to be associated with that process in the 
selected reference set by IPA using the right-tailed Fisher Exact Test. 
3.4 RESULTS  
 
To characterize changes in protein expression induced by VLCAD deficiency as well as 
fasting, mitochondrial proteome profiles in livers from male VLCAD deficient mice and 
corresponding wild type mice were quantitatively examined. Three pairs of comparisons were 
conducted in five independent experiments to identify the changes in protein expression between 
deficient mice and wild type mice under both normal feeding and fasting conditions. An 
overview of experimental approach is shown in Table 1. The aim of the first two experiments 
was to identify proteins altered in VLCAD deficient mice in the fed state in comparison with the 
wild type mice. The third experiment examined protein alterations in VLCAD deficient mice as 
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compared to wild type animals in the fasted state. The fourth and fifth experiments were 
designed to identify the proteins altered in response to fasting regardless of genotypes. 8-plex 
ITRAQ reagents were utilized to label trypsin-digested peptides.  Proteins were identified and 
quantitated with nano-LC/LTQ-Orbitrap mass spectrometry.  Numerous protein were identified 
and in each dataset. IPA was employed to identify the affected pathways and reconstruct the 
networks as inferred from proteins with altered expression.  
3.4.1 Differentially expressed proteins in VLCAD deficient mice in the fed state 
A total of 721 proteins and 490 proteins were identified with at least 2 peptides for each 
protein at p≤0.001 corresponding to a false discovery frequency of 0.002 in two independent 
experiments. Two different reagents were used to label the same peptides sample to minimize the 
variations of labeling efficiency. Moreover, to reduce the biological variance among individual 
mice, mitochondrial protein samples from two individual mice were pooled together to give one 
mixed protein sample. Peptide samples were first fractionated using isoelectric focusing with 
IPG strips at a range of pH 3.5-5.0 for the best resolution of peptides, and then were separated 
chromatographically by nano-LC, which separated the peptides efficiently.  
Among the proteins that were differentially expressed, 43 proteins were classified as 
significantly changed in VLCAD deficient mice when compared to the wild type (Table 9). Only 
those proteins with consistently over 1.3-fold changes or less than 0.7-fold changes and their 
changes were significant (p≤0.05) in both of two experiments in VLCAD deficient mice were 
considered as significantly altered. The detailed description of the identification and 
quantification information including gene symbol, gene names, minimum peptides detected in 
two experiments, averaged ratios of protein values in deficient mice compared to those in wild 
  80 
types and the biological annotations related to these proteins are provided in the table. Among 
the changed proteins, 31 proteins were decreased and 12 proteins were increased. The location of 
some identified proteins in this experiment are not indicated if they have been recognized as 
being in only mitochondria, whereas the mitochondrial location of others are reported if they 
have been localized to multiple organelles, and were identified and recognized in this experiment 
(Table 9).  
Ingenuity Pathway Analysis was used to classify proteins altered in VLCAD deficient 
mice into different functional groups  (Appendix A) and determine whether they were associated 
with related pathways and/or different cellular activities. Of the 43 altered proteins, 27 could be 
included in the network analysis and 36 could be used for canonical pathway analysis and 
functions analysis. Some of the remaining proteins that could not be included in the analysis may 
be due to the lack of the information from current literature, or being hypothetical proteins, 
duplicates with synonymous names or having the same encoding gene. Several significant 
functions that were associated with altered proteins were reported in Figure 11. The numbers of 
proteins that were classified into the top 5 molecular and cellular functional groups are shown in 
Table 11. The function that was most significantly associated with the altered proteins in 
VLCAD deficient mice in the fed state was lipid metabolism and small molecule chemistry 
(defined as those functions of small molecules not, included in the more specific categories of 
DNA, RNA, protein, lipids and carbohydrates). A larger number of molecules were classified 
into this functional group. 12 and 14 of them were altered respectively in the first and second 
experiment. IPA also identified an association with nucleic acid metabolism, however, only 4 
molecules were detected involving in this function. 
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Table 9. Statistically significant altered proteins in VLCAD deficient mice in the fed state 
 
  Gene 
symbol Gene Names 
Minimum 
peptides 
Minimum 
Protein 
score 
Protein 
Mass 
Ratio of 
protein 
expression 
(fed VLCAD-/-: 
fed VLCAD+/+) ACADVL Very long-chain specific acyl-CoA dehydrogenase 9 121 83625 -4.03 CP2A5 Cytochrome P450 2A5  32 567 67139 -3.5 CP239 Cytochrome P450  6 221 65895 -3.3 THIKB 3-ketoacyl-CoA thiolase B, peroxisomal  61 1058 49857 -3.10 SOX Peroxisomal sarcosine oxidase  17 192 50913 -2.54 NUDT7 Peroxisomal coenzyme A diphosphatase  59 1399 31283 -2.29 GSTP2 Glutathione S-transferase P 2 70 27615 -2.13 MA2B1 Lysosomal alpha-mannosidase  4 96 127768 -2.08 CES3 Carboxylesterase 3 18 227 72626 -2.03 HIUH 5-hydroxyisourate hydrolase 10 85 15514 -1.98 PAHX Phytanoyl-CoA dioxygenase, peroxisomal  33 309 45339 -1.96 NLTP Non-specific lipid-transfer protein  210 5205 73857 -1.93 OCTC Peroxisomal carnitine O-octanoyltransferase 11 184 81602 -1.83 GPDA Glycerol-3-phosphate dehydrogenase [NAD+] 7 137 45659 -1.80 IDHC Isocitrate dehydrogenase [NADP] cytoplasmic 9 157 58512 -1.78 GSTP1 Glutathione S-transferase P 1 10 245 27687 -1.76 PPA5 Tartrate-resistant acid phosphatase type 5  3 77 41485 -1.75 ECHP Peroxisomal bifunctional enzyme  91 1236 92343 -1.74 HAOX1 Hydroxyacid oxidase 1  30 346 48202 -1.70 CATA Catalase 470 1766 69996 -1.69 CP3AB Cytochrome P450  14 193 72999 -1.65 ALDOB- Fructose-bisphosphate aldolase B 13 185 46847 -1.64 CP2CT Cytochrome P450 2C29  15 241 67197 -1.64 HYES Epoxide hydrolase 2  38 684 73582 -1.63 THIKA 3-ketoacyl-CoA thiolase A, peroxisomal 71 1060 49465 -1.60 NUD19 Nucleoside diphosphate-linked moiety X motif 19, mitochondrial  8 69 44057 -1.60 PECR Peroxisomal trans-2-enoyl-CoA reductase  8 111 38399 -1.59 GNS N-acetylglucosamine-6-sulfatase 6 87 70860 -1.53 AMACR Alpha-methylacyl-CoA racemase  11 177 48052 -1.53 ACOX1 Peroxisomal acyl-coenzyme A oxidase 1  107 1543 87382 -1.51 CP2DQ Cytochrome P450 2D26  3 87 64166 -1.50 ASSY Argininosuccinate synthase  7 94 57128 -1.49 GABT 4-aminobutyrate aminotransferase 44 798 66398         1.33 ATPB ATP synthase subunit beta 312 5985 63566         1.33 
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CH60 60 kDa heat shock protein 129 3678 77787        1.33 QCR6 Cytochrome b-c1 complex subunit 6 20 869 13092        1.36 COX41 Cytochrome c oxidase subunit 4 isoform 1 37 240 24431        1.36 QCR1 Cytochrome b-c1 complex subunit 1 48 485 57546        1.37 ETHE1 Protein ETHE1, mitochondrial  7 196 30569        1.39 KMO Kynurenine 3-monooxygenase 29 461 63169        1.43 NDUV1 NADH dehydrogenase [ubiquinone] flavoprotein 1 4 209 59567        1.45 IMMT Mitochondrial inner membrane protein  34 624 101206        1.48 M2GD Dimethylglycine dehydrogenase 68 799 113197        1.48 DHTK1 Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1 10 85 115495        1.83 
 
43 unique proteins were significantly changed (p≤0.05) in two experimental replicates. They were identified with a 
minimum of 2 peptides. The table includes the significantly changed proteins with gene symbol, gene names, 
minimum peptides detected for each protein (Min. Peptides), minimum proteins score, and protein mass and 
averaged ratios of expression in deficient mice to that in Wild type. p-values were not shown (p≤0.05, Student’s t 
test. Averaged ratio values were calculated from their corresponding two experiments if they were significant 
(p≤0.05) in the same up-regulation or down-regulation directions.  Additionally, the protein was considered to show 
a significant up-regulation or down-regulation if their expression ratios were �1.3 or 0.7, respectively. 
 
 
 
 
 
 
 
Table 9  Continued 
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Figure 11. Molecular and cellular functions of altered proteins in fed VLCAD deficient mice   The molecular and cellular functions associated with altered proteins in fasted VLCAD deficient mice were analyzed by IPA. Definitions of functions are provided in Appendix A. The Y-axis denotes the associated functions. The X-axis represents the -log (p-value) of the association (Fisher’s exact test). The altered proteins were those expressed differentially in fed VLCAD deficient mice as compared to fed wild type mice. 
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The top-rated network related to the 3 functions including lipid metabolism, molecular 
transport and small molecule chemistry was identified through Functional Analysis of IPA. A 
network (Figure 12) was generated by merging two networks with scores of 32 and 8 containing 
the same functions to provide an overview of the biological functions associated with them. It 
included a total of 19 proteins of the 27 eligible used for these network analyses. Of these 
proteins, 17 were enzymes. The same named network of lipid metabolism, molecular transport 
and small molecule chemistry were previously identified as being significantly altered in short 
chain acyl-CoA dehydrogenase deficient mice. However, more proteins classified into this 
network were down-regulated in VLCAD deficient animals than those in SCAD deficient 
animals. 
Several transcription regulators inferred from the lPA knowledge base linked this 
network (Figure 12). They include the nuclear receptors of PPARA, PPARG and PPARGC1A 
and HNF4A. Expression of SCP2, a non-specific lipid transfer protein with multiple functions of 
protein binding, lipid binding and sterol carrier was decreased in VLCAD deficient mice. 
Interestingly, it has been previously identified as up-regulated in SCAD deficient mice. HSP60 
(HSPD1), a mitochondrial protein functioning in protein folding was identified as up regulated in 
VLCAD deficient mice as did in SCAD deficient mice in the fed state. 
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Figure 12. Top-rated network of altered proteins in fed VLCAD deficient mice 
This network (lipid metabolism, molecular transport and small molecule chemistry) was generated by 
IPA. Red nodes indicate that the protein is up-regulated in fed VLCAD deficient mice compared to fed 
wild type mice. Green indicates that the protein is down-regulated. The color intensity corresponds to the 
degree of abundance. Proteins in white are those inferred from the Ingenuity Pathways Knowledge Base. 
The shapes denote the molecular class of the protein. A solid line indicates a direct molecular interaction, 
and a dashed line indicates an indirect molecular interaction. A full explanation of lines and relationships 
is provided in Appendix B. 
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An analysis of the canonical pathways that are associated with quantitatively changed 
proteins revealed that most of affected pathways were defined by down-regulated proteins 
(Figure 13.) The canonical pathways that were the most significant in association with altered 
proteins included the fatty acid metabolism, tryptophan metabolism, bile acid biosynthesis, and 
fatty acids elongation in the mitochondria. All of these canonical pathways were associated with 
down-regulated proteins in VLCAD deficient mice. In contrast, the oxidative phosphorylation 
pathway was significantly associated with up-regulation of components of all four electron 
transport chain complexes. As expected, fatty acid metabolism was identified as the top 
significantly changed canonical pathway in the analysis, involving 9 molecules among a total of 
117 contained in this pathway. Fatty acid elongation in mitochondria was one of the most 
significantly associated pathways. Three down-regulated proteins were mapped to fatty acid 
elongation in mitochondrial with coverage of 19% of molecules in this pathway (3/16 molecules 
in the IPA knowledge database, p≤0.05; Figure 13). Additional altered proteins were associated 
with other diseases pathways such as skeletal and muscular diseases and hepatic system disease.  
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Figure 13. Affected canonical pathways in fed VLCAD deficient mice 
The canonical pathways associated with altered proteins in fed VLCAD deficient mice compared to fed wild type mice were generated by IPA. Green indicates 
that the protein is down-regulated. Red indicates that the protein is up-regulated. Yellow dot represents the -log (p-value) of the association (Fisher’s exact test). 
The X-axis denotes the associated functions. The Y-axis represents the percentage of altered proteins among all available molecules in Ingenuity Knowledge 
database associated with the functional group denoted by X-axis.
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3.4.2 Differentially expressed proteins in VLCAD deficient mice in the fasted state 
VLCAD deficient patients and mice exhibit an abnormal response to fasting, ultimately 
resulting in hypoglycemia and a wide range of metabolic derangements. To examine biological 
changes in the fasted state unique to VLCAD deficiency, the mitochondrial proteomic profiles in 
VLCAD deficient mice in the fasted state were compared to fasted wild type mice. All of mice 
were fasted for 16 hours before sacrifice. A total of 286 unambiguous proteins meeting the 
identification criterion having significance of p≤0.001 corresponding to a false discovery rate 
≤0.002 were identified. Only those peptides identified with ≥95% confidence were included in 
the quantification of the parent protein using the algorithm provided by Mascot software.  
Proteins with at least 2 peptides and mascot score of over 65 were used for further statistical data 
analysis. To increase the detection of significantly changed proteins, a selection criterion of 
significance p≤0.10 (student t-test) was set. Among the proteins that were differentially 
expressed in VLCAD deficient mice, 54 proteins were classified as significant (≤0.75-fold or 
≥1.25-fold change; p≤0.10) in experiment 3 (Table 3). Detailed information about the 
identification and quantification information including accession number, gene symbol, number 
of minimum iTRAQ peptides related to these proteins identified, protein mass, and the minimum 
protein score obtained in Mascot were described. 31 proteins had decreased expression while 24 
were increased (Table 10). 
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Table 10.  Statistically significant altered proteins in VLCAD deficient mice in the fasted state  
 
Gene 
symbol Gene Names 
Minimum 
Protein 
score  
Protein 
Mass 
Minimum  
peptides  
Ratio of 
protein 
expression 
(fasted VLCAD 
-/-:fasted 
VLCAD+/+) ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 121 83625 2 -3.41 NUDT7 Peroxisomal coenzyme A diphosphatase  232 31283 10 -2.49 ALDH2 Aldehyde dehydrogenase, mitochondrial  683 66346 76 -2.35 DHRS4 Dehydrogenase/reductase SDR family member  69 35249 9 -2.22 OAT Ornithine aminotransferase, mitochondrial  1113 56859 55 -2.2 PHS2 Pterin-4-alpha-carbinolamine dehydratase 2  74 17604 3 -2.17 GPX1 Glutathione peroxidase 1  171 25238 19 -2.13 ODO2 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial  607 57453 59 -2.03 IVD Isovaleryl-CoA dehydrogenase, mitochondrial  193 54527 12 -1.99 CH10 10 kDa heat shock protein, mitochondrial  954 14606 118 -1.99 LACB2 Beta-lactamase-like protein 2  125 38439 7 -1.96 CYC Cytochrome c, somatic  1336 17470 159 -1.92 NLTP Non-specific lipid-transfer protein  1162 73587 150 -1.87 MMAB Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial  803 31658 13 -1.77 RT31 28S ribosomal protein S31, mitochondrial  440 55597 22 -1.67 THIM 3-ketoacyl-CoA thiolase, mitochondrial  3486 49804 215 -1.61 FUMH Fumarate hydratase, mitochondrial  500 64559 17 -1.59 NDUV2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  1165 32107 23 -1.56 ETHE1 Protein ETHE1, mitochondrial  467 30569 8 -1.56 AATM Aspartate aminotransferase, mitochondrial  496 57133 64 -1.5 MCEE Methylmalonyl-CoA epimerase, mitochondrial  133 23356 2 -1.53 SUOX Sulfite oxidase, mitochondrial  605 67216 16 -1.51 FABPL Fatty acid-binding protein, liver  509 19758 32 -1.49 SODM Superoxide dismutase [Mn], mitochondrial  2476 29943 63 -1.47 SPYA Serine--pyruvate aminotransferase, mitochondrial  106 52192 10 -1.45 3HIDH 3-hydroxyisobutyrate dehydrogenase, mitochondrial  87 42431 3 -1.43 KAD2 Adenylate kinase 2, mitochondrial  406 33070 23 -1.42 NFU1 NFU1 iron-sulfur cluster scaffold homolog, mitochondrial  107 32430 10 -1.42 SHC1 SHC-transforming protein 1  94 70283 2 -1.40 ETFA Electron transfer flavoprotein subunit alpha, mitochondrial  3298 43477 65 -1.36 FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2  106 19427 11 1.32 PDIA1 Protein disulfide-isomerase  3175 72944 125 1.38 
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GRP78 78 kDa glucose-regulated protein  3997 91330 247 1.44 RMD3 Regulator of microtubule dynamics protein 3  90 59878 3 1.50 QCR7 Cytochrome b-c1 complex subunit 7  241 17474 51 1.56 GLU2B Glucosidase 2 subunit beta  258 69272 27 1.58 HMCS2 Hydroxymethylglutaryl-CoA synthase, mitochondrial  430 66631 15 1.61 PAHX Phytanoyl-CoA dioxygenase, peroxisomal  540 45339 26 1.75 PECI Peroxisomal 3,2-trans-enoyl-CoA isomerase  119 52992 3 1.84 NUCB1 Nucleobindin-1  599 62502 51 1.86 PRDX5 Peroxiredoxin-5, mitochondrial  69 27027 2 1.86 ACNT1 Acyl-coenzyme A amino acid N-acyltransferase  64 54272 3 1.86 MYH9 Myosin-9  462 289864 27 1.86 CP2DA Cytochrome P450 2D10 /2D16 110 62948 5 1.87 PDIA3 Protein disulfide-isomerase A3  333 72829 49 1.91 RRBP1 Ribosome-binding protein 1  457 244936 38 1.95 ALR FAD-linked sulfhydryl oxidase ALR  118 26272 2 2.08 ASPG N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase  107 43192 29 2.12 IMMT Mitochondrial inner membrane protein  200 101206 19 2.16 TTHY Transthyretin  549 18900 20 2.21 ACBD5 Acyl-CoA-binding domain-containing protein 5  264 66727 14 2.35 GOLI4 Golgi integral membrane protein 4  86 87736 2 2.35 GANAB Neutral alpha-glucosidase AB  68 116338 8 3.11 MIA3 Melanoma inhibitory activity protein 3  70 255118 6 3.45 
 
54 unique proteins that were significantly changed (p≤0.10) in the fasted deficient mice compared to fasted wild 
type mice. They were identified with a minimum of 2 peptides. The table includes the significantly changed proteins 
with gene symbol, gene names, minimum peptides detected for each protein, minimum protein score, protein mass 
and averaged ratios of protein expression in deficient mice to those in wild type mice. p-values were not shown 
(p≤0.10, Student’s t test). The protein was considered to be up-regulated or down-regulated if its expression ratio 
was over 1.25 or less than 0.75, respectively.  
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Analysis of the biological functions associated with differentially expressed proteins 
showed that the majority of the proteins with significant alterations were associated with the 
functional classifications of carbohydrate metabolism, lipid metabolism, molecular transport and 
small molecule chemistry. Protein degradation and synthesis were also uniquely altered with 
fasting in VLCAD deficient mice. (Figure 14 and Table 12). The protein networks of lipid 
metabolism with a score of 24 and cell function and carbohydrate metabolism with a score of 9 
were merged as shown in Figure 15. In addition to the network of lipid metabolism, molecular 
transport and small molecule chemistry, which was identified as being the top-rated network in 
VLCAD deficient mice, the network of carbohydrate was also identified as one of the top-rated 
networks of altered proteins in VLCAD deficient mice reflecting the functional response to 
fasting in VLCAD deficient mice (Figure 15,18). 
Examination of proteins with altered expression composing the merged network revealed 
that the majority of altered proteins in fasted VLCAD deficient mice differed from those changed 
in fed VLCAD deficient mice. Fewer proteins were included in the network of lipid metabolism 
identified in fasted VLCAD deficient mice than those included in the same network of lipid 
metabolism in fed VLCAD deficient mice. Only 2 proteins encoded by SCP2 and NUDT7 were 
decreased in VLCAD deficient mice in both the fed and fasted states. A sulfur dioxygenase 
encoded by ETHE1 and located in the mitochondrial matrix was decreased when VLCAD 
deficient mice were fasted. Superoxide dismutase 2 encoded by SOD2 was only decreased in the 
fasted state but maintained a steady level in the fed state.   
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Figure 14. Molecular and cellular functions of altered proteins in fasted VLCAD deficient mice  The molecular and cellular functions associated with altered proteins in fasted VLCAD deficient mice were analyzed by IPA. Definitions of functions are provided in Appendix A. The Y-axis denotes the related functions. The X-axis represents the –log (p-value) of the association (Fisher’s exact test). The altered proteins were those expressed differentially in fasted VLCAD deficient mice as compared to fasted wild type mice. 
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Figure 15. Top-rated networks of altered proteins in fasted VLCAD deficient mice  
This network (lipid metabolism, molecular transport and small molecule chemistry, cell function and carbohydrate 
metabolism) was generated by IPA. Red nodes indicates that the protein is up-regulated in fasted VLCAD deficient 
mice compared to fasted wild type mice. Green indicates that protein is down-regulated in VLCAD deficient mice in 
the fasted state. The color intensity corresponds to the degree of abundance. Proteins in white are those inferred 
from the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. A solid line 
indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction.  
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The most affected canonical pathways associated with quantitatively changed proteins in 
VLCAD deficient mice in the fasted state were pathways of valine, leucine and isoleucine 
metabolism, fatty acid metabolism and amino acid metabolism including arginine, proline, 
tyrosine, phenylalanine and ß-alanine. The citrate acid cycle and propionate metabolism were 
also significantly altered (Figure 16). Most of the affected pathways encompassed down-
regulated proteins. Galactose metabolism was identified as a significantly associated pathway, 
showing a compensatory pattern associated with up-regulated enzymes including alpha-
glucosidase encoded by GANAB and glucosidase II that catalyze the exohydrolysis of 1,4-alpha-
glucosidic linkages with release of alpha-glucose.  
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Figure 16. Affected canonical pathways in fasted VLCAD deficient mice  
The canonical pathways associated with altered proteins in fasted VLCAD deficient mice compared to fasted wild type mice were generated by IPA Green 
indicates that the protein is down-regulated. Red indicates that the protein is up-regulated. Yellow dot represents the -log (p-value) of the 
association (Fisher’s exact test). The X-axis denotes the associated functions. The Y-axis represents the percentage of altered proteins among all 
available molecules in Ingenuity Knowledge database associated with the functional group denoted by X-axis.  
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3.4.3 Comparison of differentially expressed proteins in VLCAD deficient mice between 
two feeding states  
To evaluate global biological changes induced by fasting and VLCAD deficiency, altered 
mitochondrial proteins in fasted VLCAD deficient mice were compared with the altered proteins 
in fed VLCAD deficient mice.  The altered proteins in VLCAD deficient mice as compared to 
wild type mice under the same feeding condition have been identified in the previous two 
experiments (Table 9 and Table 10). The majority of changed proteins in VLCAD deficient mice 
in the fasted state differed from those altered proteins identified in VLCAD deficient mice in the 
fed state, while only a few proteins were identified in both datasets. The NUDT7 encoding 
protein was significantly decreased in both states. A non-specific lipid transfer protein encoded 
by NLTP (SCP2) with multiple functions of protein binding, lipid binding and sterol carrier was 
down regulated in deficient mice in both states. This suggests that non-specific lipid 
transportation was decreased due to the lack of availability of long-chain fatty acids related to the 
deficiency of VLCAD regardless of the feeding state. A sulfur dioygenase encoded by ETHE1 
and localized in the mitochondrial matrix functioning in sulfide catabolism was increased in 
VLCAD deficient mice in the fed while its expression was decreased in VLCAD deficient mice 
in the fasted state. The heat shock protein HSP60 was up-regulated in VLCAD deficient mice in 
the fed state, however, it lost its compensatory change in the fasted deficient animals showing no 
significant change with the protein expression in fasted VLCAD deficient mice. The up-
regulation of HSP60 in VLCAD deficient mice in the fed state was consistent with the result 
from SCAD deficient mice in the fed state, in which, HSP60 was also up-regulated. These results 
suggest that changes in the functional group of protein binding, ATP binding and protein folding 
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in mitochondria were related to ACAD deficiencies and that fasting in VLACAD deficiency 
negated these changes.  
The function of Comparison Analysis in IPA was used to further differentiate the effects 
of VLCAD deficiency and feeding state in deficient and wild type mice. Mitochondrial proteins 
in VLCAD deficient mice in one of the feeding states were compared to wild type mice in the 
same feeding state in the previous experiments. All altered proteins identified in each experiment 
were inputted into the software, and associated functions and canonical pathways altered in each 
dataset were then compared. Eleven common molecules were identified in the network of lipid 
metabolism, molecular transport and small molecule chemistry, which rated as the most altered 
network in both fed and fasted VLCAD deficient mice. This result suggests that lipid metabolism 
was likely affected by the VLCAD deficiency primarily rather than as a result of fasting as a 
stressor (Figure 17). It should be noted that altered proteins were defined as significantly 
changed in VLCAD deficient mice in one of the feeding states when compared to wild type mice 
in the same feeding state.  
Comparison of the top-rated networks containing altered proteins between fasted and fed 
VLCAD deficient mice reveals that the function categories of cellular function and maintenance 
and carbohydrate metabolism involved more altered proteins in fasted than in fed VLCAD 
deficient animals. This unique network of carbohydrate metabolism that was assigned into its 
high-level functional categories (cellular function, cell maintenance, cell death and carbohydrate 
metabolism in IPA)  was only identified in the fasted state in VLCAD deficient mice (Figure 18) 
was constructed based primarily on proteins decreased with expression. Functional analysis also 
demonstrates that carbohydrate metabolism was the most significantly associated functions in 
VLCAD deficient mice in the fasted state (Table 11, Table 12). This finding suggests that 
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deficient mice are more vulnerable to fasting stress than the wild type mice consistent with the 
observation that VLCAD-deficient mice demonstrated a milder phenotype and only developed 
hypoglycemia after prolonged fasting or cold-induced stress (Cox et al, 2001a).  
A fasting induced difference was also seen in the associated functions group of protein 
degradation and synthesis and amino acid metabolism (Figure 19).  However, the significance of 
global function of the lipid metabolism, small molecule chemistry and cellular assembly and 
molecular transport was not altered by fasting in VLCAD deficient mice (Figure 11, Figure 14, 
Table 11 and Table 12).   
The significance of canonical pathways of valine, leucine and isoleucine degradation, 
fatty acid elongation in mitochondria, and oxidative phosphorylation associated to altered 
proteins in fasted deficient mice were altered in fed deficient mice (Figure 20). These results 
suggest that the significance differences in these pathways are likely dependant on the feeding 
status of VLCAD deficient mice (Figure 13, Figure 16 and Figure 20). Fatty acid metabolism, 
lipid metabolism, mitochondrial dysfunction pathways were altered in mutant animals in the fed 
state. Amino acid metabolism, especially branched chain amino acid metabolism and 
carbohydrate metabolism, as well as the fatty acid metabolism were more significantly altered in 
the fasted deficient mice than in the fed deficient mice. The oxidative phosphorylation pathway 
was significantly affected based primarily on increased proteins seen in the fed VLCAD 
deficient mice. However, this pathway was normalized by fasting in VLCAD deficient mice. 
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Figure 17. Comparison of the most significant networks associated with altered proteins in fed and fasted 
VLCAD deficient mice  
The same named networks of lipid metabolism, molecular transport and small molecule chemistry associated with 
altered protein in fed and fasted VLCAD deficient mice were generated and merged by IPA. Red nodes indicate that 
the protein is up-regulated in VLCAD deficient mice compared to wild type mice. Green indicates that the protein is 
down-regulated. The color intensity corresponds to the degree of abundance. Proteins in white are those identified 
through the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. A solid line 
indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction.  
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Figure 18. Carbohydrate metabolism (shown with its high-level functional category) 
altered in fasted VLCAD deficient mice  
This network of cellular function, cell maintenance, death and carbohydrate metabolism associated with altered 
proteins in fasted VLCAD deficient mice compared to fasted wild type mice was generated by IPA. Red nodes 
indicate that the protein is up-regulated in the fasted VLCAD deficient mice compared to wild type. Green indicates 
that protein is down-regulated. The color intensity corresponds to the degree of abundance. Proteins in white are 
those inferred from the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. 
A solid line indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction.  
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The pathway of synthesis of ketone bodies was not significantly changed either in the fed 
VLCAD deficient or the fasted mutant mice, consistent with the clinically observation that 
patients with VLCAD deficiency are hypoketonic when fasted. However, 3-ketoacyl-CoA 
thiolase A (ACAA1), which is involved in the synthesis and degradation of ketone bodies in 
peroxisomes, was decreased in VLCAD deficient mice in the fed state. In the fasted state, 3-
hydroxy-3-methylgutaryl-CoA synthase2 (HMGCS2), an enzyme that catalyzes the condensation 
of acetyl-CoA and acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) was 
increased. Nevertheless, the pathway of ketone bodies production was not affected based on the 
significance of association in IPA analysis.  
Overall, the fatty acid elongation pathway was not altered significantly in the fasting 
mutant animals despite the finding that several changes occurred in this pathway. The protein 
encoded by ACAA2, which catalyzes the last step of the mitochondrial FAOD, changed in the 
fasted deficient animals. Three enzymes encoded by ACAA1, ACAA1b and PECR, which are the 
acetyl-CoA acyltranserases, and peroxisomal trans-2-2-enoyl-CoA reductase encoded by 
NADPH2 in the fatty acid elongation pathway were reduced in the VLCAD mutants in the fed 
state. However, these changes did not cause the pathway to be significantly altered.  
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Table 11. Molecular and cellular functions associated with changed proteins in  
VLCAD deficient mice in the fed state  
Name  p-value # Molecules 
Lipid Metabolism 7.83E-06-4.87E-02 12 
Nucleic Acid Metabolism 7.83E-06-2.16E-02 4 
Small Molecule Biochemistry 7.83E-06-4.87E-02 14 
Drug Metabolism 2.84E-05-4.58E-02 7 
Molecular Transport  3.36E-04-4.87E-02 6 
 
 
Table 12. Molecular and cellular functions associated with changed proteins in 
 VLCAD deficient mice in the fasted state  
 
Name  p-value # Molecules 
Carbohydrate Metabolism 4.31E-05-4.88E-02 3 
Lipid Metabolism 4.31E-05-4.88E-02 8 
Small Molecule Biochemistry 4.31E-05-4.88E-02 12 
Nucleic Acid Metabolism 1.09E-03-1.53E-02 4 
Cellular Assembly and Organization 1.27E-03-4.51E-02 6 
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Figure 19. Functions associated with altered proteins in VLCAD deficient mice in fed and fasted states  
The dark blue color shows functions associated with altered proteins in fasted VLCAD deficient as compared to 
fasted wild type mice. The light blue color shows functions associated with altered proteins in fed VLCAD deficient 
as compared to fed wild type mice. X-axis: significance of associations with observed changed molecules in a 
specific function (p=0.05). 
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Figure 20.  Canonical pathways associated with altered proteins in VLCAD deficient mice  
in fed and fasted states  
The dark blue color shows functions associated with altered proteins in fasted VLCAD deficient as compared to 
fasted wild type mice. The light blue color shows functions associated with altered proteins in fed VLCAD deficient 
as compared to fed wild type mice. X-axis: significance of associations with observed changed molecules in a 
specific function (p≤0.05). 
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3.4.4 Fasting effects on deficient and wild type mice 
To further explore the differential effect of fasting on wild type and VLCAD deficient 
mice, two additional experiments were performed comparing proteomic profiles in the 
mitochondria isolated from both genotypes between the fasting and fed states. One of 
experiments (Experiment 4 in Table 8) compared the proteomic profiles of mitochondria in 
VLCAD deficient mice in the fasted state to the profiles of deficient mice in the fed state.  
Another experiment (Experiment 5 in Table 8) was performed to compare the proteomic profiles 
of wild type animals in the fasted state to the profiles of wild type animals in the fed state. 
Among the proteins that were differentially expressed in VLCAD deficient mice in the 
fasted state compared to those in the fed state, 35 were classified as significant (p≤0.05, 
Student’s test, 1 side) with over 1.25-fold change or less than 0.75-fold change (Table 11). Using 
the same selection criteria, 41 proteins were classified as significantly changed in wild-type mice 
in the fasted state (Table 13). The detailed information on significantly altered proteins in each 
experiment was provided in Table 13 and Table 14. Most of altered proteins in both datasets 
were down-regulated, and the majority of altered proteins in fasted VLCAD deficient mice were 
different from those that were altered in fasted wild type animals. Few proteins were similarly 
altered with fasting in both genotype animals. One such protein was acetyl-CoA acyltransferase 
2 encoded by ACAA2, which catalyzes the last step of mitochondrial fatty acid oxidation.  It was 
up regulated in wild type and mutant mice with fasting. The data from previous experiments had 
showed that ACAA2 was down-regulated in the deficiency of VLCAD in the fed state (Table 9).  
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Table 13.  Statistically significant altered proteins in fasted VLCAD deficient mice  
compared to fed VLCAD deficient mice  
 
Gene 
symbol 
 
Gene Name 
Protein 
score  
Protein 
mass 
Minimum 
peptides 
Averaged 
ratio 
FKO: NKO M2GD Dimethylglycine dehydrogenase,  1678 113197 111 -2.97 PHB Prohibitin  831 33803 5 -2.90 CP2F2 Cytochrome P450 2F2  357 62789 3 -2.39 SARDH Sarcosine dehydrogenase, mitochondrial  875 110963 38 -2.39 CPSM Carbamoyl-phosphate synthase [ammonia], mitochondrial  5588 196508 294 -2.26 CP2DQ Cytochrome P450 2D26  78 64166 2 -2.13 NDUA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  187 12059 8 -2.11 QCR1 Cytochrome b-c1 complex subunit 1 76 57546 9 -1.96 ABCD3 ATP-binding cassette sub-family D member 3  594 88929 21 -1.88 COX2 Cytochrome c oxidase subunit 2  419 27922 18 -1.82 ATPA ATP synthase subunit alpha 9622 69542 265 -1.82 QCR2 Cytochrome b-c1 complex subunit 2 113 56769 5 -1.82 CISY Citrate synthase 103 60451 3 -1.77 PYC Pyruvate carboxylase 4282 148148 67 -1.74 PRDX5 Peroxiredoxin-5, mitochondrial  361 27027 8 -1.71 THIL Acetyl-CoA acetyltransferase,  744 54798 24 -1.68 PCCB Propionyl-CoA carboxylase beta chain, mitochondrial  1616 66164 8 -1.66 ECHA Trifunctional enzyme subunit alpha 3713 103551 43 -1.6 KAD2 Adenylate kinase 2, mitochondrial  464 33070 21 -1.50 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  1494 43064 6 -1.42 HMGCL Hydroxymethylglutaryl-CoA lyase 468 40895 2 -1.42 CY1 Cytochrome c1, heme protein 827 40052 19 -1.37 DLDH Dihydrolipoyl dehydrogenase, mitochondrial  80 66516 11 -1.35 ALDH2 Aldehyde dehydrogenase, mitochondrial  2155 66346 72 -1.32 MDHM Malate dehydrogenase, mitochondrial  27170 43866 380 1.36 CH10 10 kDa heat shock protein, mitochondrial  406 14606 43 1.38 PDIA1 Protein disulfide-isomerase  3853 72944 118 1.41 RT36 28S ribosomal protein S36, mitochondrial  239 14136 31 1.42 GRP78 78 kDa glucose-regulated protein  3498 91330 23 1.58 GPX1 Glutathione peroxidase 1  246 25238 8 1.65 THIM 3-ketoacyl-CoA thiolase, mitochondrial  12121 49804 185 1.67 SODC Superoxide dismutase [Cu-Zn]  3257 19113 47 1.73 UK114 Ribonuclease UK114  224 17030 2 1.89 
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MUP2 Major urinary protein 2  722 24835 75 2.38 LACB2 Beta-lactamase-like protein 2  64 38439 3 2.43 
 
35 unique proteins that were significantly changed (p≤0.10, Student’s t-test) in the fasted deficient mice compared to 
fed deficient mice. They were identified with a minimum of 2 peptides. The table includes the significantly changed 
proteins with gene symbol, gene names, minimum peptides detected for each protein, minimum proteins score, 
protein mass and averaged ratios of protein expression in fasted VLCAD deficient mice versus in fed VLCAD 
deficient mice  (FKO: NKO). p-values were not shown (p≤0.10, Student’s t test). The protein ratio was considered 
to be a significant up-regulation or down-regulation if its expression ratio was ≥1.25 or ≤0.75, respectively. FKO 
(protein expression in VLCAD deficient mice in the fasted state). NKO (protein expression in VLCAD deficient 
mice in the fed state). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13  Continued 
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Table 14. . Statistically significant altered proteins in fasted wild type mice  
compared to fed wild type mice   
 
Gene 
symbol 
Gene names Protein 
score 
Protein 
mass 
Minimum 
peptides 
Averaged 
ratio 
FWT:NWT NUD12 Peroxisomal NADH pyrophosphatase NUDT12  144 61156 3 -2.54 ENPL Endoplasmin  593 116072 21 -2.46 LICH Lysosomal acid lipase/cholesteryl ester hydrolase  86 53052 4 -2.38 GANAB Neutral alpha-glucosidase AB  62 116338 2 -2.37 CP2D9 Cytochrome P450 2D9  97 62968 3 -2.25 UD2A1 UDP-glucuronosyltransferase 2A1  69 73117 4 -2.24 UD2A2 UDP-glucuronosyltransferase 2A2  69 71552 4 -2.24 NDUA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  115 12059 2 -2.23 MMSA Methylmalonate-semialdehyde dehydrogenase [acylating],  700 67981 11 -2.21 UD2A3 UDP-glucuronosyltransferase 2A3  69 72933 3 -2.07 UDB17 UDP-glucuronosyltransferase 2B17  69 73444 3 -2.07 NDUA9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9,  123 48963 2 -2.0 AL3A2 Fatty aldehyde dehydrogenase  214 64315 2 -1.80 PDIA3 Protein disulfide-isomerase A3  337 72829 28 -1.77 EFGM Elongation factor G, mitochondrial  260 98392 14 -1.72 CP3AB Cytochrome P450 3A11  300 72999 19 -1.72 BDH D-beta-hydroxybutyrate dehydrogenase 216 45837 7 -1.63 NLTP Non-specific lipid-transfer protein  2066 73587 43 -1.63 ECHA Trifunctional enzyme subunit alpha,  554 103551 13 -1.60 THIKB 3-ketoacyl-CoA thiolase B, peroxisomal  1044 49857 36 -1.59 HYES Epoxide hydrolase 2  1422 73582 14 -1.56 ALDH2 Aldehyde dehydrogenase,  1918 66346 64 -1.55 THIKA 3-ketoacyl-CoA thiolase A, peroxisomal  1460 49465 39 -1.55 CYB5 Cytochrome b5  1004 18578 13 -1.53 PAHX Phytanoyl-CoA dioxygenase, peroxisomal  845 45339 18 -1.49 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  179 81400 7 -1.48 THTR Thiosulfate sulfurtransferase  1827 38192 15 -1.44 RETST All-trans-retinol 13,14-reductase  489 80565 13 -1.42 DHB4 Peroxisomal multifunctional enzyme type 2  2156 95056 12 -1.40 AL4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial  550 72482 13 -1.39 GRP78 78 kDa glucose-regulated protein  4429 91330 78 -1.38 TRI14 Tripartite motif-containing protein 14  213 55987 8 -1.36 PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial 111 32552 7 1.38 
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ETHE1 Protein ETHE1, mitochondrial  695 30569 3 1.44 THIM 3-ketoacyl-CoA thiolase,  3925 49804 94 1.48 CBR1 Carbonyl reductase [NADPH] 1  198 37240 4 1.59 CH10 10 kDa heat shock protein 165 14606 14 1.65 MUTA Methylmalonyl-CoA mutase,  343 98491 4 1.71 ACBP Acyl-CoA-binding protein  146 14861 4 1.82 NDUV2 NADH dehydrogenase [ubiquinone] flavoprotein 2  1679 32107 11 1.90 BOLA1 BolA-like protein 1 102 16029 4 2.48 
 
41 unique proteins that were significantly changed (p≤0.10, Student’s t-test) in the fasted wild type mice compared 
to fed wild type mice. They were identified with a minimum of 2 peptides. The table includes the significantly 
changed proteins with gene symbol, gene names, minimum peptides detected for each protein, minimum proteins 
score, protein mass and averaged ratios of protein expression in fasted wild type mice versus in fed wild type mice  
(FWT: NWT). p-values were not shown (p≤0.10, Student’s t test). The protein ratio was considered to be a 
significant up-regulation or down-regulation if its expression ratio was ≥1.25 or ≤0.75, respectively. FWT (protein 
expression in wild type mice in the fasted state). NWT (protein expression in wild type mice in the fed state). 
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Two mitochondrial chaperonin proteins were differently altered in these experiments 
(Experiment 4 and 5) and the previous ones (Experiment 1, 2 and 3). Chaperonin 10 (HSPE1) 
was up-regulated in both VLCAD deficient and wild type mice in the fasted state as compared to 
the fed state, but was down-regulated in fasted VLCAD deficient mice as compared to the fasted 
wild type mice.  However, this protein was similarly expressed in fed VLCAD deficient and fed 
wild type mice. HSP60 (HSPD1), a HSP10(HSPE1) co-chaperonin, showed a different pattern of 
changes. HSP60 showed higher expressions in VLCAD deficient mice in the fed state compared 
to fed wild type animals but no changes in fasted VLCAD deficient mice as compared to fasted 
wild type mice.  Its expression was unchanged in fasted animals of either genotype compared to 
the fed state.  
HADHA encodes the alpha subunit of the mitochondrial trifunctional protein responsible 
for catalyzing the last three steps of mitochondrial ß-oxidation for long chain substrates. This 
enzyme of hydroxyacyl-CoA dehydrogenase is also a member of acetyl-CoA C-acetyltransferase 
family. It was down-regulated in both genotypic mice in the fasted state as compared to the fed 
state (Experiment 4 and 5). Further examination of the data in fasted VLCAD deficient mice 
showed that it was down-regulated in fasted VLCAD deficient mice (averaged ratio=0.75) as 
compared to fasted wild type animals, but that this change (p-value=0.08) didn’t meet the criteria 
for significance. HADHA expression level was unchanged in VLCAD deficient mice in the fed 
state compared to fed wild type animals, indicating that the down-regulation of this enzyme was 
due to fasting rather than VLCAD deficiency. A similar pattern of change was seen in ALDH2, 
which was down-regulated in fasted animals as compared to normal fed animals regardless of the 
genotypes. Its down-regulation was also observed in fasted VLCAD deficient mice compared to 
the fasted wild type mice. However, there is no change observed in fed VLCAD deficient mice 
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as compared to the fed wild type mice. Therefore, fasting had effects on the down-regulation of 
this enzyme in either type of animals but it is difficult to clarify if it had the same degree of 
effects on deficient animals as it did on the wild type animals. 
The merged networks of altered proteins from two datasets (Experiment 4 and 5) are 
shown in Figure 9 and 10. The top rated network of lipid metabolism and molecular transport 
was identified in each data set. A few common molecules including proteins encoded by HSPA5, 
HADHA and GPX1 were shared in two dataset. However, in merged networks, the majority of 
these common molecules were inferred from the Ingenuity knowledge database that linked the 
connections between the changed proteins. They include the nuclear receptor PPARA, the 
transcription regulator PPARGC14, the transporter APOA4 and the growth factor leptin. Several 
of these linkers were also inferred from the top-rated network of altered proteins in fasted 
VLCAD deficient mice and fed VLCAD deficient mice (Figure 12 and Figure 15). The results 
from both datasets clearly showed that fasting have significant effects on fatty acid elongation in 
the mitochondria and synthesis and degradation of ketone bodies. 
The toxic analysis function of the IPA software was designed to characterize specific 
organ system changes related to exposure to suspected toxins. This analysis was utilized to 
identify patterns of altered protein expression in VLCAD deficient mice suggestive of pathologic 
changes resulting from primary VLCAD deficiency or induced secondary abnormalities. The 
prediction of toxicity based on the pattern of altered proteins in fed VLCAD deficient mice and 
in the fasted VLCAD deficient mice is shown in Figure 23. Interestingly, a pattern of protein 
changes indicative of cardiac damage was more pronounced in fasted VLCAD deficient mice 
than in fed deficient animals, consistent with the known risk for development of cardiomyopathy 
in VLCAD deficient patients under metabolic stress. A pattern of protein changes consistent with 
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liver steatosis was present in fed VLCAD deficient mice and did not change with fasting 
suggesting that avoidance of fasting may not alter liver dysfunction in these patients. Of note, 
fasting effects on liver and heart were slightly seen in the patterns of protein expression in mice 
of both genotypes, but were more significantly associated with liver steatosis in deficient mice 
(Figure 24). The pattern of protein changes suggesting liver steatosis was slightly more 
exaggerated in fasted VLCAD deficient mice than in fasted wild type, and a greater protective 
response to fasting was seen in the liver of wild type animals.  
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Figure 21. Merged networks of altered proteins with fasting  
The network of altered proteins with fasting on VLCAD deficient mice ( proteome profile in fasted 
VLCAD deficient mice was compared to that in fed VLCAD deficient mice) was overlaid with the effects 
of fasting on wild type mice (proteome profile in fasted wild type mice was compared to that in fed wild 
type). Red nodes indicate that the protein is up-regulated in the fasted VLCAD deficient mice as 
compared to fed deficient mice. Green indicates that the protein is down-regulated in the fasted VLCAD 
deficient mice. The color intensity corresponds to the degree of abundance. Proteins in white are those 
inferred from the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the 
protein. A solid line indicates a direct molecular interaction, and a dashed line indicates an indirect 
molecular interaction. Solid blue line highlights the molecules shown in the network of altered proteins in 
fasted deficient mice as compared to fed deficient mice. 
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Figure 22. Merged networks of altered proteins with fasting  
The network of altered proteins with fasting on wild type mice (proteome profile in fasted wild type mice 
was compared to that in fed wild type) was overlaid with the effects on VLCAD deficient mice (proteome 
profile in fasted VLCAD deficient mice was compared to that in fed VLCAD deficient mice). Red nodes 
indicate that the protein is up-regulated in the fasted wild type as compared to fed wild type mice. Green 
indicates that the protein is down-regulated. The color intensity corresponds to the degree of abundance. 
Proteins in white are those inferred from the Ingenuity Pathways Knowledge Base. The shapes denote the 
molecular class of the protein. A solid line indicates a direct molecular interaction, and a dashed line 
indicates an indirect molecular interaction. Solid blue line highlights the molecules shown in the network 
of altered proteins in fasted wild type mice as compared to fed wild type mice. 
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Figure 23. Prediction of toxicity of altered proteins in VLCAD deficient mice in fasted and fed states  
Toxicity analysis was performed in IPA based on the pattern of altered proteins in VLCAD deficient mice 
in both fasting and fed states. Dark blue color denotes toxicity predicted by changed proteins in fasted 
VLCAD deficient mice compared to fasted wild type mice. Light blue shows toxicity predicted by 
changed proteins in fed VLCAD deficient mice compared to fasted wild type mice. Y-axis: significance 
of toxicity arising from the changed proteins( p≤0.05). 
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Figure 24. Prediction of toxicity of altered proteins due to fasting in VLCAD deficient and wild type mice  
Toxicity analysis was performed in IPA based on the pattern of altered proteins due to fasting in VLCAD 
deficient mice and wild type mice. Light blue shows toxicity predicted by changed proteins in VLCAD 
deficient mice due to fasting. Dark blue color denotes toxicity predicted by changed proteins in wild type 
mice due to fasting. 
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3.5 DISCUSSION 
The underlying mechanism of clinical and genetic heterogeneity in VLCAD deficiency is 
unknown, and likely includes genetic and environmental factors, as well as their interaction. To 
explore the biological effects of these factors and their relationships to the disease manifestation, 
proteomic changes in mitochondria in VLCAD deficient mice in the fasting and fed states and 
changes in mitochondrial protein profiles induced by fasting in mutant and wild type animals 
were quantitatively measured. The novelty of this study lies in the use of animal models to 
screen for global biological changes related to genotypic and environmental changes and to 
explore the relevance of alterations in specific functions and pathways using well defined control 
groups. It is the first large scale quantitative proteomics profiling of VLCAD deficient animals, 
and as such it has allowed us to characterize the molecular impact of physiologic stress in these 
animals and investigate genetic-environmental interactions at a global level. The mitochondrial 
proteome of wild type and VLCAD deficient mice while fed and fasted, and each type of mice in 
the fed state to the fasted stated were compared. The results revealed expression changes in 
numerous proteins associated with lipid metabolism in both the fed and fasted states and with 
deficiency regardless of feeding state. In the fed state, the most significantly changed proteins in 
VLCAD deficient mice were those involved in fatty acid metabolism, while alterations in amino 
acid metabolism and fatty acid metabolism predominated in the fasted mutant mice. The proteins 
that were altered only with fasting induction and those that were modified with the deficiency of 
ACADVL alone were identified by comparing altered proteins from different pair-wise 
experiments. The evaluation of fasting effects on VLCAD deficient and wild type mice within 
independent experiments offers a better understanding of these genotype specific 
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environmentally induced changes, which will provide greater insight into the mechanism and 
possible points of therapeutic intervention in this disorder.  
The network of lipid metabolism, molecular transport and small molecule chemistry was 
identified as altered in SCAD deficient mice (Chapter 2). The same named network was shown 
to be the top-rated network associated with altered proteins in VLCAD deficient mice as 
compared to wild type mice. However, more down-regulated proteins were detected in VLCAD 
deficiency than in SCAD deficiency. This observation implies a more severe physiologic impact 
caused by deficiency of VLCAD than SCAD, in keeping with the more severe clinical 
phenotypes seen in patients with VLCAD deficiency. The diverse changes in canonical pathways 
of energy metabolism in VLCAD deficiency highlight the alterations of fatty acid metabolism in 
this disorder, while changes in the mitochondrial proteome in fasted deficient mice identify 
secondary changes that occur due to fasting. NLTP (SCP2), encoding a non-specific lipid transfer 
protein with multiple functions of protein binding, lipid binding and sterol carrier, was decreased 
in VLCAD deficient mice in the fed and fasted states suggesting that lipid transport was 
decreased due to the derangement of metabolism of long-chain fatty acids arising from the 
deficiency of VLCAD. However, the same protein was up-regulated in SCAD deficient mice 
indicating that it was responding to a different, unknown metabolic signal.  
HSP60, a mitochondrial chaperonin protein encoded by HSPD1, was up-regulated in fed 
VLCAD and SCAD deficient mice suggesting that mitochondrial protein folding is affected in 
both deficiencies. However, no changes were identified in fasted deficient animals as compared 
to fasted wild type animals. It did not alter in either VLCAD deficient animals or wild type 
animals with fasting when compared to their non-fasted counterparts suggesting the physiologic 
stress (fasting) is unrelated to its change. Therefore, the disappearance of compensatory change 
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of HSP60 in fasted deficient animals indicates that interaction of gene (ACADVL) and 
environment (fasting) may exist in the expression of HSP60. It should be noted that lack of 
significant changes identified in the fasted animals might simply be due to the difficulty in 
detecting of proteins with low levels of expression in the fasted samples. In contrast, chaperonin 
10 (HSPE1), another mitochondrial chaperonin protein, was up-regulated in the fasting state in 
both VLCAD deficient and wild type animals as compared to the fed state indicating that fasting 
impacts the expression of chaperonin 10. However, it was down-regulated in fasted VLCAD 
deficient mice as compared to the fasted wild type mice, again indicating the interaction of gene 
(ACADVL) and environment (fasting) in the expression of HSPE1. Thus, mitochondrial folding 
appears to adjust to the environmental conditions (i.e., fasting) and may provide another 
secondary pathway for modulation of phenotype in various disorders under different conditions.  
Comparison of the findings with alterations of proteins or encoding genes altered in other 
diseases with changes seen in VLCAD deficient mice helps provide some insight into the 
pathophysiology of VLCAD deficiency. ASS1 (argininosuccinic acid synthase 1) and PIPOX 
(with a synonymous name of SOX, peroxisomal sarcosine oxidase) have been shown to have 
changes associated with skeletal and muscular diseases. Defects in GPD1 (glycerol-3-phoshate 
dehydrogenase 1) and PHYH (phytanoyl-COA hydroxylase 2) and SOD2 (superoxide dismutase 
2) have been associated with systemic hepatic disease. Mice mutant for GPD1 gene 
(homozygous knock out) and a mutant Slc25a13 gene showed increased hyperammonemia, 
hepatic steatosis and hypoglycemia (Saheki et al, 2007). Homozygosity for a PHYH knock out 
allele increased hepatic steatosis in mouse, which was increased by Phytol-enrich diets 
(Ferdinandusse et al, 2008). Similarly, the mutant SOD2 animals had increased hepatic steatosis 
(Begriche et al, 2006). In fed VLCAD deficient mice, proteins encoded by GPD1 and PHYH 
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were decreased, whereas in the fasted VLCAD deficient mice, the protein encoded by PHYH was 
increased. Superoxide dismutase 2 was down-regulated in VLCAD deficient mice in the fasted 
state.  These findings may provide insight into the myopathic and hepatic phenotypes seen in 
VLCAD deficiency. 4-Aminobutyric transaminase (ABAT), which catalyzes the conversion of 4-
aminobutyric acid (GABA) and 2-oxoglutarate into succinic semialldehyde and glutarate in 
mitochondria, was increased in VLCAD deficient mice, but decreased in SCAD deficient 
animals. ABAT deficiency presents with prominent neurologic symptoms(Gibson et al, 1985), 
and may reflect the complicated reported pattern of neurologic symptoms in SCAD deficient 
patients, but rarely seen in VLCAD deficiency. Thus, ABAT encoding protein may prove to be a 
risk marker for development of a neurological phenotype in FAODs. 
Proteins in the most significantly altered constructed network in fed and fasted VLCAD 
deficient mice were linked by several well described transcription factors inferred from the IPA 
knowledge database. They included nuclear receptors of PPARA, PPARG, PPARGC1A, and 
NR3C1 (nuclear receptor subfamily 3, group C) highlighting the importance of nuclear receptors 
in the molecular response to VLCAD deficiency. A similar relationship has been demonstrated in 
one previous study that showed that expression of the PPARA and PPARG genes were increased 
in VLCAD deficient mice in the fasted state, but was unchanged or slightly reduced in the fed 
state (Goetzman et al, 2005). 3-hydroxy-3-methylglutaryl-CoA reductase  (HMGCR) is the rate-
limiting enzyme for cholesterol synthesis and is regulated via a negative feedback mechanism 
mediated by sterols and non-sterol metabolites. Leptin (LEP) is secreted by white adipocytes and 
plays a major role in the regulation of body weight. These molecules were inferred on the basis 
of relationships with other molecules incorporated in the IPA knowledge database to participate 
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in regulating changes in the function of lipid metabolism in VLCAD deficient mice. Further 
studies are needed to demonstrate their roles in determining clinical symptoms in FAODs.  
Multiple proteins are altered in fasted VLCAD deficient mice as compared to fasted wild 
type mice, consistent with an earlier report that mutant animals express some specific 
pathological and biochemical phenotype symptoms under this condition(Cox et al, 2001b). 
However, the relative effects of fasting vs. ACADVL gene deficiency were not well delineated in 
that study. To further define the altered proteins and pathways responsible for abnormal response 
to fasting, independent comparisons between fasted animals of both genotypes and fed animals 
were conducted. The analyses revealed that fasting had significantly different effects in wild type 
animals than VLCAD deficient ones, and, furthermore that gene-environment interactions 
existed, which were indicative by the observations on several proteins and some associated 
functional groups and canonical pathways. Acetyl-CoA acyltransferase 2 (ACAA2), which 
catalyzes the last step of mitochondrial fatty acid oxidation, was up regulated in wild type and 
mutant mice with fasting. However, it was down-regulated in fed VLCAD deficient as compared 
to fed wild type mice (Table 9). It is suggestive that the fasting resulted in a compensatory 
change in this enzyme for the release of acetyl CoA for Krebs cycle activity when the energy 
was depleted in the fasting state. The alteration of its expression from down-regulation in 
VLCAD deficiency to up-regulation due to fasting indicated that the effect of fasting 
counteracted with the effect of gene deficiency leading to the unchanged expression in the fasted 
VLCAD deficient mice. A similar phenomenon was seen in ACAA2 expression in fasted 
VLCAD deficient mice to fasted wild type mice, in which ACAA2 did not show changes. An 
apparent gene-environment interaction was also demonstrated in the expression of chaperonins 
HSP60 and HSP10 as discussed earlier.  
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While lipid metabolism was the predominant change seen in fed mutant animals and both 
differed compared to wild type mice, the carbohydrate metabolism with its assigned higher-level 
functional category with cellular function, cell maintenance and cell death was most altered in 
fasted VLCAD deficient mice. However, most altered proteins that were grouped into the 
carbohydrate metabolism include proteins encoded by SCP2 with down-regulation and GANAB 
and PRKCSH with up-regulation in VLCAD deficient mice with fasting. Comparison between 
altered proteins in fasted VLCAD deficient mice and those changed in fed VLCAD mice (as 
both compared to wild type mice in each feeding condition) support this finding. The decrease in 
proteins associated with carbohydrate metabolism is not likely related to the observation that 
VLCAD deficient mice are well in the fed state and develop hypoglycemia only after prolonged 
fasting (Cox et al, 2001a). Rather, identification of altered carbohydrate metabolism was related 
to up-regulation of GANAB and PRKCSH, two proteins related to galactose metabolism (Figure 
16). In addition, SOD2 was down-regulated in fasted VLCAD deficient mice and is related to 
carbohydrate metabolism indirectly through other molecules. Significant differences were also 
seen in the functions of protein degradation, synthesis and amino acid metabolism (Figure 19). 
Overall, findings in this study identify an environmental effect specific to the VLCAD deficient 
genotype, leaving mutant animals more vulnerable than wild type mice to the stress of fasting.  
Canonical pathway analysis identified significant changes in fasting animals of both 
genotypes, including alterations in proteins involved in branched chain amino acid metabolism, 
fatty acid metabolism, pyruvate metabolism, and the synthesis and degradation of ketone bodies. 
In contrast, fewer differences in the significance was seen between the changes in deficient mice 
and in wild type mice, indicating that the changes in these pathways were related to fasting but 
not genotype. In response to energy demands during fasting, fatty acids stored as triacylglycerols 
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in the body are mobilized for use by peripheral tissues. The results from this proteomic study 
confirm that the normal physiologic response to fasting remains intact in the face of VLCAD 
deficiency.  
It is noteworthy that well characterized biochemical abnormalities seen in individuals 
with fatty acid oxidation defects are reflected in changes in the protein profiles in VLCAD 
deficient mice. Although expression of some individual proteins changed, association analysis 
showed that in total, the pathway of ketone bodies production was not significantly up regulated 
in fasting as in wild type animals. Alteration of other pathways is more difficult to interpret. The 
pathways of amino acid metabolism, especially branched chain amino acid metabolism, as well 
as carbohydrate and fatty acid metabolism were more significantly altered in the fasted state than 
in the fed state in mutant mice suggesting a more global derangement in cellular metabolism in 
fasting mutant animals. The greatest differences were in the oxidative phosphorylation and citric 
acid cycle pathway and bile acid synthesis. An increased pattern in oxidative phosphorylation 
identified in fed VLCAD deficient mice disappeared when they were fasted. The oxidative 
phosphorylation pathway was unchanged when wild type mice were fasted. However, fasting 
induced the down-regulation of several proteins in OXPHOS in mutant animals. Thus a 
presumed compensatory change in the mutant animals appears to be negated during fasting, and 
may play a role in the development of symptoms.  
The global changes on protein expression resulting from fasting and gene deficiency were 
investigated. The clinical relevance to secondary changes associated with ACADVL gene 
deficiency was further evaluated through the toxicity analysis function in the IPA software to 
provide additional insight into the pathologic alterations induced by ACADVL gene deficiency 
and fasting. Mice deficient for VLCAD develop hepatic steatosis upon fasting (Cox et al, 
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2001b). They also accumulate microvesicular lipids and demonstrate marked mitochondrial 
proliferation in heart (Exil et al, 2003). Both phenotypes are seen in the human deficiency to 
some extent. In one study, 12 of 15 patients with VLCAD deficiency showed dilated or 
hypertrophic cardiomyopathy (Mathur et al, 1999). Toxicity analysis using the IPA software 
indeed identified a pattern of protein changes predictive of liver damage (steatosis) in VLCAD 
deficient mice under both feeding states and the liver changes were slightly exacerbated in 
VLCAD deficient mice with fasting. A pattern of protein changes predictive of significant 
cardiac effects of fibrosis, enlargement and dilation) was identified in fasted deficient mice 
suggesting that fasting may play more of roles in the development of cardiac than liver 
symptoms in affected patients. It has been hypothesized that the myocardial damage may be due 
to the accumulation of toxic metabolites during starvation (Strauss et al, 1995). We propose that 
the cardiac effects of VLCAD deficiency are a consequence of a combination of the primary 
acute stress combined with resultant secondary physiologic manifestations in the genetic 
deficiency. 
Proteomic experiments in this study benefited from the sensitivity and quantitation of 
LC-MS/MS, but considerable challenges remained. First, experiments were performed and all 
samples were collected over time, thus, variability in sample handling and storage were 
introduced into experiments, which is a significant issue in light of the high sensitivity of this 
technique. Much of the assay variability can be attributed to the inherent limitations arising from 
the efficiency of commercially available reagents and approaches, variability of biological 
replicates, the data analysis tools and database used for mass spectra and pathway analysis. For 
examples, IEF was used for the separation of peptides. Most, but not all, of the peptides could 
further be separated and captured by MS, which include those having pKa around 3.5-4.5, 
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leading to inefficiency of separation. Columns used for the purification and elution of peptides 
introduced additional reproducibility issues. Second, changes in the level of low abundance 
proteins are difficult to quantitate, and thus, alterations induced by the primary gene defect and 
its interaction with the environment (fasting) are likely to be under recognition. It should be 
noted that while few proteins were altered with the same pattern in deficient mice in both feeding 
states, this might be due to that fewer proteins in the fasted deficient mice were under detection. 
Fewer proteins were identifiable in deficient mice than in wild type mice when they were fasted. 
This issue may be arisen from the unfavorable reproducibility rather than that fewer proteins 
were present. It is also important to note that alterations of some low level proteins identified in 
only one experiment could be real even though it is not reproducible in repeat experiments. 
Additional experiments will be necessary to validate such changes if they are of interest. 
Identifying more differentially expressed proteins was of particular interest in this study. To 
maximize the identification of significantly changed proteins for further comparisons among 
datasets, the selection criterion of significance was set to be at p≤0.05 (1 side), which was under 
the assumption that one specific protein was significantly changed as either up-regulated or 
down-regulated. However, this approach did not negate the levels of changes in abundant 
proteins in the fasted animals.  
Finally, these proteome studies on VLCAD deficient mice focused on mitochondria and 
thus are limited to proteins whose genes are located either on the mitochondrial chromosome or 
are nuclear encoded but imported into mitochondria after translation. A broader examination of 
changes in other cellular compartments may provide additional evidence for secondary 
derangements caused by and important to this deficiency.  
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In conclusion, the mitochondrial proteome changes in VLCAD deficient mice were 
quantitatively characterized and effects related to fasting in both mutant and wild type animals 
were identified in this study. Some of these changes reflect known physiologic and pathologic 
alterations previously characterized in VLCAD deficiency and fasting. Others provide novel 
insights into possible new secondary effects of the defect and mechanisms for disease 
heterogeneity. The results from this study identify an aberrant fasting response in VLCAD 
deficient mice and provide possible physiologic explanations for the diversity of disease severity 
in patients with VLCAD deficiency. The secondarily altered proteins in mutant animals define 
interactions of both genes and specific environmental interactions with the ACADVL gene. These 
experiments demonstrate the power of the system in this study to examine altered responses to 
environmental factors related to a primary genetic deficiency and offer the possibility of 
identifying new strategies for treatment of acute symptoms and long-term sequelae. Further 
exploration with this system and subsequent functional studies suggested from this study will 
allow elucidation of the mechanisms that underlie the phenotypic complexity in VLCAD 
deficiency.  
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4.0  ENVRIRONMENTAL EFFECTS AND GENE INTERACTION IN TWO FATTY 
ACID BETA OXIDATION DISORDERS 
 
4.1 INTRODUCTION 
It has become increasingly recognized that many common diseases arise as a result of 
both genetic and environmental factors, as well as the interactions between them. It is not 
hyperbole to suggest that virtually all-human diseases could be viewed as being the result of the 
interaction of genetic susceptibility factors and modifiable environmental factors. Even the 
phenotype of Mendelian disorders is subject to modulation by expression of other genes 
interacting with the environment. However, few of the modifying factors in this situation have 
been identified. Disorders of fatty acid oxidation (FAODs) exemplify these issues. Patients with 
disorders of FAODs often present with recurrent rhabdomyolysis and hypoglycemia but the 
clinical spectrum is pleiotropic and variable. For example, the severity of symptoms in patients 
with deficiencies of the acyl-CoA dehydrogenases (ACADs) that catalyze the first intra-
mitochondrial step of fatty acid oxidation varies from asymptomatic to life threatening metabolic 
crisis. Symptoms are often induced by fasting or physiologic stress, illustrating the importance 
role of environmental factors in the pathophysiology of these disorders. Carriers for a mutation 
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on one allele in one of the ACADs are usually asymptomatic, but individuals heterozygous for 
mutations in more than one gene involved in energy metabolism can become symptomatic, a 
phenomenon termed “synergistic heterogeneity” (Vockley et al, 2000). In total, these 
observations demonstrate the complexity of gene-gene and gene-environment interactions that 
define genetic disease. 
The ACADs are a family of related enzymes that consists of at least 9 members. DNA 
sequencing studies show that the amino acid sequences of the various ACADs share 30-35% 
identical residues but sequencing identities between species approach 90%, indicative of 
evolutionary divergence of a common ancestral gene (Matsubara et al, 1989b; Su et al, 2002; 
Swigonova et al, 2009). ACADs catalyze the β-dehydrogenation of acyl-CoA esters in the 
mitochondrial matrix but differ in their substrate specificity. VLCAD is most active against acyl-
CoA substrates of chain length of 14-20 carbons, and SCAD is optimally active with C4 and C6-
CoA substrates. In Chapters 2 and 3, I have used global analysis of the mitochondrial proteome 
to identify proteins secondarily altered in mice with genetic defects in SCAD and VLCAD 
deficiency. Proteomic changes induced by fasting in VLCAD deficient mice were likewise 
globally surveyed to systemically evaluate the biological response to this physiologic stress. 
Extending these analyses to define consensus proteins altered in both animal models would help 
delineate the common mechanisms of molecular changes induced by both deficiencies, providing 
insight into common potential opportunities for therapeutic intervention. In contrast, 
identification of the proteins changes unique to each genetic variant would allow targeted 
intervention optimized to each disorder and provide new biomarkers to confirm diagnosis and 
monitor therapy. 
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The effect of environmental factors on phenotype and identification of gene-environment 
interactions are usually measured in epidemiological studies on individuals who are genetically 
susceptible to an environmental exposure. However, genetic variation and inconsistent 
environmental exposure make such studies challenging. Restricting the search for gene–
environment interactions to well defined genetic models that interact in the same or related 
biological pathways offers an attractive option to better dissect the relative roles of genes and 
environment in the development of disease. In this chapter, proteome changes in VLCAD and 
SCAD deficient mice are compared to define the secondarily altered proteins unique to and 
shared by these disorders. Network analysis allowed comparison of the annotated functions and 
canonical pathways associated with the changed proteins in the two models. Ultimately, defining 
alterations related to the primary genetic defects, environmental effects on them, the relationship 
of the two defects, and interactions of secondarily altered proteins due to each defective gene 
will provide insight into the pathogenesis of these disorders and allow the development of 
appropriate interventions for high-risk individuals.  
4.2 METHODS 
4.2.1 Pathway and Network Analysis 
All changed proteins in fed VLCAD deficient mice, fed SCAD deficient mice, and fasted 
VLCAD deficient mice were individually compared to changes in wild types (Chapter 2 and 
Chapter 3). The differentially expressed proteins in each dataset were then subjected to the 
comparison analysis incorporated in IPA. Filters and general settings were set as for previous 
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analyses. Comparison analysis in IPA allows direct comparison of changes in biological states 
across a set of observations. I utilized this function to assess the functional annotations, canonical 
pathways and relevant pathological endpoints from the changed proteins/genes across the 
genotypes (SCAD and VLCAD) and stresses (fasted and fed) states within VLCAD. 
4.2.2 Regression model  
To assess the associations between VLCAD gene knock-out, fasting effects and changed 
genes/proteins and explore better biomarkers in the predication of ACADS gene changes, a 
simple regression analysis was used to describe their relationships. The genetic factor VLCAD 
and fasting stress were defined as explanatory variable X, while the proteins that were 
significantly altered were considered as response variables. The relationship is described as the 
equation: y = α + β1x + β2x+ ε, where the component ε is comprised of factors that are 
unobservable, or at least unobserved. The protein values in biological experimental replicates 
were log2-transformed (Chapter 3). In this analysis, the protein value relative to 113 labeled one 
was the response variable y in each independent calculation.  The SCAD or VLCAD variable 
was assigned to have two values, 0 and 1, in the regression analysis, based on the absence or 
presence of the deficient gene. Fasting was assigned to have two values 0 and 1 depending on the 
feeding status of mice. A protein was to have a changed value of folds change when VLCAD-/- 
or SCAD -/- had a value of 0 in deficient mice, and a value of 1 in wild type. Parameter α, β and 
ε were computed from the equation using the software package Stata (College station, Texas). β 
was used to test the significance of associations.  
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4.3 RESULTS 
To characterize the changes in the mitochondrial proteome related to SCAD deficiency, I 
utilized DIGE analysis with MALDI-TOF/TOF for protein identification and quantification 
(Chapter 2). iTRAQ labeling followed by peptide separation and identification with LC-MALDI-
TOF/TOF was performed to evaluate the proteomic changes resulting from VLCAD deficiency 
as well as fasting stress on the animals (Chapter 3).  
4.3.1 Consensus and inconsistently altered proteins  
An overview of the consensus proteins that were changed in both deficient animal models 
is shown in Table 15. Six proteins were consistently identified in both SCAD deficient and 
VLCAD deficient mice in the fed state. However, only one of them, HSP60 (HSPD1) was 
altered in the same direction. In contrast, 5 proteins were identified as altered in both SCAD 
deficient mice and VLCAD deficient mice but with different patterns of changes. 4-
aminobutyrate aminotransferase encoded by ABAT was decreased in SCAD deficiency but 
increased in VLCAD deficiency. SCP2, a non-specific lipid transfer protein was increased in 
SCAD deficient mice but decreased in VLCAD deficient mice. Down-regulation of SCP2 did not 
occur in fasted VLCAD deficient mice. IMMT, an inner membrane protein mitofilin, was down-
regulated in SCAD deficiency but increased in VLCAD deficiency regardless of the feeding 
status.  
Several proteins, including aldehyde dehydrogenase, 2-oxoglutarate dehydrogenase 
complex, electron transfer flavoprotein, fumarate hydratase 1 precursor, and ornithine 
aminotransferase, were up-regulated in SCAD deficient mice but down-regulated in VLCAD 
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deficient mice only when they were fasted. Examination of fasting effects on both wild type and 
VLCAD deficient mice showed that expression of ALDH2 (aldehyde dehydrogenase) was 
decreased in both animals. However, no expression differences were detected in other proteins, 
including ornithine aminotransferase and electron transfer flavoprotein, in response to fasting in 
either VLCAD deficient or wild type mice. 
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Table 15. Consensus proteins changed in SCAD deficient and VLCAD deficient mice  
 
 
 
Gene symbol 
 
 
Gene names 
Ratio of 
protein 
expression  
fed SCAD -/-: 
fed SCAD+/+ 
Ratio of 
protein 
expression 
fed VLCAD-/-: 
fed VLCAD+/+ 
Ratio of protein 
expression 
fasted VLCAD-/- : 
fasted VLCAD+/+ 
ABAT/GABT 4-aminobutyrate 
aminotransferase 
-1.47 1.329  
ALDH2 Aldehyde dehydrogenase, 
mitochondrial 
3.11  -2.351 
CATA Catalase 1.59 -1.689  
CYP2d26 Cytochrome P450 2D26  -1.498 1.873 
DLST/ODO2 Component of 2-oxoglutarate 
dehydrogenase complex 
2.42  -2.034 
ETHE1 Protein ETHE1  1.393 -1.557 
ETFA Electron transfer flavoprotein 
subunit alpha 
1.980  -1.357 
FH/FUMH Fumarate hydratase 1 precursor 1.490  -1.594 
HSPD1/CH60 60 kDa heat shock protein 1.65 1.332  
IMMT Mitochondrial inner membrane 
protein 
-1.493 1.48 2.161 
PHYH/PAHX Phytanoyl-CoA dioxygenase, 
peroxisomal 
 -1.957 1.746 
NUDT7 Peroxisomal coenzyme A 
diphosphatase 
 -2.286 -2.486 
OAT Ornithine aminotransferase, 
mitochondrial 
2.100  -2.212 
RRBP1 Ribosome-binding protein 1 1.74  1.945 
SCP2/NLTP Non-specific lipid-transfer 
protein 
1.92 -1.932 -1.874 
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4.3.2 Comparison of annotated functions  
The biological functions associated with differentially expressed proteins were compared 
among animals with SCAD deficiency, VLCAD deficiency in the fed state, and VLCAD 
deficiency in the fasted state. The difference of associated functions with top significance 
(p≤0.05) is shown in Figure 25. Differences in associated functions included immunological 
disease, inflammatory disease, respiratory disease and hematological disease, which were only 
discovered in VLCAD deficient mice when they were fasted. Proteins that implicate these 
functions include ALDH2, P4HB, PDIA3, MYH9, HSPA5, SOD2, and SCP2, most of them with 
overlapping in associations. However, most of them were up regulated rather than down 
regulated in fasted VLCAD deficient animals.  
Proteins associated with carbohydrate metabolism were more significantly altered in 
fasted VLCAD deficient mice than in fed VLCAD deficient mice and fed SCAD deficient mice. 
Comparison analysis also showed altered proteins in SCAD deficiency associated with 
neurological disease and amino acid metabolism, but there was no clear associations between 
neurological disease and altered proteins in VLCAD deficiency in the fed state. Altered proteins 
associated with neurological disease are shown in Table 16. They include SOD2 (down-
regulated) and aspartylglucosaminidase (up-regulated), both of which were identified in fasted 
VLCAD deficient mice as compared to fasted wild type mice. SOD2 was only reduced in 
VLCAD deficient animals in the fasted status. This protein was unchanged in fed VLCAD or fed 
SCAD deficient mice. Prominent effects associated with neurological disease were found in 
SCAD deficiency involving 6 altered proteins with encoding genes of OTC, NDUFS7, ABAT, 
GLUD1, HSPD1, and MDH2 (Chapter 2). All except HSP60 (HSPD1) were decreased in SCAD 
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deficiency. No proteins associated with neurological disease were identified in fed VLCAD 
deficient mice. 
Less difference in association significance was seen in the functions of lipid metabolism, 
small molecule chemistry and metabolic disease between SCAD and VLCAD deficiencies 
(Figure 25). More similarities of these functions were found between fed and fasted VLCAD 
deficient mice than between SCAD and VLCAD deficiency. In general, changes in fed and 
fasted VLCAD deficient mice were more closely related to each other than to SCAD deficiency. 
 
Table 16. Altered proteins associated with neurological disease  
Deficiency Altered proteins Associated functions/diseases 
VLCAD deficiency in the 
fasted state 
SOD2(-), AGA(+) Neurological disease 
SCAD deficiency OTC(-), NDUFS7(-), ABAT(-), 
GLUD1(-), HSPD1(+), MDH2 
Neurological disease 
(-­‐)	  denotes	  the	  up-­‐regulation,	  (+)	  denotes	  the	  down-­‐regulation	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Figure 25.  Comparison of annotated functions associated with altered proteins 
Comparison of functions associated with differentially expressed proteins in deficient mice when 
compared to corresponding wild type mice. Light blue- SCAD deficiency. Mild blue-VLCAD deficiency 
in the fed status. Dark blue-VLCAD deficiency in the fasted status. p-value: Fisher’s exact test (threshold 
p=0.05). 
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4.3.3 Comparison of involved canonical pathways  
Most of the canonical pathways associated with secondarily altered proteins differed 
between VLCAD deficiency and SCAD deficiency (Figure 26). The amino acid metabolism 
related pathways such as arginine and proline metabolism, glutamate metabolism, histidine 
metabolism, and ß-alanine metabolism were more significantly altered in SCAD deficiency. 
Fatty acid metabolism was almost equivalently altered in SCAD deficiency and VLCAD 
deficiency in the fed states. Though few overlapping molecules involved in this fundamental 
pathway in ACADD were identified in the three datasets, most of them were of similar function 
(Table 17). For example, proteins encoded by ACAA1 and ACAA2 performed the same 
enzymatic (acetyl-CoA acyltransferase) activity but with different substrates. Enoyl-CoA delta 
isomerase 1 encoded by ECI1 is a member of the hydratase/isomerase superfamily involved in 
-oxidation of unsaturated fatty acids. ECI2 (PECI) is an auxiliary enzyme that catalyzes an 
isomerization step required for the beta-oxidation of unsaturated fatty acids. 
More significant changes in protein expression were involved in mitochondrial 
dysfunction and oxidative phosphorylation in SCAD deficiency than in VLCAD deficiency 
(Figure 26), with the majority of proteins involved in mitochondrial dysfunction being included 
in the oxidative phosphorylation pathway (Table 17). Moreover, the changes in SCAD 
deficiency differed remarkably from those seen in VLCAD deficiency. Multiple complex I, III, 
and IV subunits were decreased in SCAD deficiency, but fewer of them were altered in VLCAD 
deficiency (fed), and those that were altered, were increased. Only ATP synthase (complex V) 
was increased in both SCAD deficiency and VLCAD deficiency in the fed state. 
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Figure 26. Comparison of canonical pathways associated with altered proteins 
Comparison of canonical pathways associated with differentially expressed proteins in deficient mice 
compared to corresponding wild type mice. Light blue- SCAD deficiency. Mild blue-VLCAD deficiency 
in the fed state. Dark blue-VLCAD deficiency in the fasted state. p-value: Fisher’s exact test (threshold 
p=0.05). 
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Table 17. Altered proteins and their involved canonical pathways  
in SCAD deficiency (fed state )and VLCAD deficiency (fed state, fasted state)  
Deficiency Altered proteins  Pathway -log(p-
value) VLCAD deficiency in the fasted state ALDH2 (-), Cyp2d26 (+), CYP2D10 (+), ACADVL (-), ECI2 (+), IVD (-), ACAA2 (-), DHRS4 (-)  Fatty acid metabolism  7.93E00 VLCAD deficiency in the fed state Acaa1b (-), Cyp2d26 (-), ACAA1 (-), ACADVL (-), CYP3A4 (-), PECR (-), Cyp2c29 (-) Fatty Acid Metabolism   1.02E01 SCAD deficiency in the fed state ALDH4A1 (+), ALDH2 (+), ACADL (+), CPT2 (-), ALDH9A1 (+), ACAA2 (+), ECI1 (+), ACADS (-) Fatty Acid Metabolism    8.89E00 VLCAD deficiency in the fasted state SOD2 (-), NDUFV2 (-), PRDX5 (+) Mitochondrial Dysfunction 2.02E00 VLCAD deficiency in the fed state NDUFV1 (+), ATP5B (+), CAT (-), UQCRC1 (+), COX4I1 (+)  Mitochondrial Dysfunction 4.59E00 SCAD deficiency in the fed state COX6B1 (-), NDUFS7 (-), ATP5A1 (+), NDUFB7 (-), UQCRC2 (-), CAT (+), UQCRFS1 (-), NDUFA7 (-), AIFM1 (-) 
 Mitochondrial Dysfunction 1.08E01 
VLCAD deficiency in the fasted state NDUFV2 (-) Oxidative Phosphorylation 4.09E-01 VLCAD deficiency in the fed state  NDUFV1 (+), UQCRHL (+), ATP5B (+), UQCRC1 (+), COX4I1 (+)  Oxidative Phosphorylation 4.35E00 SCAD deficiency in the fed state  COX6B1 (-), NDUFS7 (-), ATP5A1 (+), NDUFB7 (-), UQCRC2 (-), UQCRFS1 (-), NDUFA7 (-)  Oxidative Phosphorylation 7.33E00 
(-) denotes the up-regulation, (+) denotes the down-regulation 
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4.3.4 Comparison of clinical relevance  
The toxic function analysis incorporated in the IPA software attempts to assess the 
toxicity of small molecules on organs such as liver, heart and kidney. I instead used it to flag 
potentially clinically relevant changes induced in these organs by SCAD and VLCAD 
deficiency. In this analysis, the SCAD or VLCAD gene deficiency and secondary changes 
identified in the proteome were defined as a “toxins” and assigned to functional pathways as 
with more traditional small molecule studies (Figure 27). The toxicity results and their related 
proteins used in the analysis are shown in Table 18. The analysis identified a pattern of protein 
changes associated with cardiac enlargement, fibrosis and dilation only in fasting VLCAD 
deficient animals including the proteins encoded by SOD2 and GPX1. The liver steatosis in 
VLCAD deficiency was predicted on the basis of changes in expression of SOD2 and PHYH. 
However, the prediction of liver steatosis in SCAD deficiency was based on only one molecule 
LCAD, which has been previously demonstrated to cause hepatic steatosis (Beattie et al, 2008; 
Zhang et al, 2007).  
Biomarker comparison analysis revealed that several potential biomarkers were unique to 
one dataset with no identified potential biomarkers common to all three datasets. The predicted 
biomarkers as well as their biofluid or tissue locations are summarized in Table 19. Specifically, 
there were no common biomarkers identified between SCAD deficiency and VLCAD deficiency, 
and only two enzyme biomarkers were shared between fed and fasting VLCAD deficient mice. 
The majority of enzyme biomarkers were unique to one feeding state in VLCAD deficient mice 
(Table 20). A simple linear regression analysis did not return a presumably significant 
assessment for the association test.  
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(Table 20). A simple linear regression analysis did not return a presumably significant 
assessment for the association test.  
 
 
 
 
Figure 27. Clinically relevant changes associated with altered proteins  
Prediction of pathological alterations from secondarily changed proteins and defective genes. Dark blue -
VLCAD deficiency (fasted state). Mild blue- VLCAD deficiency (fed state). Light blue-SCAD 
deficiency(fed state)  Y-axis: significance of toxicity arising from the changed proteins ( p=0.05).  
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 Table 18. Molecules used in the assessment of related toxic functions  
Category Analysis Name Molecules  Cardiac Enlargement VLCAD deficient (fasted)  SOD2  Hepatocellular Peroxisome Proliferation VLCAD deficient (fasted, fed), SCAD deficient (fed)  SCP2  Cardiac Fibrosis VLCAD deficient (fasted)  GPX1  Liver Steatosis VLCAD deficient (fasted, fed)  SOD2, PHYH  Liver Steatosis SCAD deficient (fed)  ACADL  Cardiac Dilation VLCAD deficient (fasted)  SOD2, GPX1 
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                                           Table 19.  Unique biomarkers in SCAD deficiency or VLCAD deficiency  Gene Deficiency Symbol Entrez Gene Name Family Fold Change Species Tissues/Biofluid VLCAD deficiency (fed)  ACP5  Acid phosphatase 5,  tartrate resistant  phosphatase  -1.752 Human, Mouse Blood, plasma/serum, B lymphocyte, liver VLCAD deficiency (fed)  AMACR  alpha-methylacyl-CoA racemase enzyme  -1.531 Human, Mouse Not detected in biofluid but in macrophages, monocytes, liver. VLCAD deficiency (fed)  CYP3A4  cytochrome P450, family 3, subfamily A, polypeptide 4  enzyme  -1.646 Human, Mouse urine,B lymphocyte, liver. VLCAD deficiency (fed)  EPHX2  epoxide hydrolase 2, cytoplasmic  enzyme  -1.626 Human, Mouse urine,liver. VLCAD deficiency (fed)  GPD1  glycerol-3-phosphate dehydrogenase 1 (soluble)  enzyme  -1.799 Human, Mouse urine, Bronchoalveolar Lavage Fluid, liver VLCAD deficiency(fasted)  FABP1  fatty acid binding protein 1, liver  transporter  -1.486 Human, Mouse Blood,Plasma/Serum,urine, liver  VLCAD deficiency(fasted)  GPX1  glutathione peroxidase 1  enzyme  -2.126 Human, Mouse Blood,Plasma/Serum,liver VLCAD deficiency (fasted)  HMGCS2  3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)  enzyme  1.613 Human, Mouse Not detected in biofluid,liver. VLCAD deficiency (fasted)  HSPA5  heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)  other  1.443 Human, Mouse Blood,Plasma/Serum,Urine, liver. VLCAD deficiency (fasted)  NUCB1  nucleobindin 1  other  1.856 Human, Mouse liver VLCAD deficiency(fasted)  PDIA3  protein disulfide isomerase family A, member 3  peptidase  1.905 Human, Mouse Blood,Urine,liver  VLCAD deficiency (fasted)  SOD2  superoxide dismutase 2, mitochondrial  enzyme  -1.467 Human, Mouse Blood,Plasma/Serum,Urine, liver  SCAD deficiency(fed)  ACADL  acyl-CoA dehydrogenase, long chain  enzyme  2.000 Human, Mouse Not detected in biofluid,liver  SCAD deficiency(fed)  ACADS  acyl-CoA dehydrogenase, C-2 to C-3 short chain  enzyme  -3.580 Human, Mouse Not detected in biofluid,liver SCAD deficiency(fed)  CPT2  carnitine palmitoyltransferase 2  enzyme  -2.703 Human, Mouse Blood,Plasma/Serum,liver SCAD deficiency(fed)  EPHX1  epoxide hydrolase 1, microsomal (xenobiotic)  peptidase  1.500 Human, Mouse Not detected in biofluid,liver  SCAD deficiency(fed)  GLUD1  glutamate dehydrogenase 1  enzyme  -2.041 Human, Mouse Blood,liver etc. SCAD deficiency(fed)  PC  pyruvate carboxylase  enzyme  1.560 Human, Mouse Not detected in biofluid,liver  SCAD deficiency(fed) PHB  prohibitin transcription regulator  -1.786 Human, Mouse Blood, liver  
*These candidate biomarkers were predicted by IPA. 
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Table 20. Common biomarkers in VLCAD deficiency in the fed state and fasted state  
 
Symbol 
 
Entrez Gene Name 
 
Family 
Fold Change 
in VLCAD 
deficiency 
(fed) 
Fold Change in 
VLCAD 
deficiency 
(fasted) 
 ACADVL  acyl-CoA dehydrogenase, 
very long chain 
 enzyme  -4.033  -3.416 
 NUDT7  Nudix  (nucleoside 
diphosphate linked moiety 
X)-type motif 7 
 enzyme  -2.286  -2.486 
 PHYH  phytanoyl-CoA 2-
hydroxylase 
 enzyme  -1.957  1.746 
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4.4 DISCUSSION 
Mitochondrial fatty acids β-oxidation proceeds via a series of enzymatic reactions in 
which an acyl-CoA ester is oxidized, hydrated, and oxidized again, with a final thiolytic cleavage 
to remove a two carbon acetyl-CoA moiety. Electrons are then channeled to oxidative 
phosphorylation through complex I of the respiratory chain by the electron transfer flavoprotein 
(ETF) (Figure 1). Multiple enzymes function at each step, depending largely on the chain length 
of the substrate. Genetic disorders in humans exist in nearly every enzyme in the pathway and 
patients can present with a bewilderingly wide array of symptoms. The mechanism for this 
clinical variability is completely unknown. Secondary changes in other pathways in energy 
production may, in part, explain some of this variation as well as an individual’s response to 
environmental stimuli. In this study, I have attempted to clarify these issues through examination 
of the mitochondrial proteomic profile changes in models of VLCAD and SCAD deficiency 
under different environmental conditions. Secondarily altered proteins induced by these genetic 
deficiencies as well as their associated functions and involved pathways were compared to 
identify differences of potential import to determining phenotypic variation. Importantly, the 
majority of altered proteins differed in the two different deficiencies, implicating fundamentally 
different mechanisms of pathophysiology in the two disorders. Of note, even those proteins that 
were altered in both deficiencies showed different patterns of alterations. Thus, the very different 
phenotypes seen in patients with defects in these two ACADs are likely to at least in part be 
explained by the divergent changes induced by the primary gene defects.  
Changes observed in chaperonin proteins provide some insights into secondary effects of 
these deficiencies on the process of protein folding or binding in the mitochondrial matrix. 
HSP60 was up-regulated in both deficient mice, suggesting that these functions represent a 
  146 
compensatory mechanism related to disruption of fatty acid ß-oxidation in general rather than 
one specific to either defect. HSP60 encoded by HSPD1 is involved in mitochondrial protein 
folding, and the accumulation of unfolded protein within the mitochondrial matrix results in the 
transcriptional up-regulation of chaperonin 60 and chaperonin 10 (Martin, 1997; Zhao et al, 
2002). Fibroblasts with point mutations from patients with SCAD deficiency have been shown to 
have increased levels of HSP60 chaperonin presumably due to the accumulation of abnormal 
SCAD protein (Bross et al, 2007). It should be noted, however, that both of the mouse models of 
SCAD deficiency and VLCAD deficiency used in this study are null, so the effect in chaperonin 
function is not a result of the presence of abnormal or mutant protein. Up-regulation of HSP60 in 
VLCAD deficient mice suggests a compensatory response in vivo when fatty acids are not being 
used as the major energy resource. In normal individuals, FAO functions primarily as an 
endocrine mediated response to fasting and increased energy demands due to glycogen depletion. 
However, alteration of HSP60 in VLCAD deficient animals was not linked to fasting, suggesting 
a non-energy based stimulus for this change. In contrast, HSP10, which binds HSP60 to form a 
symmetric functional heteromer enhancing protein folding in an ATP-dependent manner (Burns 
et al, 1992), was down-regulated in VLCAD deficient mice in the fasted state, suggesting that 
this molecule change was energy induced. Considering these apparently divergent results, I 
hypothesize that protein folding is initially compensatory in the face of ACAD deficiency, but 
that this rescue mechanism is compromised with the more dramatic energy deficit caused by 
VLCAD deficiency, especially during fasting.  
SCAD was originally characterized in children and adults with a wide variety of 
symptoms but is now most frequently identified in asymptomatic children through newborn 
screening. The preponderance of asymptomatic individuals is very different from other FAO 
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deficiencies. In this study, the pattern of altered mitochondrial proteins differed markedly 
between SCAD and VLCAD deficient mice. Specifically, 4-aminobutyrate aminotransferase 
involved in the conversion of 4-aminobutanoic acid (GABA) was decreased in SCAD deficiency 
but increased in VLCAD deficiency. GABA is the primary inhibitory neurotransmitter in the 
central nervous system. The down-regulation of this enzyme and other related enzymes may 
explain the preponderance of neurological symptoms reported in patients with manifesting 
SCAD deficiency. Additionally, the up-regulation level of this enzyme in VLCAD deficient mice 
suggests a compensatory response and may relate to the paucity of neurologic symptoms seen in 
this disorder. Interestingly, this potential protective response in this enzyme disappeared in 
VLCAD deficient mice when they were exposed to fasting suggesting that patients with this 
disorder may face added risk for neurologic dysfunction during fasting.  
SCP2, a non-specific lipid transfer protein, was increased in SCAD deficient mice but 
decreased in fed and fasted VLCAD deficient mice as compared to the wild type mice in the 
same feeding state. This protein was decreased by fasting in wild type mice but was not altered 
further by fasting in VLCAD deficient mice. The discrepancy of SCP2 expression in two 
different defects of ACADs further demonstrated the distinctive features in patients with two 
deficiencies. It is illustrative that a defect of short chain fatty acids ß-oxidation induced the 
functions of lipid binding, and transferase activities as a compensatory response, while defective 
long-chain fatty acids ß-oxidation resulted in the reduction of these functions. The significance 
of reduction of SCP2 in VLCAD deficient mice compared to wild type mice in both feeding 
states likely reflects reduced needs for the lipid binding and transferase activities due to the 
accumulation of long chain fatty acids. Changes in fed VLCAD deficient mice are analogous to 
those seen in fasting wild type animals, leaving no room for further response during fasting in 
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VLCAD deficient mice. Opposite changes were seen in IMMT, an inner membrane protein 
mitofilin with critical functions in mitochondrial morphology and mitochondrial fusion and 
fission. This protein was down-regulated in SCAD deficiency but up-regulated in VLCAD 
deficiency regardless of the feeding status. The functional significance of these changes remains 
to be determined.  
Aldehyde dehydrogenase encoded by ALDH2 was decreased in both wild type and 
VLCAD deficient animals. Thus, the expression difference in aldehyde dehydrogenase in fasted 
VLCAD deficient mice is likely dictated by fasting rather than the genetic defect. However, 
expression differences in other proteins including ornithine aminotransferase and electron 
transfer flavoprotein can not be explained solely by fasting effects as changes were not seen in 
fasted VLCAD deficient mice. Thus, in contrast to SCAD deficiency, the environmental factor 
fasting and the genetic effect of VLCAD deficiency played synergistic roles in down-regulating 
these proteins.  
As discussed in chapter 3, proteins involved in carbohydrate metabolism were mostly up-
regulated in VLCAD deficient mice upon fasting rather than down-regulated as in wild type 
animals, thus representing a compensatory response specific to stressed VLCAD deficient 
animals. However, changes in SCAD deficient mice in proteins related to neurological disease 
and amino acid metabolism were not reflected in VLCAD deficiency in the fed state. It seems 
like that fasting induce alterations in these functions with milder significance. However, these 
alterations in SCAD deficiency include up-regulated aspartylglucosaminidase (AGA) and down-
regulated SOD2, leaving the consequence of this association uncertain. 
Examination of the literature on the neurologic disease related proteins altered in SCAD 
but not VLCAD deficient animals provides some potential insights into the mechanism of 
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neurologic damage in the former condition. Six proteins associated with neurological disease are 
altered in SCAD deficiency including proteins encoded by the OTC, NDUFS7, ABAT, GLUD1, 
HSPD1 and MDH2 genes. Of these proteins, all except heat shock protein 60 were decreased in 
SCAD deficiency. These proteins remain unchanged in VLCAD deficiency. In contrast, 
superoxide dismutase 2 (SOD2) and aspartylglucosaminidase (AGA) were both altered in fasted 
VLCAD deficient mice. AGA, involved in the catabolism of N-Linked oligosaccharides of 
glycoproteins, has been found to be associated with gliosis, aspartylgulcosaminuria and 
schizophrenia. This enzyme was up-regulated rather than down-regulated in VLCAD deficient 
mice only upon fasting. SOD2 appears to protect against reactive oxygen species and its 
dysfunction has been linked to a variety of neurological diseases. It was reduced in fasted but not 
fed VLCAD deficient animals. Thus, it is difficult to link them to significant deleterious effects 
in VLCAD deficiency.  
It is perhaps not surprising that while some alterations in protein profiles differed in 
SCAD and VLCAD deficient mice, changes in proteins related to such major functions as lipid 
metabolism, small molecule chemistry, and metabolic disease were similar in both mouse models 
(Figure 25), especially comparing fasted VLCAD with fed SCAD deficient mice. More 
similarities of these functions were between VLCAD deficiency in the fasted status and in the 
fed status rather than between SCAD deficiency and VLCAD deficiency. Overall, changes 
reflecting defects in fatty acid metabolism displayed almost the same significance in the 
canonical pathway analysis (Figure 26). Although there is no doubt that the two deficiencies 
altered the same canonical pathway of fatty acid metabolism, the pattern of proteins altered in the 
two deficiencies showed some divergence. Further studies of these differences should provide 
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insight into the divergent pathophysiologic changes resulting from mutations in these 
evolutionarily and functionally conserved enzymes. 
Dramatic alterations in the oxidative phosphorylation pathway observed in both VLCAD 
deficient and SCAD deficient likely reflect relative energy adjustments in response to defective 
fatty acid ß-oxidation. However, changes of protein expression in the OXPHOS pathway in 
SCAD deficient mice differed remarkably from those seen in VLCAD deficient animals. 
Specifically, multiple subunits in complex I, III and IV were decreased in SCAD deficiency, 
while fewer (but not the same) subunits were increased in fed VLCAD deficiency. This apparent 
compensatory response in VLCAD animals was lost with fasting, a situation that would 
exacerbate energy deficiency in these animals. In contrast, defects in this pathway in fed SCAD 
deficient animals identify reduced OXPHOS even when fed, and may be important in the 
development of clinical symptoms in this disorder. These opposite findings further highlight the 
distinctive features of SCAD and VLCAD deficiency and the significant effects of fasting 
imposed on VLCAD deficiency.  
The toxic function analysis incorporated in the IPA software, which aims to assess the 
toxicity of small molecules on organs such as liver and heart in humans, was utilized in this 
study to help provide additional insight into the pathologic alterations induced by SCAD and 
VLCAD deficiency (Figure 26). The results identified a pattern in fasted VLCAD deficient 
animals associated with cardiac enlargement, fibrosis and dilation, particularly involving the 
proteins SOD2 and GPX1. This is in keeping with the identification of VLCAD deficiency as a 
cause of cardiomyopathy and sudden death in humans. A pattern of liver steatosis was seen in 
SCAD deficient mice. Of note, steatosis has previously been demonstrated in LCAD but not 
SCAD deficient animals (Zhang et al, 2007). However, microvesicular fatty changes in 
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hepatocytes from SCAD mutant mice have been reported (Wood et al, 1989), and SCAD 
deficient BALB/cBy mice have been shown to develop a fatty liver upon fasting or dietary fat 
challenge (Armstrong et al, 1993). In VLCAD deficient animals, liver steatosis may be due to or 
exacerbated by alterations in SOD2 and PHYH. Alterations in human SOD2 have been reported 
in association with a decrease of hepatocytes apoptosis induced by ethanol (Wheeler et al, 2001) 
and has been proposed as a biomarker for diagnosis of steatohepatitis (Iacobellis et al, 2006). 
Finally, mitochondrial SOD2 has been found to be associated with dilation and enlargement of 
heart (Lebovitz et al, 1996). It is possible that SOD2 played important roles in both the 
development of fatty changes in liver and cardiac damage with fasting in VLCAD deficiency.  
Systematic natural history and pathophysiologic studies of patients with FAODs are 
difficult. Patients identified through newborn screening are often clinically asymptomatic, and 
the immediate need of correction of metabolic crises does not allow careful study of the patients 
in the symptomatic state. Although mouse models of genetic disease do not always completely or 
accurately reflect their human counterparts, the findings in the current studies suggest strong 
parallels. However, findings with the mouse models will ultimately require confirmation in 
human patients. Despite the significant advantages gained from incorporating MS/MS into 
proteomic studies, there are considerable challenges in interpretation of the accumulated 
data. Chief among these is the fact that some experiments were performed at different times in 
mice with different genetic backgrounds. Additionally assay variability can be introduced by 
inherent limitations arising from the efficiency of commercially available reagents and 
approaches, variability of biological replicates, and the data analysis tools and database used for 
mass spectra and pathway analysis.  
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It should be noted that mitochondria are multifunctional organelles in eukaryotic cells 
and play a critical role in energy metabolism. Several recent proteomic studies have focused on 
the characterization of global survey of this organelle. However, the detection of mitochondrial 
proteins with different proteomic approaches is variable (Kislinger et al, 2006; Mootha et al, 
2003). The annotation of identified proteins has largely relied on additional computational 
methods to account for systematic or spurious noise. It is not surprising, therefore, that the 
number of proteins in mouse liver mitochondria identified in these studies differs from other 
published reports and the number of predicted mitochondrial proteins. This is especially true of 
the fasted animals, as all other reported studies were performed on fed animals, In addition, 
incomplete coverage of mitochondrial proteins may be related to technical variables such as 
peptide fractionation and analyzing only peptides with pI‘s of 3.5-4.5. Nevertheless, 
mitochondrial data obtained from these mouse studies augment information in the current 
mitochondrial proteome database.  
 The recognition that many proteins shuttle between cellular compartments performing 
multiple roles in the cell, as well as probable cross-contamination during fractionation, highlight 
the ongoing challenges of rigorously defining subcellular localization of proteins (Phizicky et al, 
2003), and caution is justified in interpretation of data on proteins supposedly restricted to the 
mitochondria. For example, Nudix  (nucleoside diphosphate linked moiety X-type motif 7)is  a 
member of acetyl-CoA hydrolase family originally localized to peroxisomes. However, the 
Nudix 7 protein was subsequently identified in liver mitochondria from 12 week old male mice 
through LC-MS studies (Douette et al, 2005), The exact role of this protein in mitochondria is 
still unclear but the finding illustrates the potential for new discoveries through non-directed 
proteomic analyses and the need for further validation to discern real variation.  
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 Any inconsistencies if observed between proteomic patterns in this dissertation and the 
literature could reflect several factors including inaccurate existing annotations and shuttling of 
certain proteins between compartments. In this regard, our IPA analysis sometimes flagged 
pathways and cellular functions as being altered that are not consistent with known 
pathophysiology. For example, carbohydrate metabolism is primarily based in cytosol, however, 
IPA analysis inferred an alteration in carbohydrate metabolism based on changes in expression 
of GNANB and PRKCSH, which are categorized as having multiple or unknown locations. It is 
also important to note that the significance of functional annotations or prediction was 
sometimes inferred from a limited number of entries in the IPA knowledge base or indirectly 
from changes in other predicted protein interactions. For example, DNA replication, 
recombination and repair was a flagged as a functional category of higher level by IPA 
(Appendix A). However, this assignment was based on changes in only 2 proteins belonging to 
the disulfide isomerase family A, PDIA3 and SOD2 encoding proteins with the p-value 
calculated by considering the number of molecules that participate in that function and the total 
number of molecules that are known to be associated with that function in the Ingenuity 
Knowledge Base (Appendix A). It is not yet clear if this is in fact a real variation, and highlights 
the need to understand the basic concepts of biostatistical possibility utilized the IPA software.  
 The change in carbohydrate metabolism in fasted VLCAD deficient mice identified in the 
IPA analysis was based on the differential expression of SCP2 (down-regulation) and GANAB 
and PRKCSH (up-regulation). GANAB encodes an alpha-glucosidase that participates in 
galactose metabolism. The ß-subunit of glucosidase II (PRKCSH) may bind GANAB but is of 
unknown function(Arendt & Ostergaard, 1997; Arendt & Ostergaard, 2000). Both proteins are 
predominantly localized in cytoplasm, endoplasmice recticulum and pre-Golgi intermediate 
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vesicles (Zuber et al, 2001). However, the human glucosidase 2 complex has also been reported 
in mitochondria from HepG2 cells (Lehr et al, 2005). SOD2, which  has a variety functions in 
mitochondria and is localized in multiple subcellular organelles including mitochondria inner 
membrane, matrix, cytoplasm and others, influences carbohydrate metabolism through 
PPARGC, LEP and other molecules (Figure 30) related to carbohydrate metabolism uptake, 
transport, turn over, modification and production of D-glucose (Nishikawa et al, 2000). 
  Finally, proteomic screening methods are known to preferentially detect higher-
abundance proteins (Ghaemmaghami et al, 2003). The limited number of fractions were 
collected in these studies, not all of the subunits of well-established multimeric protein 
complexes have been captured. In addition, the annotation of these proteins may not accurately 
reflect their function. The identification of a given protein in my studies was assigned based on 
an algorithm used in the database search tool. Abundant proteins with homologous peptides 
could confound the detection of less abundant proteins and bias the annotation of that protein. 
However, despite these caveats, the altered protein patterns, functional elucidation and their roles 
in the pathogenesis of FAODs reported here should serve as a useful starting point for more 
extensive experimental characterization of core biological findings. 
In conclusion, diverse changes in energy metabolism in SCAD and VLCAD deficient 
mice help explain heterogeneous symptoms in these two disorders. Differential compensatory or 
secondary deleterious effects may play a dominant role in determining the pathophysiology of 
these deficiencies. I anticipate that functional studies and direct investigations suggested from 
these studies on patients will help to elucidate the complex mechanisms underlying phenotypic 
variability, provide more accurate diagnosis, and improve clinical outcome in patients with these 
life-threatening disorders.   
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APPENDIX A 
DEFINITION OF ANNOTATED FUNCTIONS 
Functional analysis in Ingenuity Pathway Analysis associates biological functions and 
diseases to the experimental results by leveraging the complex biological interactions that are 
stored in the Ingenuity Knowledge Base. IPA Functional Analysis has three primary categories 
of functions: Molecular and Cellular Functions; Physiological System Development and 
Function; and Diseases and Disorders. There are 85 high-level functional categories that are 
classified under these categories. Lower level functions are classified within the high-level 
categories. Specific functions are the lowest level functions found in IPA. Each lowest level 
function has a population of associated molecules. Specific functions come from the Findings 
that are stored within the Ingenuity Knowledge Base. Lower level functions and specific 
functions may be classified within multiple high-level categories. 
Amino Acid Metabolism Describes functions associated with the metabolism of amino 
acids, for example the generation of serine and the degradation of tryptophan. 
Carbohydrate Metabolism Describes functions associated with the metabolism of 
carbohydrates, for example the activation of glycogen and consumption of carbohydrate. 
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DNA replication, recombination and repair  Describes functions associated with the 
replication, recombination and repair of DNA.  Examples of these functions include formation of 
replication fork, homologous recombination of DNA, and damage of DNA. 
Lipid Metabolism Describes functions associated with the metabolism of lipids, for 
example absorption of cholesterol and adiposis. 
 Molecular Transport Describes functions associated with the intra- and extracellular 
movement of molecules, including small molecules, ions, DNA, RNA, protein, lipids and 
carbohydrates.  Examples include efflux of glutamate and depletion of DNA. 
Small Molecule Biochemistry Describes functions associated with small molecules, for 
example the generation of nitric oxide and metabolism of indole.  Functions associated with 
DNA, RNA, protein, lipids and carbohydrates are described by more specific categories and 
therefore are not included in this category. 
Neurological Disease Describes diseases and abnormalities of the neurological 
system.  Some examples include atrophy of axons, convulsion, dyskinesia and swelling of brain. 
Skeletal and Muscular Disorders Describes diseases and abnormalities of the skeletal and 
muscular system.  Some examples include destruction of bone, hyperplasia of muscle and 
osteosclerosis. 
Metabolic Disease Describes metabolic diseases.  Some examples include acidosis of 
cells, diabetes and hypolipidemia. 
Significance in Functional Analysis for a Dataset.  The significance value associated 
with Functional Analysis for a dataset is a measure of the likelihood that the association between 
a set of Functional Analysis molecules in your experiment and a given process or pathway is due 
to random chance. The smaller the p-value the less likely that the association is random and the 
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more significant the association. In general, p-values less than 0.05 indicate a statistically 
significant, non-random association. The p-value is calculated using the right-tailed Fisher Exact 
Test. 
  
In this method, the p-value for a given function is calculated by considering 
1) the number of functional analysis molecules that participate in that function and 
2) the total number of molecules that are known to be associated with that function in the 
Ingenuity Knowledge Base 
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APPENDIX B 
LEGEND OF INGENUITY PATHWAY ANALYSIS  
 
. 
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This legend is provided by IPA with a key of the main features in the networks and 
canonical pathways including molecule shapes and colors as well as relationship labels and 
types. 
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APPENDIX C 
DATA TRANFORMATION AND NORMALIZATION 
 
 
Figure 28. Example of data distribution before normalization and transformation 
Data distribution of iTRAQ labeled values in fasted VLCAD deficient mice and wild type mice.  X-axis- 
iTRAQ value of a protein in wild type mice. Y-axis-iTRAQ values of the same protein in VLCAD 
deficient mice or wild type mice. Each color represents the corresponding label value for the same protein 
either in VLCAD deficient mice or other wild type mice as replicates. KO denotes data from deficient 
mice. WT denotes data from wild type mice. 
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Figure 29.  Example of data distribution after normalization and transformation  
Data distribution of iTRAQ labeled values in fasted VLCAD deficient mice and wild type mice after 
normalization and log2 transformation as described in Chapter 3 (Page 76). X-axis- iTRAQ value of a 
protein in wild type mice. Y-axis-iTRAQ values of the same protein in VLCAD deficient mice or wild 
type mice. Each color represents the corresponding label value for the same protein either in VLCAD 
deficient mice or other wild type mice as replicates.  KO denotes data from deficient mice. WT denotes 
data from wild type mice. 
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APPENDIX D 
AN EXAMPLE OF INFERRED INFORMATION FROM IPA ANALYSIS  
 
 
Figure 30.  Network of Carbohydrate Metabolism and Inferred Information from IPA  
This picture is generated by IPA based on Figure 18 overlay with function of carbohydrate metabolism. Red nodes 
indicate that the protein is up-regulated in the fasted VLCAD deficient mice as compared to fed deficient mice. 
Green indicates that the protein is down-regulated in the fasted VLCAD deficient mice. Proteins in white are those 
inferred from the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. An 
oval frame indicates a relation to carbohydrate metabolism.  
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